 121item 9acontrols and procedures 121item 9bother information 121   part iii  122item 10directors executive officers and corporate governance 122item 11executive compensation 122item 12security ownership of certain beneficial owners and management and related stockholder matters 122item 13certain relationships and related transactions and director independence 122item 14principal accountant fees and services 122   part iv  122item 15exhibits and financial statement schedules 123   signatures 131   2part iitem 1 businessthe companyboston scientific corporation is a worldwide developer manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties our mission is to transform lives through innovative medical solutions that improve the health of patients around the world when used in this report the terms we us our and the company mean boston scientific corporation and its divisions and subsidiariesour history began in the late 1960s when our cofounder john abele acquired an equity interest in meditech inc a research and development company focused on developing alternatives to surgery in 1969 meditech introduced a family of steerable catheters used in some of the first lessinvasive procedures performed in 1979 john abele joined with pete nicholas to form boston scientific corporation which indirectly acquired meditech this acquisition began a period of active and focused new product development innovation market development and organizational growth since then we have advanced the practice of lessinvasive medicine by helping physicians and other medical professionals diagnose and treat a wide range of diseases and medical conditions and improve patients quality of life by providing alternatives to surgery and other medical procedures that are typically traumatic to the bodyour net sales have increased substantially since our formation our growth has been fueled in part by strategic acquisitions designed to improve our ability to take advantage of growth opportunities in the medical device industry and to build depth of portfolio within our focus businesses our strategic acquisitions have helped us to add promising new technologies to our pipeline and to offer one of the broadest product portfolios in the world for use in lessinvasive procedures in our target areas of cardiovascular rhythm management and medical surgical we believe that the depth and breadth of our product portfolio has also enabled us to compete more effectively in the current healthcare environment that seeks to improve outcomes and lower costs our strategy of category leadership also enables us to compete in a changing contracting landscape and position our products with physicians managed care large buying groups governments and consolidation among hospitals while also expanding internationally and managing the complexities of the global healthcare marketbusiness strategywe operate following five strategic imperatives strengthen execution to grow share expand into high growth adjacencies drive global expansion fund the journey to fuel growth and develop key capabilities we believe that our execution of these strategic imperatives will drive innovation accelerate profitable revenue growth and increase stockholder value our approach to innovation combines internallydeveloped products and technologies with those we may obtain externally through strategic acquisitions and alliances our research and development efforts are focused largely on the development of nextgeneration and novel technology offerings across multiple programs and divisions in addition we have undertaken several strategic acquisitions to help us to continue to be a leader in the medical device industry we expect to continue to invest in our core franchises and also investigate opportunities to further expand our presence in and diversify into strategic growth adjacencies and new global markets during the last several years we have completed multiple acquisitions to strengthen our core franchises and expand into high growth adjacencies and global markets to support the achievement of our strategic and organizational objectives we have an enterprise risk management program that coordinates a consolidated view of the key risks inherent in achieving our business strategies so we can anticipate and adapt to potential challenges to preserve and grow shareholder value our board of directors oversees risk management and focuses on the most significant risks facing the company including strategic operational financial and legal and compliance risksproductsduring 2016 our products were offered for sale by seven core businesses interventional cardiology cardiac rhythm management endoscopy peripheral interventions urology and pelvic health neuromodulation and electrophysiology during 2016 we derived 27 percent of our sales from our interventional cardiology business 22 percent of our sales from our cardiac rhythm management business 17 percent of our sales from our endoscopy business 12 percent of our sales from our peripheral interventions business 12 percent of our sales from our urology and pelvic health business seven percent of our sales from our neuromodulation business and three percent of our sales from our electrophysiology businessthe following section describes certain of our product offerings in addition see item 7 managements discussion and analysis of financial condition and results of operations of this annual report for further information on our core businesses and products 3cardiovascularinterventional cardiologydrugeluting coronary stent systemsour broad innovative product offerings have enabled us to become a leader in the global interventional cardiology market this leadership is due in large part to our drugeluting coronary stent product offerings coronary stents are tiny mesh tubes used in the treatment of coronary artery disease which are implanted in patients to prop open arteries and facilitate blood flow to and from the heart we believe we have further enhanced the outcomes associated with the use of coronary stents particularly the processes that lead to restenosis the growth of neointimal tissue within an artery after angioplasty and stenting through scientific research and product development of drugeluting stent systems we market the synergy everolimuseluting platinum chromium coronary stent system featuring an ultrathin abluminal outer bioabsorbable polymer coating the synergy stent is unique in that both its proprietary polymer and everolimus drug coating dissipate by three months this innovation has the potential to improve postimplant vessel healing and will eliminate longterm polymer exposure which is a possible cause of late adverse events in addition we market the promus premier promus element and promus element plus everolimuseluting stentsother coronary therapieswe market a broad line of products used to treat patients with atherosclerosis a principal cause of coronary artery obstructive disease which is characterized by a thickening of the walls of the coronary arteries and a narrowing of arterial openings caused by the progressive development of deposits of plaque our product offerings include balloon catheters rotational atherectomy systems guide wires guide catheters embolic protection devices crossing and reentry devices for the treatment of chronically occluded coronary vessels and diagnostic catheters used in percutaneous transluminal coronary angioplasty ptca procedures pci guidancewe market a family of intravascular catheterdirected ultrasound imaging catheters fractional flow reserve ffr devices and systems for use in coronary arteries and heart chambers as well as certain peripheral vessels our intravascular ultrasound imaging catheter opticross has been launched in all major markets worldwide we initiated the launch of our first ffr product the comet pressure guidewire in the us europe and japan in 2016 the ilab ultrasound imaging system with polaris software continues as our flagship console and is compatible with our full line of imaging catheters and ffr devices and are designed to enhance the diagnosis and treatment of blocked vessels and heart disorders these systems have been placed in cardiology labs worldwide and provided an installed base through which we expect to continue to pull through products including the ongoing launch of our comet ffr pressure guidewire structural heart therapiesstructural heart therapy is one of the fastest growing segments of the medical technology market and is highly synergistic with our interventional cardiology and rhythm management businesses through the acquisition of sadra medical inc sadra in january 2011 we have developed a fully repositionable and retrievable device the lotus valve system for transcatheter aortic valve replacement tavr to treat patients with severe aortic stenosis the lotus valve system employs a unique adaptive seal feature designed to minimize the incidence of paravalvular regurgitation a predictor of mortality the lotus valve system is cemarked in the european union eu in the us it is an investigational device and not available for commercial sale at the end of 2015 we completed enrollment in our reprise iii pivotal clinical trial we have three valve sizes ce marked 23 25 and 27mm and we are developing 21 and 29mm size valves to complete our size matrix in september 2016 we commenced a limited launch of our next generation catheter and sheath the lotus edge valve system in europe in october 2016 we suspended our limited launch and initiated a voluntary removal of field inventory of the lotus edge system due to reports that in some cases the device could not be fully locked during the procedure due to premature release of a pin connecting the lotus edge valve to the delivery system in february 2017 we initiated a voluntary removal of all lotus valve devices including lotus with depth guard from global commercial and clinical sites due to reports of premature release of a pin connecting the lotus valve to the delivery system as with the prior announced suspension of our lotus edge valve system device we believe that the issue is caused by excess tension in the pin mechanism introduced during the manufacturing process we expect to bring the lotus valve platform back to market in europe and other regions in the fourth quarter of 2017 we anticipate filing the us pma submission for the lotus edge valve system the next generation platform in the fourth quarter of 2017 with a us launch planned for mid2018  4through the acquisition of atritech inc atritech in march 2011 we have developed a novel device the watchman left atrial appendage closure laac device designed to close the left atrial appendage to reduce the risk of ischemic stroke in patients with atrial fibrillation af watchman device has been commercially available internationally since 2009 and is the leading device in percutaneous laac globally in march of 2015 watchman device received fda approval to treat patients who are at an elevated risk of stroke deemed suitable for warfarin and have appropriate rationale to seek a nonpharmacologic alternative to warfarin we believe that watchman device will be the only laac technology commercially available in the us for multiple years and in november 2015 we received ce mark for our next generation device watchman flx laac device shortly after approval we began a european initial market release of watchman flx device the initial market release was suspended near the end of the first quarter of 2016 due to a higher than expected rate of device embolization following an extensive data evaluation we have decided to pursue certain design enhancements prior to returning a next generation device to marketon december 12 2016 we completed the acquisition of certain manufacturing assets and capabilities of the neovasc inc advanced biological tissue business and made a 15 percent equity investment in neovasc with this acquisition we will integrate certain manufacturing assets and biologic tissue capabilities into our structural heart business for use in the manufacturing of the lotus valve system and future heart valve technologies within our interventional cardiology businesswe began the process of integrating neovasc into our interventional cardiology business in the fourth quarter of 2016 and expect to be substantially complete by the end of 2018 peripheral interventionswe sell various products designed to treat patients with peripheral arterial disease disease which appears in blood vessels other than in the heart and in the biliary tree including a broad line of medical devices used in percutaneous transluminal angioplasty pta and peripheral vascular stenting our peripheral product offerings include stents balloon catheters wires peripheral embolization devices and vena cava filters our peripheral angioplasty balloon technology includes our nextgeneration mustang pta balloon catheter our coyote balloon catheter a highly deliverable and ultralow profile balloon dilatation catheter designed for a wide range of peripheral angioplasty procedures and our charger pta balloon catheter a 0035 percutaneous transluminal angioplasty balloon catheter designed for poststent dilatation as well as conventional balloon angioplasty to open blocked peripheral arteries with our coyote mustang and charger devices we offer balloons across all size platforms our peripheral stent technology includes our epic selfexpanding nitinol stent system our carotid wallstent stent system and our innova selfexpanding stent system in addition we market our 0035 rubicon support catheter in both the us and europe we are currently conducting a pivotal study designed to evaluate the safety and performance of the eluvia drugeluting vascular stent system which received ce mark in february 2016 and is designed to treat patients with narrowing or blockages in the sfa or proximal popliteal artery ppa we are also conducting an additional study on the safety and effectiveness of our ranger drugcoated balloonin august 2014 we acquired the interventional division of bayer ag bayer the addition of bayer innovative technologies supports our strategy to provide a comprehensive portfolio of leading solutions to treat peripheral vascular disease including venous disease the transaction included the leading angiojet thrombectomy system which is used in endovascular procedures to remove blood clots from blocked arteries and veins and the jetstream atherectomy system used to remove plaque and thrombi from diseased arteries we have since launched the angiojet zelantedvt thrombectomy catheter to treat deep vein thrombosis dvt in largediameter upper and lower limb peripheral veins in the us and europe we also sell products designed to treat patients with nonvascular disease disease that appears outside the blood system primarily in interventional oncology our nonvascular suite of products includes biliary stents drainage catheters and micropuncture sets designed to treat diagnose and ease various forms of benign and malignant tumors we market our direxion torqueable microcatheter in both the us and europe in addition we continue to market our extensive line of interventional oncology product solutions including the renegade hiflo fathom microcatheter and guidewire system and interlock  35 fibered idc and 18 fibered idc occlusion system for peripheral embolization on december 31 2015 we completed the acquisition of the interventional radiology business of celonova biosciences celonova the acquisition includes drugeluting microspheres designed to be loaded with chemotherapy drugs for delivery to cancerous tumors and spherical embolic products used to treat uterine fibroids and other conditions we are in the process of integrating celonova into our peripheral interventions business and expect to be substantially complete by the second half of 2017  5rhythm managementcardiac rhythm managementwe develop manufacture and market a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities including implantable cardioverter defibrillator icd systems used to detect and treat abnormally fast heart rhythms tachycardia that could result in sudden cardiac death including the worlds only commercially available subcutaneous implantable cardiac defibrillators sicd along with implantable transvenous cardiac defibrillators and implantable cardiac resynchronization therapy defibrillator crtd systems used to treat heart failure andimplantable pacemaker systems used to manage slow or irregular heart rhythms bradycardia including implantable cardiac resynchronization therapy pacemaker crtp systems used to treat heart failure in addition in most geographies our implantable device systems include our remote latitude patient management system which enables physicians to monitor device performance remotely allowing for more frequent monitoring in order to guide treatment decisions we market several lines of icds including our dynagen el  dynagen mini inogen el and inogen mini mini is the smallest thinnest icd and el extended longevity is the longest lasting icd due to our proprietary enduralife battery technology in addition we offer our emblem mri sicd system which affords physicians the ability to treat patients who are at risk for sudden cardiac arrest without touching the heart or invading the vasculature our emblem mri sicd system offers greater longevity latitude patient management remote monitoring technology and smaller size as compared to the first generation of sicd therapy we also offer several lines of crtd systems including our x4 line of quadripolar systems a suite of acuity x4 quadripolar lv leads and the acuity pro lead delivery system we initiated the full us launch of our acuity x4 quadripolar lv leads in march 2016 and began global commercialization of the emblem mri sicd system in the second and third quarters of 2016 our current generation of transvenous icd and crtd pulse generators dynagen and inogen when paired with our most current generation of bradycardia heart failure and icd leads have mri safe labeling in most major countries outside the us in the us we plan to finish enrollment in our high voltage mri approval trial enable mri in early 2017 we market our accolade family of pacemaker systems in nearly all major markets around the world approval of our accolade pacemaker family in the us europe and japan also includes approval for use of these products in patients undergoing magnetic resonance imaging mri scans we received fda approval of our accolade mricompatible pacemaker and mricompatible ingevity bradycardia lead in april of 2016 our cardiac resynchronization therapy pacemaker product offerings include our newest generation visionist and valitudex4 quadripolar crtp devices which are built on the same platform as our high voltage cardiac resynchronization therapy defibrillator are enabled for remote patient monitoring and include features that promote ease of use for physician implantation electrophysiologywithin our electrophysiology business we develop lessinvasive medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart included in our product offerings are steerable radio frequency rf ablation catheters intracardiac ultrasound catheters diagnostic catheters delivery sheaths and other accessories our products include the blazer line of temperature ablation catheters designed to deliver enhanced performance and responsiveness our cooled ablation portfolio includes our us and ce mark approved blazer openirrigated and intellanav openirrigated ablation catheters with a unique total tip cooling design and our closedloop irrigated catheter the chilli ii cooled ablation catheter in addition to these openirrigated catheters we began global commercialization of our intellanav xp and intellanav mifi xp catheters in the second quarter of 2016 our intellatip mifi xp and intellanav mifi xp catheters include microfidelity mifi sensor technology in the catheter tip all of our intellanav catheters are designed to allow magnetic tracking when used with our rhythmia mapping system our comprehensive diagnostic catheter portfolio includes blazer dx20 dynamic tip and viking catheters we have a full offering of capital equipment including our labsystem pro recording system the rhythmia mapping system maestro rf generators and the metriq pump in 2015 the rhythmia mapping system and intellamap orion mapping catheter began full global commercialization bringing to market a next generation system capable of highdensity highresolution mapping to improve procedure efficacy in december of 2016 we began european commercialization of our next generation rhythmia hdx mapping system 6medsurgendoscopygastroenterology and pulmonarywe are dedicated to transforming the lives of patients by advancing the diagnosis and treatment of a broad range of pulmonary and gastrointestinal conditions we do this through the development of innovative devices for less invasive procedures tailored services to optimize hospital operations and patient care and programs in support of education and reimbursement common gastrointestinal gi disease states include esophageal disorders gi strictures and bleeding pancreaticobiliary disease and other associated conditions as well as esophageal biliary pancreatic and colon cancer some of our product offerings includethe spyglass ds system made available in 2015 brings digital imaging a wider field of view and a simpler setup compared to the legacy spyglass system enabling cholangioscopy to play a greater role in the diagnosis and treatment of pancreaticobiliary diseases the axios stent and electrocauteryenhanced delivery system for endoscopic ultrasoundguided transmural drainage of pancreatic pseudo cysts which provides a less invasive alternative to surgical pseudo cyst draining procedures and procedural time savings when compared to a nonelectrocautery enhanced system on april 2 2015 we acquired xlumena inc xlumena a medical device company that developed minimally invasive devices for endoscopic ultrasound eus guided transluminal drainage of targeted areas within the gastrointestinal tract we continue to grow our presence in the field of endoluminal surgery in the us and expand internationally the wallflex biliary rx fully covered stents system rmv is the first and currently only biliary metal stent to receive us fda clearance for an indication to treat benign biliary strictures due to chronic pancreatitis this stent can be safely placed and removed for up to 12 months providing additional treatment options for physicians managing their patients with this condition the resolution 360 clip launched in october 2016 and built on the marketleading technology of our legacy resolution clip is a novel hemostatic clipping technology designed to stop and help prevent bleeding during endoscopic procedures the device is constructed using a multiwire braided catheter designed to enable healthcare professionals to rotate the device in small controlled movements in both clockwise and counterclockwise directions this design enables the clip to be maneuvered to the target area and more accurately placed at the site of a gi bleed or potential gi bleed the acquire endoscopic ultrasound fine needle biopsy fnb device initially launched in may 2016 and was in full launch as of january 2017 is designed to obtain larger tissue specimens fnb devices are used during eus procedures to collect tissue specimens for histological assessment and are useful when diagnosing diseases such as pancreatic cancer liver cancer and stomach lesions this new device is designed to obtain more tissue providing physicians with confidence that the samples they extract may improve diagnostic yield to help determine the best course of treatment for a patienton november 22 2016 we completed our acquisition of endochoice holdings inc endochoice endochoice is an alpharetta georgia based company focused on the development and commercialization of infection control products pathology services and singleuse devices for specialists treating a wide range of gastrointestinal gi conditions we began the process of integrating endochoice into our endoscopy business in the fourth quarter of 2016 and expect to be substantially complete by the end of 2017on november 1 2016 we acquired the lumenr tissue retractor system from lumenr llc lumenr a privately held newark california based company the lumenr tissue retractor system is currently in development for use during endoscopic resection of lesions in the colon esophagus or stomachinterventional bronchoscopywe market devices to diagnose treat and ease pulmonary disease systems within the airway and lungs our products are designed to help perform biopsies retrieve foreign bodies from the airway open narrowings of an airway stop internal bleeding and ease symptoms of some types of airway cancers our product line includes pulmonary biopsy forceps transbronchial aspiration needles cytology brushes tracheobronchial stents used to dilate narrowed airway passages or for tumor management and the alair bronchial thermoplasty system for the treatment of severe persistent asthma   7urology and pelvic healthour urology and pelvic health business develops manufactures and sells devices to treat various urological and pelvic conditions within our urology business we sell a variety of products designed to treat patients with urinary stone disease and benign prostatic hyperplasia bph we offer a full line of stone management products including ureteral stents wires lithotripsy devices stone retrieval devices sheaths balloons and catheters within our pelvic health business we market a range of devices for the treatment of conditions such as stress urinary incontinence pelvic floor reconstruction rebuilding of the anatomy to its original state menorrhagia excessive menstrual bleeding and uterine fibroids and polyps we offer a full breadth of midurethral sling products sling materials graft materials pelvic floor reconstruction kits and suturing devices we market our genesys hydro thermablator hta system an ablation system designed to ablate the endometrial lining of the uterus in premenopausal women with menorrhagia symphion system for the removal of intrauterine fibroids and polyps on august 3 2015 we completed the acquisition of the american medical systems male urology portfolio ams portfolio acquisition which includes the mens health and prostate health businesses from endo international plc the ams male urology portfolio was integrated with our formerly named urology and womens health business and the joint businesses became urology and pelvic health the integration was substantially complete by the end of 2016on november 15 2016 we completed the acquisition of the gynecology and urology portfolio of distal access llc distal a salt lake city based company that designs minimally invasive medical devices the portfolio includes the resectr tissue resection device a singleuse solution designed to remove uterine polyps we began the process of integrating the resectr device into our urology and pelvic health business during the fourth quarter of 2016 and expect to be substantially complete by the end of 2017 neuromodulationour neuromodulation business offers the precisiontm and precision spectratm spinal cord stimulator scs systems used for the management of chronic pain the precision spectratm system is the worlds first and only scs system with 32 contacts and 32 dedicated power sources and is designed to provide improved pain relief to a wide range of patients who suffer from chronic pain we believe that we continue to have a technological advantage compared to our competitors with proprietary features such as multiple independent current control and our illumina 3d proprietary programming software which together are intended to allow the physician to target specific areas of pain and customize stimulation of nerve fibers more precisely additionally in june 2015 we launched the precision novi scs system in europe the precision novi system offers patients and physicians the smallest 16contact high capacity primary cell pc also referred to as nonrechargeable device for the treatment of chronic pain we also have regulatory approval for our vercise deep brain stimulation dbs system in various international regions such as europe latin america and asia pacific for the treatment of parkinsons disease tremor and intractable primary and secondary dystonia a neurological movement disorder characterized by involuntary muscle contractions in september 2015 we gained cemark approvals for the vercise pc dbs system with its neural navigator programming software the system allows for programming flexibility designed to treat a greater range of patients throughout their disease progression in addition we received ce mark approval for the only commercially available directional lead powered by current steering the cartesia directional lead uses multidirectional stimulation for greater precision intended to minimize side effects for patients we are currently in a us pivotal trial with our vercise dbs system for the treatment of parkinsons disease and expect to enter the us market with our vercise dbs system by the end of 2017 on july 27 2016 we acquired cosman medical inc cosman a privately held manufacturer of radiofrequency ablation systems expanding our neuromodulation portfolio and offering physicians treating patients with chronic pain a wider choice of nonopioid therapeutic options we are in the process of integrating cosman into our neuromodulation business and expect the integration to be substantially complete by the end of 2017 research and developmentour investment in research and development is critical to driving our future growth we expended 920 million on research and development in 2016 876 million in 2015 and 817 million in 2014 our investment in research and development reflects the followinginternal research and development programs regulatory design and clinical science as well as other programs obtained through our strategic acquisitions and alliances and 8engineering efforts that incorporate customer feedback into continuous improvement efforts for currently marketed and nextgeneration productswe have directed our development efforts toward innovative technologies designed to expand current markets or enter adjacent markets we are transforming how we conduct research and development and are scrutinizing our cost structure which we believe will enable increased development activity and faster concept to market timelines our approach to new product design and development is through focused crossfunctional teams we believe that our formal process for technology and product development aids in our ability to offer and manufacture innovative products in a consistent and timely manner involvement of the crossfunctional teams early in the process is the cornerstone of our product development cycle we believe this collaboration allows these teams to concentrate resources on the most viable and clinically relevant new products and technologies and focus on bringing them to market in a timely and costeffective manner in addition to internal development we work with hundreds of leading research institutions universities and clinicians around the world to develop evaluate and clinically test our products we are expanding our collaborations to include research and development teams in emerging markets these teams will focus on both global and local market requirements at a lower cost of development we believe that a part of our future success will depend upon the strength of these development effortsmarketing and salesduring 2016 we marketed our products to approximately 35000 hospitals clinics outpatient facilities and medical offices in the us and to approximately 120 countries worldwide the majority of our net sales are derived from countries in which we have direct sales organizations we also have a network of distributors and dealers who offer our products in certain countries and markets we expect to continue to leverage our infrastructure in markets where commercially appropriate and use third party distributors in those markets where it is not economical or strategic to establish or maintain a direct presence no single institution accounted for more than ten percent of our net sales in 2016 2015 or 2014 however large group purchasing organizations hospital networks and other buying groups have become increasingly important to our business and represent a substantial portion of our net sales we have a dedicated corporate sales organization in the us focused principally on selling to major buying groups and integrated healthcare networks we consistently strive to understand and exceed the expectations of our customers each of our businesses maintains dedicated sales forces and marketing teams focused on physicians who specialize in the diagnosis and treatment of different medical conditions we believe that this focus on disease state management enables us to develop highly knowledgeable and dedicated sales representatives and to foster collaborative relationships with physicians we believe that we have positive working relationships with physicians and others in the medical industry which enable us to gain a detailed understanding of new therapeutic and diagnostic alternatives and to respond quickly to the changing needs of physicians and their patients international operationsinternational net sales accounted for approximately 43 percent of our net sales in 2016 maintaining and expanding our international presence is an important component of our longterm growth strategy through our international presence we seek to increase net sales and market share leverage our relationships with leading physicians and their clinical research programs accelerate the time to bring new products to market and gain access to worldwide technological developments that we can implement across our product lines in addition we are investing in infrastructure in emerging markets in order to strengthen our sales capabilities and maximize our opportunities in these countriesas of december 31 2016 we had six principal international manufacturing facilities including three in ireland two in costa rica and one in puerto rico approximately 45 percent of our products manufactured in 2016 were produced at these facilities additionally we maintain research and development capabilities in ireland puerto rico costa rica germany india and china we operate physician training centers in france japan south africa germany italy and indiamanufacturing and raw materialswe are focused on continuously improving our supply chain effectiveness strengthening our manufacturing processes and increasing operational efficiencies within our organization we continually strive to improve the efficiency of our sourcing operations and to partner with strategic suppliers to leverage the technical expertise of the broader market by doing so we seek to focus our internal resources on the development and commercial launch of new products and the enhancement of existing products we continue to implement new systems designed to provide improved quality reliability service greater efficiency and lower supply chain costs and continue our focus on process controls and validations supplier controls distribution controls and providing our operations teams with the training and tools necessary to drive continuous improvement in product quality in addition we remain focused on examining our operations and general business activities to identify costimprovement opportunities in order to enhance our operational effectiveness 9our products are designed and manufactured in technology centers around the world either by us or third parties we consistently monitor our inventory levels manufacturing and distribution capabilities and maintain recovery plans to address potential disruptions that we may encounter many components used in the manufacturing of our products are readily fabricated from commonly available raw materials or offtheshelf items available from multiple supply sources however certain items are custom made to meet our specifications we believe that in most cases redundant capacity exists at our suppliers and that alternative sources of supply are available or could be developed within a reasonable period of time we also have an ongoing program to identify singlesource components and to develop alternative backup supplies and we regularly readdress the adequacy and abilities of our suppliers to meet our needs quality assurancewe are committed to providing high quality products to our customers our quality system starts with the initial product specification and continues through the design of the product component specification process and the manufacturing sale and servicing of the product our quality system is intended to build in quality and process control and to utilize continuous improvement concepts throughout the product life these systems are designed to enable us to satisfy the various international quality system regulations including those of the fda with respect to products sold in the us all of our manufacturing facilities and distribution centers are certified under the iso13485 quality system standard established by the international standards organization for medical devices which requires among other items an implemented quality system that applies to component quality supplier control product design and manufacturing operations this certification can be obtained only after a complete audit of a companys quality system by an independent outside auditor maintenance of the certification requires that these facilities undergo periodic reexaminationenvironmental regulation and managementwe are subject to various environmental laws directives and regulations both in the us and abroad our operations involve the use of substances regulated under environmental laws primarily in manufacturing and sterilization processes we believe that sound environmental health and safety performance contributes to our competitive strength while benefiting our customers stockholders and employees we are focused on continuous improvement in these areas by reducing pollution the depletion of natural resources and our overall environmental footprint specifically we are working to optimize energy and resource usage ultimately reducing greenhouse gas emissions and waste we are certified to the ftse4good corporate social responsibility index managed by the financial times and the london stock exchange which measures the performance of companies that meet globally recognized standards of corporate responsibility this certification recognizes our dedication to those standards and it places us in a select group of companies with a demonstrated commitment to responsible business practices and sound environmental policieswe have obtained iso 140012004 certifications at our major manufacturing plants and tier 1 distribution centers around the world as well as our corporate headquarters in marlborough massachusetts iso 140012004 is a globally recognized standard for environmental management systems established by the international standards organization which provides a voluntary framework to identify key environmental aspects associated with our business using this environmental management system and the specific attributes of our certified locations in the us ireland costa rica and the netherlands we continue to improve our environmental performance and reduce our environmental footprintcompetitionwe encounter significant competition across our product lines and in each market in which we sell our products from various companies some of which may have greater financial and marketing resources than we do our primary competitors include abbott laboratories medtronic plc and cook medical as well as a wide range of medical device companies that sell a single or limited number of competitive products or participate in only a specific market segment we also face competition from nonmedical device companies such as pharmaceutical companies which may offer alternative therapies for disease states which could also be treated using our productswe believe that our products and solutions compete primarily on their ability to deliver both clinical and economic outcomes for our customers while also continuing to perform diagnostic and therapeutic procedures safely and effectively in a lessinvasive manner as well as to provide ease of use comparative effectiveness reliability and physician familiarity in the current environment of managed care with economicallymotivated buyers consolidation among healthcare providers increased competition and declining reimbursement rates we have been increasingly required to compete on the basis of price value reliability and efficiency  10we believe the current global economic conditions and healthcare reform measures could continue to put additional competitive pressure on us including on our average selling prices overall procedure rates and addressable market sizes we recognize that our continued competitive success will depend upon our ability to offer products and solutions that provide differentiated clinical and economic outcomes create or acquire innovative scientifically advanced technologies apply our technology and solutions costeffectively and with superior quality across product lines and markets develop or acquire proprietary products and solutions attract and retain skilled personnel obtain patent or other protection for our products obtain required regulatory and reimbursement approvals continually enhance our quality systems manufacture and successfully market our products and solutions either directly or through outside parties and supply sufficient inventory to meet customer demandmedical device regulatory approvalsthe medical devices that we manufacture and market are subject to regulation by numerous worldwide regulatory bodies including the fda and comparable international regulatory agencies these agencies require manufacturers of medical devices to comply with applicable laws and regulations governing development testing manufacturing labeling marketing and distribution of medical devices devices are generally subject to varying levels of regulatory control based on the risk level of the device in the us authorization to distribute a new device can generally be met in one of three ways the first process requires that a premarket notification 510k be made to the fda to demonstrate that the device is as safe and effective as or substantially equivalent to a legally marketed device the predicate device applicants must submit performance data to establish substantial equivalence in some instances data from human clinical trials must also be submitted in support of a 510k premarket notification if so these data must be collected in a manner that conforms to the applicable investigational device exemption ide regulations the fda must issue a decision finding substantial equivalence before commercial distribution can occur changes to cleared devices that could not significantly affect the safety or effectiveness of the device can generally be made without additional 510k premarket notifications otherwise a new 510k is requiredthe second process requires the submission of a premarket approval pma application to the fda to demonstrate that the device is safe and effective for its intended use this approval process applies to most class iii devices and generally requires clinical data to support the safety and effectiveness of the device obtained in adherence with ide requirements the fda will approve the pma application if it finds that there is a reasonable assurance that the device is safe and effective for its intended purpose and that the proposed manufacturing is in compliance with the quality system regulation qsr for novel technologies the fda will generally seek input from an advisory panel of medical experts and seek their views on the safety effectiveness and benefitrisk of the device the pma process is generally more detailed lengthier and more expensive than the 510k processthe third process requires that an application for a humanitarian device exemption hde be made to the fda for the use of a humanitarian use device hud an hud is intended to benefit patients by treating or diagnosing a disease or condition that affects or is manifested in fewer than 4000 individuals in the us per year the application submitted to the fda for an hde is similar in both form and content to a pma application but is exempt from the effectiveness requirements of a pma the hud provision of the regulation provides an incentive for the development of devices for use in the treatment or diagnosis of diseases affecting smaller patient populationsin the european economic area eea we are required to comply with applicable medical device directives specifically the medical devices directive and the active implantable medical device directive and obtain ce mark certification in order to market medical devices within the eea the ce mark is applied depending on device classification either following approval from the appointed independent notified body or through selfcertification ce marking is a symbol of compliance to the applicable essential requirements of the medical devices directive and associated standards the eu regulatory bodies will finalize a new medical device regulation mdr in 2017 which will replace the existing directives and will provide three years for transition and compliance the mdr will change several aspects of the existing regulatory framework such as clinical data requirements and introduce new ones such as unique device identification udi we and the notified bodies who will oversee compliance to the new mdr face uncertainties as the mdr is rolled out and enforced by the commission and eea competent authorities creating risks in several areas including the ce marking process and data transparency in the upcoming yearswe are also required to comply with the regulations of each other country where we commercialize products before we can launch new products such as the requirement that we obtain approval from the japanese ministry of health labor and welfare mhlw and china food and drug administration many countries that previously did not have medical device regulations or minimal such regulations are now introducing them for example india is in the process of establishing new medical device regulationsthe fda and other worldwide regulatory agencies and competent authorities actively monitor compliance to local laws and regulations through review and inspection of design and manufacturing practices record keeping reporting of adverse events  11labeling and promotional practices the fda can ban certain medical devices detain or seize adulterated or misbranded medical devices order repair replacement or refund of these devices and require notification of health professionals and others with regard to medical devices that present unreasonable risks of substantial harm to the public health the fda may also enjoin and restrain a company for certain violations of the food drug and cosmetic act and the safe medical devices act pertaining to medical devices or initiate action for criminal prosecution of such violations regulatory agencies and authorities in the countries where we do business can halt production in or distribution within their respective country or otherwise take action in accordance with local laws and regulationsinternational sales of medical devices manufactured in the us that are not approved by the fda for use in the us or that are banned or deviate from lawful performance standards are subject to fda export requirements exported devices are subject to the regulatory requirements of each country to which the device is exported some countries do not have medical device regulations but in most foreign countries medical devices are regulated frequently regulatory approval may first be obtained in a foreign country prior to application in the us due to differing regulatory requirements however other countries such as china for example require approval in the country of origin first most countries outside of the us require that product approvals be recertified on a regular basis generally every five years the recertification process requires that we evaluate any device changes and any new regulations or standards relevant to the device and where needed conduct appropriate testing to document continued compliance where recertification applications are required they must be approved in order to continue selling our products in those countriesgovernment affairs we maintain a global government affairs presence headquartered in washington dc to actively monitor and advocate on myriad legislation and policies impacting us both on a domestic and an international front the government affairs office works closely with members of congress and committee staff the white house and administration offices state legislatures and regulatory agencies and governments overseas on issues affecting our business our proactive approach and depth of political and policy expertise are aimed at having our positions heard by federal state and global decisionmakers while also advancing our business objectives by educating policymakers on our positions key priorities and the value of our technologies the government affairs office also manages our political action committee and works closely with trade groups on issues affecting our industry and healthcare in generalhealthcare policiespolitical economic and regulatory influences around the world continue to subject the healthcare industry to potential fundamental changes that could substantially affect our results of operations government and private sector initiatives related to limiting the growth of healthcare costs including price regulation coverage and payment policies comparative effectiveness reviews of therapies technology assessments and health care delivery structure reforms are continuing in many countries where we do business we believe that these changes are causing the marketplace to put increased emphasis on the delivery of treatments that can reduce costs improve efficiencies andor increase patient access although we believe our lessinvasive products and technologies generate favorable clinical outcomes value and cost efficiency the resources necessary to demonstrate value to our customers patients payers and other stakeholders may be significant and new therapies may take a longer period of time to gain widespread adoptionthe impact to our business of the united states patient protection and affordable care acts aca provisions related to coverage expansion payment reforms and delivery system has been immaterial the aca and health care and education affordability reconciliation act were enacted into law in the us in 2010 the legislation imposed on medical device manufacturers a 23 percent excise tax on us sales of class i ii and iii medical devices beginning in january 2013 in december 2015 the promise for antibiotics and therapeutics for health act or path act was passed which included legislation which temporarily suspended the 23 percent excise tax until december 31 2017 we have substantially reinvested the amounts we would have expended on this tax into jobs innovation research and development collaborations with universities and other initiatives that will help treat patients and drive revenue growththe federal government as part of the aca and certain state governments have enacted laws aimed at increasing transparency or sunshine in relationships between medical device biologics and pharmaceutical companies and healthcare professionals hcps as a result we are required by law to report many types of payments and items of value provided to hcps certain foreign jurisdictions are currently acting to implement similar laws failure to comply with sunshine laws andor implement and adhere to adequate policies and practices to address changes to legal and regulatory requirements could have a negative impact on our results of operations 12the federal election results in the us may result in changes to insurance coverage financing of insurance coverage in both the employersponsored insurance and individual markets government programs such as medicare and medicaid and federal sunshine laws at this point the impact of any such changes through repeal of or major changes to the aca is unclear because specific changes in laws have not been enacted similarly the status of the medical device tax after december 31 2017 is not clear while the specific policies that the new administration and congress may enact are not known as noted below we expect certain trends to continue placing pressure on pricing in the uswe expect that pricing of medical devices will remain under pressure as alternative payment reform such as prospective payment systems for hospital care preferential site of service payments valuebased purchasing and accountable care organizations acos continue to take shape globally we also expect marketplace changes to place pressure on medical device pricing globally as hospitals consolidate and large group purchasing organizations hospital networks and other groups continue to seek to aggregate purchasing power similarly governments are increasing the use of tenders placing pressure on medical device pricing some governments also seek to limit the growth of healthcare costs through price regulation implementation of cost containment initiatives and healthcare reforms in significant markets such as the us japan and europe and other markets may limit the price of or the level at which reimbursement is provided for our products which in turn may influence a hospitals or physicians selection of products used to treat patientsthirdparty coverage and reimbursementour products are purchased principally by hospitals physicians and other healthcare providers around the world that typically bill various thirdparty payers including government programs eg medicare and medicaid in the us and private insurance payers for the services provided to their patientsthirdparty payers and governments may approve or deny coverage for certain technologies and associated procedures based on independently determined assessment criteria coverage decisions by payers for these technologies and associated procedures are based on a wide range of methodologies that may reflect the assessed resource costs clinical outcomes and economic value of the technologies and associated proceduresproprietary rights and patent litigationwe rely on a combination of patents trademarks trade secrets and nondisclosure agreements to protect our intellectual property we generally file patent applications in the us and foreign countries where patent protection for our technology is appropriate and available as of december 31 2016 we held more than 19000 patents and had approximately 6000 patent applications pending worldwide that cover various aspects of our technology in addition we hold exclusive and nonexclusive licenses to a variety of thirdparty technologies covered by patents and patent applications in the aggregate these intellectual property assets and licenses are of material importance to our business however we believe that no single patent technology trademark intellectual property asset or license except for those relating to our drugeluting coronary stent systems is material in relation to our business as a wholewe rely on nondisclosure and noncompetition agreements with employees consultants and other parties to protect in part trade secrets and other proprietary technology there has been substantial litigation regarding patent and other intellectual property rights in the medical device industry particularly in the areas in which we compete we continue to defend ourselves against claims and legal actions alleging infringement of the patent rights of others additionally we may find it necessary to initiate litigation to enforce our patent rights to protect our trade secrets or knowhow and to determine the scope and validity of the proprietary rights of others accordingly we may seek to settle some or all of our pending litigation particularly to manage risk over time settlement may include cross licensing of the patents that are the subject of the litigation as well as our other intellectual property and may involve monetary payments to or from third parties we maintain insurance policies providing limited coverage against securities claims and we are substantially selfinsured with respect to product liability claims and fully selfinsured with respect to intellectual property infringement claims the absence of significant thirdparty insurance coverage increases our potential exposure to unanticipated claims or adverse decisions see item 3 and note k  commitments and contingencies to our 2016 consolidated financial statements included in item 8 of this annual report for a discussion of intellectual property product liability and other litigation and proceedings in which we are involved  13employeesas of december 31 2016 we had approximately 27000 employees including approximately 13000 in operations 9000 in selling marketing and distribution 4000 in clinical regulatory and research and development and 3000 in administration of these employees we employed approximately 14000 outside the us approximately 8000 of whom are in the manufacturing operations functioncommunity outreachwe are committed to advancing science to transform the lives of others and the communities we all call home we bring this commitment to life by supporting local regional and global health and education initiatives striving to improve patient advocacy adhering to strong ethical standards that deliver on our commitments and minimizing our impact on the environment we know that the world can be transformed when we apply the forces of compassion and the spirit of possibility to make a difference in communities today and in the future when people have greater access to healthcare and health information and when children are given the opportunity to achieve academically communities become healthy and vibrant for example by working with project hope health opportunities for people everywhere in 2016 thousands of people in the ranchi district in india and in rural johannesburg south africa were screened for chronic diseases such as diabetes and hypertension not only were people informed about their health risks and educated about prevention but new screening protocols were implemented and healthcare workers were trained to provide services well into the future our focus on the next generation of innovators is evident in the over 150 science technology engineering and math stem events and school programs we collaborated on with others to support the evercurious minds of young learners around the world last year more than 3000 employee volunteers dedicated their time and talent to make a positive impact at more than 350 global community events in 21 countriesthrough the boston scientific foundation more than 40 nonprofit organizations across the us received nearly a million dollars in grant awards in 2016 these community grants are targeted to benefit disadvantaged populations by investing in programs that increase access to quality healthcare and improve educational opportunities particularly related to stem education in addition the foundation also provides scholarships to collegebound students of us based boston scientific employeesseasonalityour worldwide sales do not reflect any significant degree of seasonality however customer purchases have historically been lower in the third quarter of the year as compared to other quarters this reflects among other factors lower demand during summer months in the northern hemisphere particularly in european countriesavailable information copies of our annual report on form 10k quarterly reports on form 10q current reports on form 8k and amendments to those reports filed or furnished pursuant to section 13a or 15d of the securities exchange act of 1934 as amended the exchange act are available free of charge on our website wwwbostonscientificcom as soon as reasonably practicable after we electronically file the material with or furnish it to the us sec printed copies of these posted materials are also available free of charge to stockholders who request them in writing from investor relations 300 boston scientific way marlborough ma 017521234 information on our website or linked to our website is not incorporated by reference into this annual reportsafe harbor for forwardlooking statementscertain statements that we may make from time to time including statements contained in this annual report and information incorporated by reference into this annual report constitute forwardlooking statements within the meaning of section 27a of the securities act of 1933 as amended the securities act and section 21e of the securities exchange act of 1934 as amended the exchange act forwardlooking statements may be identified by words like anticipate expect project believe plan may estimate intend and similar words these forwardlooking statements are based on our beliefs assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance if our underlying assumptions turn out to be incorrect or if certain risks or uncertainties materialize actual results could vary materially from the expectations and projections expressed or implied by our forwardlooking statements as a result readers are cautioned not to place undue reliance on any of our forwardlooking statements except as required by law we do not intend to update any forwardlooking statements even if new information becomes available or other events occur in the future 14the forwardlooking statements in this annual report are based on certain risks and uncertainties including the risk factors described in item 1a under the heading risk factors and the specific risk factors discussed below and in connection with forwardlooking statements throughout this annual report which could cause actual results to vary materially from the expectations and projections expressed or implied by our forwardlooking statements these factors in some cases have affected and in the future could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the forwardlooking statements these additional factors include among other things future political economic competitive reimbursement and regulatory conditions new product introductions demographic trends intellectual property litigation and governmental investigations financial market conditions and future business decisions made by us and our competitors all of which are difficult or impossible to predict accurately and many of which are beyond our control we caution each reader of this annual report to consider carefully these factors the following are some of the important risk factors that could cause our actual results to differ materially from our expectations in any forwardlooking statements for further discussion of these and other risk factors see item 1a  risk factors our businesses our ability to increase net sales expand the market and capture market sharethe volatility of the coronary stent market and our ability to increase our drugeluting stent systems net sales including with respect to our synergy promus premier and promus element stent systems and capture market sharethe ongoing impact on our business of physician alignment to hospitals governmental investigations and audits of hospitals and other market and economic conditions on the overall number of procedures performedcompetitive offerings and related declines in average selling prices for our products particularly our drugeluting coronary stent systems and our crm productsthe performance of and physician and patient confidence in our products and technologies or those of our competitorsthe impact and outcome of ongoing and future clinical trials and market studies undertaken by us our competitors or other third parties or perceived product performance of our or our competitors products variations in clinical results reliability or product performance of our and our competitors products our ability to acquire or develop launch and supply new or nextgeneration products and technologies worldwide and across our businesses in line with our commercialization strategies in a timely and successful manner including our sicd system and the acquisition and integration of neovasc inc endochoice holdings inc the resectr tissue resection device from distal access llc the lumenr tissue retractor system from lumenr llc cosman medical inc the interventional radiology portfolio of celonova biosciences the american medical systems male urology portfolio and xlumena incthe effect of consolidation and competition in the markets in which we do business or plan to do businessdisruption in the manufacture or supply of certain components materials or products or the failure to secure alternative manufacturing or additional or replacement components materials or products in a timely mannerour ability to retain and attract key personnelthe impact of enhanced requirements to obtain regulatory approval in the us and around the world including the associated timing and cost of product approval and the impact of increased pressure on the availability and rate of thirdparty reimbursement for our products and procedures in the us and around the world including with respect to the timing and costs of creating and expanding markets for new products and technologies 15regulatory compliance and litigationthe impact of healthcare policy changes and legislative or regulatory efforts in the us and around the world to modify product approval or reimbursement processes including a trend toward demonstrating clinical outcomes comparative effectiveness and cost efficiency as well as the impact of other healthcare reform legislationrisks associated with our regulatory compliance and quality systems and activities in the us and around the world including meeting regulatory standards applicable to manufacturing and quality processesour ability to minimize or avoid future field actions or fda warning letters relating to our products and processes and the ongoing inherent risk of potential physician advisories related to medical devicesthe impact of increased scrutiny of and heightened global regulatory enforcement facing the medical device industry arising from political and regulatory changes economic pressures or otherwise including under us antikickback statute us false claims act and similar laws in other jurisdictions us foreign corrupt practices act fcpa andor similar laws in other jurisdictions and us and foreign export control trade embargo and custom lawscosts and risks associated with litigationthe effect of our litigation and risk management practices including selfinsurance and compliance activities on our loss contingencies legal provision and cash flows the impact of diversion of management attention as a result of and costs to cooperate with litigate andor resolve governmental investigations and our class action product liability contract and other legal proceedings andrisks associated with a failure to protect our intellectual property rights and the outcome of patent litigationinnovation and certain growth initiativesthe timing size and nature of our strategic growth initiatives and market opportunities including with respect to our internal research and development platforms and externally available research and development platforms and technologies and the ultimate cost and success of those initiatives and opportunitiesour ability to complete planned clinical trials successfully obtain regulatory approvals and launch new and next generation products in a timely manner consistent with cost estimates including the successful completion of inprocess projects from inprocess research and developmentour ability to identify and prioritize our internal research and development project portfolio and our external investment portfolio on profitable revenue growth opportunities as well as to keep them in line with the estimated timing and costs of such projects and expected revenue levels for the resulting products and technologiesour ability to develop manufacture and market new products and technologies in a timely and successful manner and the ability of our competitors and other third parties to develop products or technologies that render our products or technologies noncompetitive or obsolete the impact of our failure to succeed at our decision to discontinue writedown or reduce the funding of any of our research and development projects including inprocess projects from inprocess research and development in our growth adjacencies or otherwisedependence on acquisitions alliances or investments to introduce new products or technologies and to enter new or adjacent growth markets and our ability to fund them or to fund contingent payments with respect to those acquisitions alliances and investments andthe failure to successfully integrate and realize the expected benefits from the strategic acquisitions alliances and investments we have consummated or may consummate in the future 16international marketsour dependency on international net sales to achieve growth including in emerging marketsthe impact of changes in our international structure and leadershiprisks associated with international operations and investments including the timing and collectability of customer payments political and economic conditions protection of our intellectual property compliance with established and developing us and foreign legal and regulatory requirements including fcpa and similar laws in other jurisdictions and us and foreign export control trade embargo and custom laws as well as changes in reimbursement practices and policiesour ability to maintain or expand our worldwide market positions in the various markets in which we compete or seek to compete including through investments in product diversification and emerging markets such as brazil russia india and chinaour ability to execute and realize anticipated benefits from our investments in emerging markets andthe potential effect of foreign currency fluctuations and interest rate fluctuations on our net sales expenses and resulting marginsliquidityour ability to generate sufficient cash flow to fund operations capital expenditures global expansion initiatives any litigation settlements and judgments share repurchases and strategic investments and acquisitions as well as maintaining our investment grade ratings and managing our debt levels and covenant complianceour ability to access the public and private capital markets when desired and to issue debt or equity securities on terms reasonably acceptable to usthe unfavorable resolution of open tax matters exposure to additional tax liabilities and the impact of changes in us and international tax lawsthe impact of examinations and assessments by domestic and international taxing authorities on our tax provision financial condition or results of operations andour ability to collect outstanding and future receivables andor sell receivables under our factoring programscost reduction and optimization initiativesrisks associated with significant changes made or expected to be made to our organizational and operational structure pursuant to our 2016 restructuring plan as well as any further restructuring or optimization plans we may undertake in the future and our ability to recognize benefits and cost reductions from such programs andbusiness disruption and employee distraction as we execute our global compliance program restructuring and optimization plans and divestitures of assets or businesses and implement our other strategic and cost reduction initiatives 17item 1a risk factorsin addition to the other information contained in this annual report and the exhibits hereto the following risk factors should be considered carefully in evaluating our business our business financial condition cash flows or results of operations could be materially adversely affected by any of these risks this section contains forwardlooking statements you should refer to the explanation of the qualifications and limitations on forwardlooking statements set forth at the end of item 1 of this annual report additional risks not presently known to us or that we currently deem immaterial may also adversely affect our business financial condition cash flows or results of operationswe face intense competition and may not be able to keep pace with the rapid technological changes in the medical devices industry which could have an adverse effect on our business financial condition or results of operationsthe medical device markets in which we primarily participate are highly competitive we encounter significant competition across our product lines and in each market in which our products are sold from various medical device companies some of which may have greater financial and marketing resources than we do including as a result of consolidation among our competitors in the healthcare industry our primary competitors include abbott laboratories medtronic plc and cook medical as well as a wide range of medical device companies that sell a single or limited number of competitive products or which participate in only a specific market segment we also face competition from nonmedical device companies including pharmaceutical companies which may offer alternative therapies for disease states intended to be treated using our productsadditionally the medical device markets in which we primarily participate are characterized by extensive research and development and rapid technological change developments by other companies of new or improved products processes or technologies may make our products or proposed products obsolete or less competitive and may negatively impact our net sales we are required to devote continued efforts and financial resources to develop or acquire scientifically advanced technologies and products apply our technologies costeffectively across product lines and markets obtain patent and other protection for our technologies and products obtain required regulatory and reimbursement approvals and successfully manufacture and market our products consistent with our quality standards if we fail to develop or acquire new products or enhance existing products it could have a material adverse effect on our business financial condition or results of operations in addition a delay in the timing of the launch of nextgeneration products and the overall performance of and continued physician confidence in those products may result in declines in our market share and have an adverse impact on our business financial condition or results of operationswe may experience declines in market size average selling prices for our products medical procedure volumes and our share of the markets in which we compete which may materially adversely affect our results of operations and financial condition we continue to experience pressures across many of our businesses due to competitive activity increased market power of our customers as the healthcare industry consolidates economic pressures experienced by our customers and the impact of managed care organizations and other thirdparty payers these and other factors may adversely impact market sizes as well as our share of the markets in which we compete the average selling prices for our products or medical procedure volumes there can be no assurance that the size of the markets in which we compete will increase above existing levels that we will be able to regain or gain market share or compete effectively on the basis of price or that the number of procedures in which our products are used will increase above existing levels decreases in market sizes or our market share and declines in average selling prices or procedural volumes could materially adversely affect our results of operations or financial conditioncontinued consolidation in the healthcare industry or additional governmental controls exerted over pricing in key marketscould lead to increased demands for price concessions or limit or eliminate our ability to sell to certain of our significant market segments which could have an adverse effect on our business financial condition or results of operationsnumerous initiatives and reforms by legislators regulators and thirdparty payers to curb the rising cost of healthcare have catalyzed a consolidation of aggregate purchasing power as the healthcare industry consolidates competition to provide products and services is expected to continue to intensify resulting in pricing pressures decreased average selling prices and the exclusion of certain suppliers from important market segments we expect that market demand government regulation thirdparty coverage and reimbursement policies government contracting requirements and societal pressures will continue to change the worldwide healthcare industry resulting in further business consolidations and alliances among our customers which may increase competition exert further downward pressure on the prices of our products and services and may adversely impact our business financial condition or results of operations 18healthcare cost containment pressures government payment and delivery system reforms changes in private payer policies and marketplace consolidations could decrease the demand for our products the prices which customers are willing to pay for those products and the number of procedures performed using our devices which could have an adverse effect on our business financial condition or results of operations our products are purchased principally by hospitals physicians and other healthcare providers around the world that typically bill various thirdparty payers including governmental programs eg medicare and medicaid in the united states and private health plans for the healthcare services provided to their patients governments and payers may also institute changes in health care delivery systems that may reduce funding for services or encourage greater scrutiny of health care costs the ability of customers to obtain appropriate reimbursement for their products and services from private and governmental thirdparty payers is critical to the success of medical technology companies because it affects which products customers purchase and the prices they are willing to pay reimbursement varies by country and can significantly impact the acceptance of new products and technologies even if we develop a promising new product we may find limited demand for the product unless reimbursement approval is obtained from private and governmental thirdparty payers further legislative or administrative reforms to the reimbursement systems in the united states japan or other countries in a manner that significantly reduces reimbursement for procedures using our medical devices or denies coverage for those procedures including price regulation competitive bidding and tendering coverage and payment policies comparative effectiveness of therapies heightened clinical data requirements technology assessments and managedcare arrangements could have a material adverse effect on our business financial condition or results of operationswe are subject to a number of market business financial legal and regulatory risks and uncertainties with respect to our international operations that could have a material impact on our business financial condition or results of operations international net sales accounted for approximately 43 percent of our global net sales in 2016 with sales from emerging markets accounting for approximately 10 percent an important part of our growth strategy is to continue pursuing growth opportunities in net sales and market share outside of the us by expanding global presence including in emerging markets our international operations are subject to a number of market business and financial risks and uncertainties including those related to political and economic instability foreign currency exchange and interest rate fluctuations competitive product offerings local changes in health care financing and payment systems and health care delivery systems local product preferences and requirements including preferences for local manufacturers workforce instability less intellectual property protection in certain countries than exists in the united states and in certain foreign countries longer accounts receivable cycles such risks and uncertainties may adversely impact our ability to implement our growth strategy in these markets and as a result our sales growth market share and operating profits from our international operations may be adversely affected our international operations are subject to established and developing legal and regulatory requirements for medical devices in each country in which our products are marketed and sold most foreign countries have medical device regulations further most countries outside of the us require product approvals be renewed or recertified on a regular basis in order to continue to be marketed and sold there in addition several countries that previously did not have regulatory requirements for medical devices have established such requirements in recent years and other countries have expanded or plan to expand on existing regulations including requiring local clinical data in addition to global clinical data these factors have caused or may cause us to experience more uncertainty risk expense and delay in commercializing products in certain foreign jurisdictions which could affect our ability to obtain approvals for our products in those jurisdictions and adversely impact our net sales market share and operating profits from our international operationsfurther international markets are affected by economic pressure to contain healthcare costs which can lead to more rigorous evidence requirements and lower reimbursement rates for either our products directly or procedures in which our products are used governments and payers may also institute changes in health care delivery systems that may reduce funding for services or encourage greater scrutiny of health care costs in addition certain international markets may also be affected by foreign government efforts to reference reimbursement rates in other countries all of these types of changes may ultimately reduce selling prices of our products or reduce the number of procedures in which our products are used which may adversely impact our net sales market share and operating profits from our international operationsin addition our international operations are subject to other established and developing us and foreign legal and regulatory requirements including the us foreign corrupt practices act fcpa andor similar laws in other countries and us and foreign import and export controls and licensing requirements trade protection and embargo measures and customs laws global businesses including those in the medical device industry are facing increasing scrutiny of and heightened enforcement efforts with respect to their international operations any alleged or actual failure to comply with legal and regulatory requirements may subject us to government scrutiny civil andor criminal proceedings sanctions and other liabilities which may have a material adverse effect on our international operations financial condition results of operations andor liquidity  19following a referendum in june 2016 in which voters in the united kingdom uk approved an exit from the eu the uk government is expected to initiate a process to withdraw from the eu often referred to as brexit and begin negotiating the terms of the uks future relationship with the eu a withdrawal could among other outcomes result in the deterioration of economic conditions volatility in currency exchange rates and increased regulatory complexities these outcomes may adversely affect our business financial condition or results of operations any significant changes in the political and economic financial competitive legal and regulatory or reimbursement conditions where we conduct or plan to expand our international operations may have a material impact on our business financial condition or results of operations if we are unable to manage our debt levels maintain investment grade credit ratings at the three ratings agencies or experience a disruption in our cash flows it could have an adverse effect on our cost of borrowing financial condition or results of operationsas part of our strategy to maximize stockholder value we use financial leverage to reduce our cost of capital our outstanding debt balance was 5484 billion as of december 31 2016 and 5677 billion as of december 31 2015 although we currently have investment grade ratings at moodys investor service standard amp poors rating service and fitch ratings our inability to maintain investment grade credit ratings could increase our cost of borrowing funds in the future delays in our product development and new product launches disruption in our cash flow or our ability to continue to effectively manage our debt levels could have an adverse effect on our cost of borrowing financial condition or results of operations in addition our credit and security facilities contain covenants that require us to maintain specified financial ratios and place other limits on our business if we are unable to satisfy these covenants we may be required to obtain waivers from our lenders and no assurance can be made that our lenders would grant such waivers on favorable terms or at all and we could be required to repay any borrowings on demandwe may record future goodwill impairment charges or other asset impairment charges related to one or more of our global reporting units which could materially adversely impact our results of operationswe test our goodwill balances during the second quarter of each year for impairment or more frequently if indicators are present or changes in circumstances suggest that impairment may exist we assess goodwill for impairment at the reporting unit level and in evaluating the potential for impairment of goodwill we make assumptions regarding estimated revenue projections growth rates cash flows and discount rates in the second quarter of 2016 we performed our annual goodwill impairment test for all of our reporting units in conjunction with our annual test the fair value of each reporting unit exceeded its carrying value therefore it was deemed not necessary to proceed to the second step of the impairment test refer to critical accounting policies and estimates within our managements discussion and analysis of financial condition and results of operations contained in item 7 of this annual report on form 10k for a discussion of key assumptions used in our testingon a quarterly basis we monitor the key drivers of fair value to detect events or other changes that would warrant an interim impairment test of our goodwill and intangible assets relatively small declines in the future performance and cash flows of a reporting unit or asset group changes in our reporting units or in the structure of our business as a result of future reorganizations acquisitions or divestitures of assets or businesses or small changes in other key assumptions may result in the recognition of significant asset impairment charges which could have a material adverse impact on our results of operationsfailure to integrate acquired businesses into our operations successfully could adversely affect our business financial condition and operating resultsas part of our strategy to realign our business portfolio we completed several acquisitions in 2016 2015 and 2014 and may pursue additional acquisitions in the future our integration of acquired businesses requires significant efforts including corporate restructuring the coordination of information technologies research and development sales and marketing operations regulatory supply chain manufacturing quality systems and finance these efforts result in additional expenses and involve significant management time some of the factors that could affect the success of our acquisitions include among others the effectiveness of our due diligence process our ability to execute our business plan for the acquired companies the strength of the acquired technology results of clinical trials regulatory approvals and reimbursement levels of the acquired products and related procedures the continued performance of critical transition services our ability to adequately fund acquired inprocess research and development projects and retain key employees and our ability to achieve synergies with our acquired companies such as increasing sales of our products achieving cost savings and effectively combining technologies to develop new products in addition foreign acquisitions involve unique risks including those related to integration of operations across different geographies cultures and languages currency risks and risks associated with the economic political legal and regulatory environment in specific countries our failure to manage successfully and coordinate the growth of the acquired companies could have an adverse impact on our business and our future growth in addition we cannot be certain that the businesses we acquire will become profitable or remain  20so and if our acquisitions are not successful we may record related asset impairment charges in the future or experience other negative consequences on our resultswe may not be successful in our strategy relating to future strategic acquisitions of investments in or alliances with other companies and businesses which have been a significant source of historical growth for us and will be key to our diversification into new markets and technologiesour strategic acquisitions investments and alliances are intended to further expand our ability to offer customers effective high quality medical devices that satisfy their interventional needs these acquisitions investments and alliances have been a significant source of our growth if we are unsuccessful in our acquisitions investments and alliances we may be unable to grow our business the success of our strategy relating to future acquisitions investments or alliances will depend on a number of factors includingour ability to identify suitable opportunities for acquisition investment or alliance if at allthe ability of our due diligence process to uncover potential issues with target companiesour ability to finance any future acquisition investment or alliance on terms acceptable to us if at allwhether we are able to complete acquisitions investments or alliances in a timely manner on terms that are satisfactory to us if at all our ability to successfully integrate and operate acquired businessesour ability to successfully identify and retain key target employeesour ability to comply with applicable laws and regulations including foreign laws and regulations andintellectual property and litigation related to newly acquired technologies any potential future acquisitions we consummate may be dilutive to our earnings and may require additional debt or equity financing depending on their size or naturewe may not realize the expected benefits from our restructuring and optimization initiatives our longterm expense reduction programs may result in an increase in shortterm expense and our efforts may lead to unintended consequences we monitor the dynamics of the economy the healthcare industry and the markets in which we compete and assess opportunities for improved operational effectiveness and efficiency and to better align expenses with revenues while preserving our ability to make investments in research and development projects capital and our people that we believe are important to our longterm success as a result of these assessments we have undertaken restructuring and optimization initiatives in order to enhance our growth potential and position us for longterm success for example in june 2016 we announced a restructuring initiative the 2016 restructuring plan intended to develop global commercialization technology and manufacturing capabilities in key growth markets build on our plant network optimization pno strategy which is intended to simplify our manufacturing plant structure by transferring certain production lines among facilities and expand operational efficiencies in support of our operating income margin goals key activities under the 2016 restructuring plan include strengthening global infrastructure through evolving global real estate and workplaces developing global commercial and technical competencies enhancing manufacturing and distribution expertise in certain regions and continuing implementation of our pno strategy activities under the plan were initiated in the second quarter of 2016 and are expected to be substantially completed by the end of 2018 the 2016 restructuring plan is expected to result in total pretax charges of approximately 175 million to 225 million and reduce gross annual expenses by approximately 115 million to 150 million by the end of 2020 as program benefits are realized we expect a substantial portion of the savings to be reinvested in strategic growth initiatives expense reduction initiatives under the plan include various cost and efficiency improvement measures which may include movement of business activities facility consolidations and closures and the transfer of product lines between manufacturing facilities which due to the highly regulated nature of our industry requires a significant investment in time and cost to create duplicate manufacturing lines run product validations and seek regulatory approvals these measures could yield unintended consequences such as distraction of our management and employees business disruption inability to attract or retain key personnel and reduced employee productivity which could negatively affect our business sales financial condition and results of operations moreover our restructuring and optimization initiatives result in charges and expenses that impact our operating results we cannot guarantee that the activities under the 2016 restructuring plan or other optimization initiatives will result in the desired efficiencies and estimated cost savings 21current domestic and international economic conditions could adversely affect our cash flows and results of operations uncertainty about global economic conditions including as a result of credit and sovereign debt issues has caused and may continue to cause disruption in the financial markets including diminished liquidity and credit availability these conditions may adversely affect our suppliers leading them to experience financial difficulties or to be unable to borrow money to fund their operations which could cause disruptions in our ability to produce our products our customers may experience financial difficulties or be unable to borrow money to fund their operations which may adversely impact their ability or decision to purchase our products particularly capital equipment or to pay for our products they do purchase on a timely basis if at all in addition we have accounts receivable factoring programs in certain european countries continued deterioration of the global economy or increase in sovereign debt issues may impact our ability to transfer receivables to third parties in certain of those countries in the future third parties such as banks offering factoring programs in these countries are looking to reduce their exposure levels to government owned or supported debt this could result in terminations of or changes to the costs or credit limits of our existing factoring programs such terminations or changes could have a negative impact on our cash flow and days sales outstandingthe strength and timing of economic recovery remains uncertain and there can be no assurance that there will not be further deterioration in the global economy accordingly we cannot predict to what extent global economic conditions including sovereign debt issues and increased focus on healthcare systems and costs in the us and abroad may continue to negatively impact our average selling prices net sales and profit margins procedural volumes and reimbursement rates from third party payers in addition conditions in the financial markets and other factors beyond our control may adversely affect our ability to borrow money in the credit markets access the capital markets and to obtain financing for acquisitions or other general corporate and commercial purposeshealthcare policy changes including healthcare reform legislation may have a material adverse effect on our business financial condition results of operations and cash flowspolitical economic and policy influences are leading the healthcare industry to make substantial structural and financial changes that will continue affecting our results of operations government and private sector initiatives limiting the growth of healthcare costs including price regulation coverage and payment policies comparative effectiveness of therapies technology assessments and healthcare delivery structure reforms are continuing in many countries where we do business we believe that these changes are causing the marketplace to put increased emphasis on the delivery of more treatments that can reduce costs improve efficiencies andor increase patient access although we believe our lessinvasive products and technologies generate favorable clinical outcomes value and cost efficiency the resources necessary and evidence necessary to demonstrate value to our customers patients payers and other stakeholders may be significant and it may take a longer period of time to gain widespread adoption moreover there can be no assurance that our strategies will succeed for every productthe patient protection and affordable care act and health care and education affordability reconciliation act of 2010 were enacted into law in the us in march 2010 as a us headquartered company with significant sales in the united states the medical device tax included in this law has materially affected us the law imposed on medical device manufacturers a 23 percent excise tax on us sales of class i ii and iii medical devices beginning in january 2013 under the current administration there may be a permanent repeal or an alteration of some or all elements of the aca but at this time it is not definite that a change will be enacted or what new healthcare provisions may be implemented while the implementation of the medical device tax has been suspended until december 31 2017 the status of the tax for sales after december 31 2017 is not clear the tax may continue to be suspended or may be reinstated at the same or at a different level other provisions of this law including comparative effectiveness research pilot programs to evaluate alternative payment methodologies and other changes to the payment systems could meaningfully change the way healthcare is developed and delivered and may adversely affect our business and results of operationswe cannot predict the specific healthcare programs and regulations that will be ultimately implemented by regional and national governments globally however any changes that lower reimbursements for either our products andor procedures using our products reduce medical procedure volumes or increase cost containment pressures on us or others in the healthcare sector could adversely affect our business and results of operations 22we are subject to extensive and dynamic medical device regulation which may impede or hinder the approval or sale of our products and in some cases may ultimately result in an inability to obtain approval of certain products or may result in the recall or seizure of previously approved products our products marketing sales and development activities and manufacturing processes are subject to extensive and rigorous regulation by the fda pursuant to the federal food drug and cosmetic act fdc act by comparable agencies in foreign countries and by other regulatory agencies and governing bodies under the fdc act medical devices must receive fda clearance or approval or an exemption from such clearance or approval before they can be commercially marketed in the us in the european union we are required to comply with applicable medical device directives including the medical devices directive and the active implantable medical devices directive and obtain ce mark certification in order to market medical devices the ce mark is applied following approval from an independent notified body or declaration of conformity the process of obtaining marketing approval or clearance from the fda or by comparable agencies in foreign countries for new products or with respect to enhancements or modifications to existing products couldtake a significant period of timerequire the expenditure of substantial resourcesinvolve rigorous preclinical and clinical testing as well as increased postmarket surveillancerequire changes to products andresult in limitations on the indicated uses of products in addition exported devices are subject to the regulatory requirements of each country to which the device is exported some countries do not have medical device regulations but in most foreign countries medical devices are regulated frequently regulatory approval may first be obtained in a foreign country prior to application in the us due to differing regulatory requirements however other countries such as china for example require approval in the country of origin or legal manufacturer first most countries outside of the us require that product approvals be renewed or recertified on a regular basis generally every four to five years the renewal or recertification process requires that we evaluate any device changes and any new regulations or standards relevant to the device and conduct appropriate testing to document continued compliance where renewal or recertification applications are required they may need to be renewed andor approved in order to continue selling our products in those countries there can be no assurance that we will receive the required approvals for new products or modifications to existing products on a timely basis or that any approval will not be subsequently withdrawn or conditioned upon extensive postmarket study requirementsour global regulatory environment is becoming increasingly stringent and unpredictable which could increase the time cost and complexity of obtaining regulatory approvals for our products as well as the clinical and regulatory costs of supporting those approvals several countries that did not have regulatory requirements for medical devices have established such requirements in recent years and other countries have expanded on existing regulations certain regulators are exhibiting less flexibility and are requiring local preclinical and clinical data in addition to global data while harmonization of global regulations has been pursued requirements continue to differ significantly among countries we expect this global regulatory environment will continue to evolve which could impact our ability to obtain future approvals for our products or could increase the cost and time to obtain such approvals in the future the european union regulatory bodies will finalize a new medical device regulation mdr in 2017 which will replace the existing directives and will provide three years for transition and compliance the mdr will change several aspects of the existing regulatory framework such as clinical data requirements and introduce new ones such as unique device identification udi we and the notified bodies who will oversee compliance to the new mdr face uncertainties as the mdr is rolled out and enforced by the commission and eea competent authorities creating risks in several areas including the ce marking process and data transparency in the upcoming yearsthe fda and other worldwide regulatory agencies actively monitor compliance with local laws and regulations through review and inspection of design and manufacturing practices recordkeeping reporting of adverse events labeling and promotional practices the fda can ban certain medical devices detain or seize adulterated or misbranded medical devices order repair replacement or refund of these devices and require notification of health professionals and others with regard to medical devices that present unreasonable risks of substantial harm to the public health the fda can take action against a company that promotes offlabel uses the fda may also enjoin and restrain a company for certain violations of the fdc act and other amending acts pertaining to medical devices or initiate action for criminal prosecution of such violations any adverse regulatory action depending  23on its magnitude may restrict a company from effectively marketing and selling its products may limit a companys ability to obtain future premarket clearances or approvals and could results in a substantial modification to the companys business practices and operations international sales of medical devices manufactured in the us that are not approved by the fda for use in the us or that are banned or deviate from lawful performance standards are subject to fda export requirements regulations regarding the development manufacture and sale of medical devices are evolving and subject to future change we cannot predict what impact if any those changes might have on our business failure to comply with regulatory requirements could have a material adverse effect on our business financial condition and results of operations later discovery of previously unknown problems with a product or manufacturer could result in fines delays or suspensions of regulatory clearances or approvals seizures or recalls of products physician advisories or other field actions operating restrictions andor criminal prosecution we may also initiate field actions as a result of a failure to strictly comply with our internal quality policies the failure to receive product approval clearance on a timely basis suspensions of regulatory clearances seizures or recalls of products physician advisories or other field actions or the withdrawal of product approval by the fda or by comparable agencies in foreign countries could have a material adverse effect on our business financial condition or results of operationsour products are continually subject to clinical trials conducted by us our competitors or other third parties the results of which may be unfavorable or perceived as unfavorable by the market and could have a material adverse effect on our business financial condition or results of operationsas a part of the regulatory process of obtaining marketing clearance for new products and new indications for existing products we conduct and participate in numerous clinical trials with a variety of study designs patient populations and trial endpoints unfavorable or inconsistent clinical data from existing or future clinical trials conducted by us by our competitors or by third parties or the fdas or the markets perception of this clinical data may adversely impact our ability to obtain product approvals our position in and share of the markets in which we participate and our business financial condition results of operations or future prospectsour future growth is dependent upon the development of new products and enhancement of existing products which requires significant research and development clinical trials and regulatory approvals all of which may be very expensive and timeconsuming and may not result in commercially viable productsin order to develop new products and enhance existing products we focus our research and development programs largely on the development of nextgeneration and novel technology offerings across multiple programs and businesses the development of new products and enhancement of existing products requires significant investment in research and development clinical trials and regulatory approvals the results of our product development efforts may be affected by a number of factors including our ability to anticipate customer needs innovate and develop new products complete clinical trials obtain regulatory approvals and reimbursement in the united states and abroad manufacture products in a costeffective manner obtain appropriate intellectual property protection for our products and gain and maintain market approval of our products there can be no assurance that any products now in development or that we may seek to develop in the future will achieve technological feasibility obtain regulatory approval or gain market acceptance if we are unable to develop and launch new products and enhanced products our ability to maintain or expand our market position in the markets in which we participate may be materially adversely impacted further we are continuing to investigate and have completed several acquisitions that involve opportunities to further expand our presence in and diversify into priority growth areas by accessing new products and technologies there can be no assurance that our investments will be successful or we will be able to access new products and technologies on terms favorable to us or that these products and technologies will achieve commercial feasibility obtain regulatory approval or gain market acceptance a delay in the development or approval of new products and technologies or our decision to reduce our investments may adversely impact the contribution of these technologies to our future growthadditionally certain products or groups of products in particular new products or enhancements of existing products may have a disproportionate impact on our business financial condition and results of operations failure to meet growth projections poor clinical outcomes increasing regulatory requirements launch delays and inability to effectively scale manufacturing and achieve targeted margins with respect to any of these products or groups of products in particular may materially adversely impact on our business financial condition and results of operations 24the medical device industry and its customers continue to face scrutiny and regulation by governmental authorities and are often the subject of numerous investigations often involving marketing and other business practices or product quality issues including device recalls or advisories these investigations could result in the commencement of civil and criminal proceedings imposition of substantial fines penalties and administrative remedies including corporate integrity agreements stipulated judgments or exclusion diversion of our employees and managements attention imposition of administrative costs and have an adverse effect on our financial condition results of operations and liquidity and may lead to greater governmental regulation in the future the medical devices we design develop manufacture and market are subject to rigorous regulation by the fda and numerous other federal state and foreign governmental authorities these authorities continue to highly scrutinize our industry we have received and in the future may receive subpoenas and other requests for information from congress and other state and federal governmental agencies including among others the us department of justice the office of inspector general of the department of health and human services hhs and the department of defense as well as from foreign governments and agencies the requests andor subpoenas we have received relate primarily to financial arrangements with healthcare providers regulatory compliance and sale andor product promotional practices we have cooperated with these subpoenas and other requests for information and expect to continue to do so in the future we cannot predict when a matter will be resolved the outcome of the matter or its impact on us and cooperation may involve significant costs including document production costs an adverse outcome in any matter could include the commencement of an investigation civil and criminal proceedings substantial fines penalties and administrative remedies including exclusion from government reimbursement programs entry into corporate integrity agreements cias with governmental agencies and amendments to any existing cias in addition resolution of any matter could involve the imposition of additional and costly compliance obligations for example in 2009 we entered into a civil settlement with the doj regarding the dojs investigation relating to certain postmarket surveys conducted by guidant corporation before we acquired guidant in 2006 as part of the settlement we entered into a 5year cia with the office of inspector general for hhs which required various provisions including enhancements to certain compliance procedures related to financial arrangements with healthcare providers cooperation with requests and investigations from external agencies result in employee resource costs and diversion of employee focus if any requests or investigations continue over a long period of time they could divert the attention of management from the daytoday operations of our business and impose significant additional administrative burdens on us these potential consequences as well as any adverse outcome from these requests or investigations could have a material adverse effect on our financial condition results of operations and liquidityin addition certain foreign governments state governments including that of massachusetts where we are headquartered and the us federal government have enacted legislation aimed at increasing transparency of our interactions with healthcare providers as an example compliance with the us physician payment sunshine act requires us by law to disclose payments and other transfers of value to all us physicians and us teaching hospitals at the us federal level made after august 1 2013 any failure to comply with these legal and regulatory requirements could impact our business in addition we have and may continue to devote substantial additional time and financial resources to further develop and implement enhanced structure policies systems and processes to comply with enhanced legal and regulatory requirements which may also impact our businesswe anticipate that governmental authorities will continue to scrutinize our industry closely and that additional regulation may increase compliance and legal cost and exposure to litigation and have additional adverse effects on our operationschanges in tax laws unfavorable resolution of tax contingencies or exposure to additional income tax liabilities could have a material impact on our financial condition results of operations andor liquiditywe are subject to income taxes as well as nonincome based taxes in both the us and various foreign jurisdictions we are subject to ongoing tax audits in various jurisdictions tax authorities may disagree with certain positions we have taken and assess additional taxes we regularly assess the likely outcomes of these audits in order to determine the appropriateness of our tax provision and have established contingency reserves for material known tax exposures however the calculation of such tax exposures involves the application of complex tax laws and regulations in many jurisdictions as well as interpretations as to the legality under european union state aid rules of tax advantages granted in certain jurisdictions therefore there can be no assurance that we will accurately predict the outcomes of these disputes or other tax audits or that issues raised by tax authorities will be resolved at a financial cost that does not exceed our related reserves and the actual outcomes of these disputes and other tax audits could have a material impact on our results of operations or financial conditionon july 19 2016 we entered into a stipulation of settled issues with the internal revenue service irs intended to resolve certain transfer pricing issues as well as certain issues related to our transaction with abbott for the 2001 through 2007 tax years the stipulation of settled issues is contingent upon irs office of appeals irs appeals applying the same basis of settlement to all transfer pricing issues for the companys 2008 2009 and 2010 tax years and if applicable review by the us congress joint committee on taxation in october 2016 we reached an agreement in principle with irs appeals as to the resolution of the  25transfer pricing issues in 2008 2009 and 2010 tax years subject to additional calculations of tax as well as documentation to memorialize our agreement the final resolution of these issues is contingent and if the stipulation of settled issues is not finalized it could have a material impact on our financial condition results of operations or cash flowsadditionally changes in tax laws could materially impact our effective tax rate for example proposals for fundamental us corporate tax reform if enacted could have a significant adverse impact on our future results of operations additionally the us congress government agencies in nonus jurisdictions where we and our affiliates do business and the organization for economic cooperation and development have recently focused on issues related to the taxation of multinational corporations one example is in the area of base erosion and profit shifting where profits are claimed to be earned for tax purposes in lowtax jurisdictions or payments are made between affiliates from a jurisdiction with high tax rates to a jurisdiction with lower tax rates the organization for economic cooperation and development has released several components of its comprehensive plan to create an agreed set of international rules for fighting base erosion and profit shifting as a result the tax laws in the us and other countries in which we and our affiliates do business could change on a prospective or retroactive basis and any such changes could materially adversely affect our businessour operations in puerto rico and costa rica presently benefit from various tax incentives and grants unless these incentives and grants are extended they will expire between 2023 and 2028 if we are unable to renew extend or obtain new incentive and grants the expiration of the existing incentives and grants could have a material impact on our financial results in future periodswe may not effectively be able to protect our intellectual property or other sensitive data which could have a material adverse effect on our business financial condition or results of operationsthe medical device market in which we primarily participate is largely technology driven physician customers have historically moved quickly to new products and new technologies as a result intellectual property rights particularly patents and trade secrets play a significant role in product development and differentiation however intellectual property litigation is inherently complex and unpredictable and appellate courts can overturn lower court decisions furthermore as our business increasingly relies on technology systems and infrastructure our intellectual property other proprietary technology and other sensitive data are potentially vulnerable to loss damage or misappropriation finally our ability to protect novel business models is uncertain competing parties in our industry frequently file multiple suits to leverage patent portfolios across product lines technologies and geographies and to balance risk and exposure between the parties in some cases several competitors are parties in the same proceeding or in a series of related proceedings or litigate multiple features of a single class of devices these forces frequently drive settlement not only of individual cases but also of a series of pending and potentially related and unrelated cases in addition although monetary and injunctive relief is typically sought remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal accordingly the outcomes of individual cases are difficult to time predict or quantify and are often dependent upon the outcomes of other cases in other geographiesa number of third parties have asserted that our current and former product offerings infringe patents owned or licensed by them we have similarly asserted that products sold by our competitors infringe patents owned or licensed by us adverse outcomes in one or more of the proceedings against us could limit our ability to sell certain products in certain jurisdictions or reduce our operating margin on the sale of these products and could have a material adverse effect on our financial condition results of operations or liquiditypatents and other proprietary rights are and will continue to be essential to our business and our ability to compete effectively with other companies will be dependent upon the proprietary nature of our technologies we rely upon trade secrets knowhow continuing technological innovations strategic alliances and licensing opportunities to develop maintain and strengthen our competitive position we pursue a policy of generally obtaining patent protection in both the us and abroad for patentable subject matter in our proprietary devices and attempt to review thirdparty patents and patent applications to the extent publicly available in order to develop an effective patent strategy avoid infringement of thirdparty patents identify licensing opportunities and monitor the patent claims of others we currently own numerous us and foreign patents and have numerous patent applications pending we also are party to various license agreements pursuant to which patent rights have been obtained or granted in consideration for cash crosslicensing rights or royalty payments no assurance can be made that any pending or future patent applications will result in the issuance of patents that any current or future patents issued to or licensed by us will not be challenged or circumvented by our competitors or that our patents will not be found invalid in addition we may have to take legal action in the future to protect our patents trade secrets or knowhow or to assert them against claimed infringement by others any legal action of that type could be costly and time consuming and no assurances can be made that any lawsuit will be successful we are generally involved as both a plaintiff and a defendant in a number of patent infringement and other intellectual propertyrelated actions the invalidation of key patents or proprietary rights that we own or an unsuccessful outcome in lawsuits to protect our intellectual property could have a material adverse effect on our business financial condition or results of operations 26in addition the laws of certain countries in which we market and plan on manufacturing some of our products in the near future do not protect our intellectual property rights to the same extent as the laws of the united states if we are unable to protect our intellectual property in these countries it could have a material adverse effect on our business financial condition or results of operationsfurthermore our intellectual property other proprietary technology and other sensitive data are potentially vulnerable to loss damage or misappropriation from system malfunction computer viruses unauthorized access to our data or misappropriation or misuse thereof by those with permitted access and other events while we have invested to protect our intellectual property and other data and continue to work diligently in this area there can be no assurance that our precautionary measures will prevent breakdowns breaches cyberattacks or other events such events could have a material adverse effect on our reputation business financial condition or results of operationswe rely on the proper function availability and security of information technology systems to operate our business and a cyberattack or other breach of these systems could have a material adverse effect on our business financial condition or results of operations we rely on information technology systems to process transmit and store electronic information in our daytoday operations similar to other large multinational companies the size and complexity of our information technology systems makes them vulnerable to a cyberattack malicious intrusion breakdown destruction loss of data privacy or other significant disruption our information systems require an ongoing commitment of significant resources to maintain protect and enhance existing systems and develop new systems to keep pace with continuing changes in information processing technology evolving systems and regulatory standards the increasing need to protect patient and customer information and changing customer patterns in addition third parties may attempt to hack into our products to obtain data relating to patients or disrupt performance of our products or to access our proprietary information any failure by us to maintain or protect our information technology systems and data integrity including from cyberattacks intrusions or other breaches could result in the unauthorized access to patient data and personally identifiable information theft of intellectual property or other misappropriation of assets or otherwise compromise our confidential or proprietary information and disrupt our operations in the us federal and state privacy and security laws require certain of our operations to protect the confidentiality of personal information including patient medical records and other health information in europe the data protection directive requires us to manage individually identifiable information in the eu and the new general data protection regulation may impose fines of up to four percent of our global revenue in the event of violations internationally some countries have also passed laws that require individually identifiable data on their citizens to be maintained on local servers and that may restrict transfer or processing of that data we believe that we meet the expectations of applicable regulations and that the ongoing costs and impacts of ensuring compliance with such rules are not material to our business however there is no guarantee that we will avoid enforcement actions by governmental bodies enforcement actions can be costly and interrupt regular operations of our business any of these events in turn may cause us to lose existing customers have difficulty preventing detecting and controlling fraud have disputes with customers physicians and other health care professionals be subject to legal claims and liability have regulatory sanctions or penalties imposed have increases in operating expenses incur expenses or lose revenues as a result of a data privacy breach or theft of intellectual property or suffer other adverse consequences any of which could have a material adverse effect on our business financial condition or results of operationspending and future intellectual property litigation could be costly and disruptive to uswe operate in an industry that is susceptible to significant intellectual property litigation and in recent years it has been common for companies in the medical device field to aggressively challenge the patent rights of other companies we are currently the subject of various patent litigation proceedings and other proceedings described in more detail under note k  commitments and contingencies to our 2016 consolidated financial statements included in item 8 of this annual report intellectual property litigation is expensive complex and lengthy and its outcome is difficult to predict adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins financial condition results of operation or liquidity pending or future patent litigation may result in significant royalty or other payments or injunctions that can prevent the sale of products and may significantly divert the attention of our technical and management personnel in the event that our right to market any of our products is successfully challenged we may be required to obtain a license on terms which may not be favorable to us if at all if we fail to obtain a required license or are unable to design around a patent our business financial condition or results of operations could be materially adversely affected 27pending and future product liability claims and other litigation including private securities litigation stockholder derivative suits and contract litigation may adversely affect our financial condition and results of operations or liquiditythe design manufacturing and marketing of medical devices of the types that we produce entail an inherent risk of product liability claims many of the medical devices that we manufacture and sell are designed to be implanted in the human body for long periods of time or indefinitely a number of factors could result in an unsafe condition or injury to or death of a patient with respect to these or other products that we manufacture or sell including physician technique and experience in performing the surgical procedure component failures manufacturing flaws design defects offlabel use or inadequate disclosure of productrelated risks or productrelated information these factors could result in product liability claims a recall of one or more of our products or a safety alert relating to one or more of our products product liability claims may be brought by individuals or by groups seeking to represent a classwe are currently the subject of product liability litigation proceedings and other proceedings described in more detail under note k  commitments and contingencies to our 2016 consolidated financial statements included in item 8 of this annual report the outcome of litigation particularly class action lawsuits is difficult to assess or quantify plaintiffs in these types of lawsuits often seek recovery of very large or indeterminate amounts including not only actual damages but also punitive damages the magnitude of the potential losses relating to these lawsuits may remain unknown for substantial periods of time in addition the cost to defend against any future litigation may be significant product liability claims securities and commercial litigation and other litigation in the future regardless of the outcome could have a material adverse effect on our financial condition results of operations or liquidity additionally we maintain an insurance policy providing limited coverage against securities claims and we are substantially selfinsured with respect to product liability claims and fully selfinsured with respect to intellectual property infringement claims the fact that we do not maintain thirdparty insurance coverage for all categories of losses increases our exposure to unanticipated claims and adverse decisions and these losses could have a material adverse effect on our financial condition results of operations or liquidityany failure to meet regulatory quality standards applicable to our manufacturing and quality processes could have an adverse effect on our business financial condition and results of operations as a medical device manufacturer we are required to register our establishments and list our devices with the fda and are subject to periodic inspection by the fda for compliance with its quality system regulation requirements which require manufacturers of medical devices to adhere to certain regulations including testing quality control and documentation procedures in addition the federal medical device reporting regulations require us to provide information to the fda whenever there is evidence that reasonably suggests that a device may have caused or contributed to a death or serious injury or if a malfunction were to occur could cause or contribute to a death or serious injury compliance with applicable regulatory requirements is subject to continual review and is monitored rigorously through periodic inspections by the fda which may result in observations on form 483 and in some cases warning letters that require corrective action in the european community we are required to maintain certain international standards organization iso certifications in order to sell our products and must undergo periodic inspections by notified bodies to obtain and maintain these certifications many other countries in which we do business have requirements similar to those of the us or the eu and other foreign governments or agencies may subject us to periodic inspections as well if we or our manufacturers fail to adhere to quality system regulations or iso requirements this could delay production of our products and lead to fines difficulties in obtaining regulatory clearances recalls enforcement actions including injunctive relief or consent decrees or other consequences which could in turn have a material adverse effect on our financial condition or results of operationsinterruption of our manufacturing operations could adversely affect our results of operations and financial condition our products are designed and manufactured in technology centers around the world either by us or third parties in most cases the manufacturing of our products is concentrated in one or a few locations factors such as a failure to follow specific internal protocols and procedures equipment malfunction environmental factors or damage to one or more of our facilities could adversely affect our ability to manufacture our products in the event of an interruption in manufacturing we may be unable to quickly move to alternate means of producing affected products or to meet customer demand in the event of a significant interruption for example as a result of a failure to follow regulatory protocols and procedures we may experience lengthy delays in resuming production of affected products due primarily to needs for regulatory approvals as a result we may experience loss of market share which we may be unable to recapture and harm to our reputation which could adversely affect our results of operations and financial conditiondisruptions in the supply of the materials and components used in manufacturing our products or the sterilization of our products by thirdparty vendors could adversely affect our results of operations and financial condition  28we purchase many of the materials and components used in manufacturing our products from thirdparty vendors certain of these materials and components are purchased from single sources due to quality considerations expertise costs or constraints resulting from regulatory requirements in certain cases we may not be able to establish additional or replacement vendors for such materials or components in a timely or cost effective manner largely as a result of fda regulations that require validation of materials and components prior to their use in our products and the complex nature of our and many of our vendors manufacturing processes a reduction or interruption in the supply of materials and components used in manufacturing our products an inability to timely develop and validate alternative sources if required or a significant increase in the price of such materials or components could adversely affect our results of operations and financial condition in addition many of our products require sterilization prior to sale and we utilize a mix of internal resources and contract sterilizers to perform this service to the extent we or our contract sterilizers are unable to sterilize our products whether due to capacity availability of materials for sterilization regulatory or other constraints we may be unable to transition to other contract sterilizer sterilizer locations or sterilization methods in a timely or cost effective manner or at all which could have an adverse impact on our results of operations and financial conditionour share price has been volatile and may fluctuate and accordingly the value of an investment in our common stock may also fluctuatestock markets in general and our common stock in particular have experienced significant price and volume volatility over recent years the market price and trading volume of our common stock may continue to be subject to significant fluctuations due to factors described under this item 1a entitled risk factors as well as economic and geopolitical conditions in general and also to variability in the prevailing sentiment regarding our operations or business prospects as well as among other things changing investment priorities of our stockholders because the market price of our common stock fluctuates significantly stockholders may not be able sell their shares at attractive prices if we are unable to attract or retain key personnel it could have an adverse effect on our business financial condition and results from operations  in our industry there is substantial competition for key personnel in the regions in which we operate and we may face increased competition for such employees particularly in emerging markets as the trend toward globalization continues our business depends to a significant extent on the continued service of senior management and other key personnel the development of additional management personnel and the hiring of new qualified employees there can be no assurance that we will be successful in retaining and developing existing personnel or recruiting new personnel the loss of one or more key employees our ability to attract or develop additional qualified employees or any delay in hiring key personnel could have material adverse effects on our business financial condition or results of operations 29item 1b unresolved staff commentsnoneitem 2 properties our world headquarters is located in marlborough massachusetts with regional headquarters located in singapore and voisinslebretonneux france as of december 31 2016 our principal manufacturing and technology centers were located in minnesota california and indiana within the us as well as internationally in ireland costa rica and puerto rico our products are distributed worldwide from customer fulfillment centers in massachusetts and the netherlands as of december 31 2016 we maintained 13 principal manufacturing facilities including seven in the us three in ireland two in costa rica and one in puerto rico as well as various distribution and technology centers around the world many of these facilities produce and manufacture products for more than one of our divisions and include research facilities the following is a summary of our facilities as of december 31 2016 in approximate square feet  owned  leased  totalus 4256000 1824000 6080000international 1522000 1483000 3005000  5778000 3307000 9085000 includes our principal manufacturing facilities in minnesota ireland puerto rico and one facility in costa rica our customer fulfillment centers in massachusetts the netherlands and japan and our global headquarters location in marlborough massachusetts includes our principal manufacturing facilities in california indiana and one facility in costa rica and our regional headquarters located in singapore and voisinslebretonneux francewe regularly evaluate the condition and capacity of our facilities to ensure they are suitable for the development manufacturing and marketing of our products and provide adequate capacity for current and expected future needs further our 2016 restructuring plan continues the implementation of our plant network optimization pno strategy which is intended to simplify our manufacturing plant structure by transferring certain productions lines among facilities refer to restructuring initiatives within results of operations included in item 7 of this annual report and note h  restructuringrelated activities to our 2016 consolidated financial statements included in item 8 of this annual reportitem 3 legal proceedingssee note k  commitments and contingencies to our 2016 consolidated financial statements included in item 8 of this annual report and incorporated herein by referenceitem 4 mine safety disclosuresnone 30part iiitem 5 market for registrants common equity related stockholder matters and issuer purchases of equity securitiesmarket informationour common stock is traded on the new york stock exchange nyse under the symbol bsx the following table provides the market range for the closing price of our common stock for each of the last eight quarters based on reported sales prices on the nyse2016 high lowfirst quarter 1882 1607second quarter 2337 1894third quarter 2448 2311fourth quarter 2377 2009     2015    first quarter 1807 1322second quarter 1851 1718third quarter 1802 1578fourth quarter 1894 1642holdersthe closing price of our common stock on january 31 2017 was 2406 as of january 31 2017 there were 9573 holders of record of our common stockdividendswe did not pay a cash dividend in 2016 or 2015 and currently we do not intend to pay cash dividends we may consider declaring and paying a cash dividend in the future however there can be no assurance that we will do sosecurities authorized for issuance under equity compensation plansplease see item 12 security ownership of certain beneficial owners and management and related stockholder matters under part iii of this annual report for information on where to find information required by item 201d of regulation skpurchases of equity securities by the issuer and affiliated purchaseson january 25 2013 our board of directors approved and on january 29 2013 we announced a program authorizing the repurchase of up to 10 billion of our common stock during 2014 we used 125 million of cash generated from operations to repurchase approximately 10 million shares of our common stock pursuant to our share repurchase authorizations discussed in note l  stockholders equity to our consolidated financial statements contained in item 8 of this annual report we made no share repurchases in 2016 or 2015 as of december 31 2016 we had approximately 535 million remaining available under the 2013 share repurchase program 31stock performance graphthe graph below compares the fiveyear total return to stockholders on our common stock with the return of the standard amp poors sampp 500 stock index and the sampp health care equipment index the graph assumes 100 was invested in our common stock and in each of the named indices on december 31 2011 and that all dividends were reinvestednote the stock price performance shown on the graph above is not indicative of future price performance this graph shall not be deemed filed for purposes of section 18 of the exchange act or otherwise subject to the liabilities of that section nor shall it be deemed incorporated by reference in any filing under the securities act or the exchange act regardless of any general incorporation language in such filing  32item 6  selected financial datafiveyear selected financial datain millions except per share dataoperating datayear ended december 31 2016 2015 2014 2013 2012net sales 8386 7477 7380 7143 7249gross profit 5962 5304 5170 4969 4900total operating expenses 5515 5631 5471 4849 8768operating income loss 447 327 301 120 3868income loss before income taxes 177 650 509 223 4107net income loss 347 239 119 121 4068net income loss per common share          basic 026 018 009 009 289assuming dilution 025 018 009 009 289balance sheet dataas of december 31 2016 2015 2014 2013 2012cash cash equivalents and marketable securities 196 319 587 217 207working capital 348 1041 760 1187 1250total assets 18096 18133 17024 16549 17136borrowings shortterm 64 3 403 3 4borrowings longterm 5420 5674 3841 4215 4234stockholders equity 6733 6320 6457 6539 6870book value per common share 494 469 486 495 507book value per common share is calculated using shares outstanding as of december 31 for each year respectively shownthe data above include certain charges credits recorded in conjunction with goodwill and other intangible asset impairments acquisitions divestitures restructuring and restructuringrelated activities debt extinguishment charges amortization pension termination charges discrete tax items andor litigation the data above should be read in conjunction with our consolidated financial statements including the notes thereto included in item 8 of this annual report as well as prior year form 10k filings  33item 7 managements discussion and analysis of financial condition and results of operationsthe following discussion and analysis provides information management believes to be relevant to understanding the financial condition and results of operations of boston scientific corporation and its subsidiaries for full understanding of financial condition and results of operations you should read this discussion along with our consolidated financial statements and accompanying notes included in item 8 of this annual reportexecutive summary financial highlights and trendsin 2016 we generated net sales of 8386 billion as compared to 7477 billion in 2015 an increase of 909 million or 12 percent our net sales were unfavorably impacted by 99 million from foreign currency fluctuations in 2016 as compared to 2015 excluding the impact of foreign currency exchange rates our net sales increased 1008 billion or 12 percent as compared to the prior year1 this increase included net sales of approximately 236 million in 2016 with no prior year period related net sales due to the ams portfolio acquisition and the endochoice holdings inc endochoice acquisition refer to the business and market overview section for further discussion of our net sales by global businessour reported net income in 2016 was 347 million or 025 per diluted share our reported results for 2016 included intangible asset impairment charges acquisitionrelated net charges restructuring and restructuringrelated net charges litigationrelated charges and amortization expense totaling 1187 billion aftertax or 086 per share excluding these items net income for 2016 was 1534 billion or 111 per share1our reported net loss in 2015 was 239 million or 018 per share our reported results for 2015 included intangible asset impairment charges acquisitionrelated net charges restructuring and restructuringrelated net charges litigationrelated charges pension termination charges debt extinguishment charges discrete tax items and amortization expense totaling 1506 billion aftertax or 111 per share excluding these items net income for 2015 was 1267 billion or 093 per share1 1 adjusted net sales growth rates which exclude the impact of changes in foreign currency exchange rates and adjusted net income and adjusted net income per share which exclude certain items required by generally accepted accounting principles in the united states us gaap are not prepared in accordance with us gaap refer to additional information for a discussion of managements use of these nongaap financial measures 34the following is a reconciliation of our results of operations prepared in accordance with us gaap to those adjusted results considered by management refer to results of operations for a discussion of each reconciling item  year ended december 31 2016     tax   impact per in millions except per share data pretax impact aftertax share gaap net income loss 177 170 347 025 nongaap adjustments         intangible asset impairment charges 11 1 10 001acquisitionrelated net charges 136 10 126 009restructuring and restructuringrelated net charges 78 17 61 004litigationrelated net charges 804 292 512 037amortization expense 545 67 478 035adjusted net income 1751 217 1534 111   year ended december 31 2015     tax   impact per in millions except per share data pretax impact aftertax share gaap net income loss 650 411 239 018 nongaap adjustments         intangible asset impairment charges 19 3 16 001acquisitionrelated net charges 255 33 222 017restructuring and restructuringrelated net charges 83 14 69 005litigationrelated net charges 1105 400 705 052pension termination charges 44 16 28 002debt extinguishment charges 45 16 29 002discrete tax items  9 9 001amortization expense 495 49 446 033adjusted net income 1396 129 1267 093 assumes dilution of 215 million shares for 2015 for all or a portion of these nongaap adjustmentscash provided by operating activities was 972 million in 2016 as compared to cash provided by operating activities of 600 million in 2015 this increase in cash provided by operating activities was primarily driven by the increase in net income for 2016 compared to 2015 our cash generated from operations continues to be a significant source of funds for investing in our growth including acquisitions and strategic alliances managing our contingencies and reducing our debt levelsas of december 31 2016 we had total debt of 5484 billion cash and cash equivalents of 196 million and a working capital deficit of 348 million we hold investmentgrade ratings with all three major creditrating agencies we believe our investment grade credit profile reflects the size and diversity of our product portfolio our leading share position in several of our served markets our strong cash flow our solid financial fundamentals and our financial strategy refer to liquidity and capital resources for further discussion  35business and market overviewcardiovascularinterventional cardiology our interventional cardiology division develops and manufactures technologies for diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions product offerings include coronary stents including drugeluting and bare metal stent systems balloon catheters rotational atherectomy systems guide wires guide catheters embolic protection devices crossing and reentry devices for the treatment of chronically occluded coronary vessels diagnostic catheters and intravascular ultrasound ivus imaging systems our structural heart product offerings include a device for transcatheter aortic valve replacement and a device designed to close the left atrial appendage in patients with atrial fibrillation that are at risk for ischemic strokeour worldwide net sales of interventional cardiology products were 2281 billion for 2016 or approximately 27 percent of our consolidated net sales for the year our worldwide net sales of interventional cardiology products increased 248 million or 12 percent in 2016 as compared to 2015 excluding the impact of changes in foreign currency exchange rates which had a 34 million negative impact on our interventional cardiology net sales in 2016 as compared to 2015 net sales of these products increased 282 million or 13 percent this yearoveryear increase was primarily related to sales of our drugeluting stents led by our ongoing global launch of the synergy stent our watchman device following the us commercial launch during the first quarter of 2015 and our lotus valve system in the eu along with operational growth in our pci guidance system product offeringsworldwide sales from our drugeluting coronary stents were 1199 billion during 2016 as compared to 1074 billion during 2015 representing a significant portion of our interventional cardiology net sales our drugeluting stent systems include our next generation synergy everolimuseluting platinum chromium coronary stent system and our promus premier everolimuseluting platinum chromium coronary stent system both of which are designed to provide physicians with improved drugeluting stent performance in treating patients with coronary artery disease synergy features an ultrathin abluminal outer bioabsorbable polymer coating while promus premier features a unique customized platinum chromium alloy stent architecture and an enhanced stent delivery system we received fda approval of the synergy stent technology and japanese regulatory approval in the fourth quarter of 2015our structural heart product offerings include our lotus valve system a device for transcatheter aortic valve replacement and our watchman device designed to close the left atrial appendage in patients with nonvalvular atrial fibrillation who are at risk for ischemic stroke the lotus valve system consists of a stentmounted tissue valve prosthesis and catheter delivery system for guidance and placement of the valve the original lotus valve system as well as our next generation lotus edge system are cemarked in the european union eu and in the us they are investigational devices and not commercially available in october 2016 we suspended our limited launch and initiated a voluntary removal of field inventory of the lotus edge system due to reports that in some cases the device could not be fully locked during the procedure due to premature release of a pin connecting the lotus edge valve to the delivery system in february 2017 we initiated a voluntary removal of all lotus valve devices including lotus with depth guard from global commercial and clinical sites due to reports of premature release of a pin connecting the lotus valve to the delivery system as with the prior announced suspension of our lotus edge valve system device we believe that the issue is caused by excess tension in the pin mechanism introduced during the manufacturing process we expect to bring the lotus valve platform back to market in europe and other regions in the fourth quarter of 2017 we anticipate filing the us pma submission for the lotus edge valve system the next generation platform in the fourth quarter of 2017 with a us launch planned for mid2018   the watchman left atrial appendage closure technology watchman is the first device studied in a randomized clinical trial to offer an alternative to warfarin and is marketed in cemark countries and other international countries as well as the us following fda approval in march 2015 we believe that watchman will be the only laac technology commercially available in the us for multiple years in november 2015 we received ce mark for our next generation device watchman flx shortly after approval we began a european initial market release of watchman flx the initial market release was suspended near the end of the first quarter of 2016 due to a higher than expected rate of device embolization following an extensive data evaluation we have decided to pursue potential design enhancements prior to returning a next generation device to marketon december 12 2016 we completed the acquisition of certain manufacturing assets and capabilities of the neovasc inc neovasc advanced biological tissue business and made a 15 percent equity investment in neovasc for a total upfront cash payment of 75  36million with this acquisition we will integrate certain manufacturing assets and biologic tissue capabilities into our structural heart business for use in the manufacturing of the lotus valve system and future heart valve technologies within our interventional cardiology business we expect this integration to be substantially completed by the end of 2018peripheral interventionsour peripheral interventions pi product offerings include stents balloon catheters wires peripheral embolization devices and other devices used to diagnose and treat peripheral vascular disease along with products to treat diagnose and ease various forms of cancerour worldwide net sales of pi products were 1011 billion for 2016 or approximately 12 percent of our consolidated net sales for the year our worldwide net sales of pi products increased 107 million or 12 percent in 2016 as compared to 2015 excluding the impact from changes in foreign currency exchange rates which had an 11 million negative impact on our worldwide pi net sales in 2016 as compared to 2015 net sales of these products increased 118 million or 12 percent this yearoveryear increase was primarily driven by revenues from our atherectomy and thrombectomy systems as well as growth in our core pi franchises particularly our stent franchise following fda approval and launch of our innova vascular selfexpanding stent system in the us and japan our interventional oncology franchise and our drugeluting product franchiseon december 31 2015 we completed the acquisition of the interventional radiology business of celonova biosciences celonova the acquisition includes drugeluting microspheres designed to be loaded with chemotherapy drugs for delivery to cancerous tumors and spherical embolic products used to treat uterine fibroids and other conditions we are in the process of integrating celonova into our peripheral interventions business and expect to be substantially complete by the second half of 2017 rhythm managementcardiac rhythm managementour cardiac rhythm management crm business develops manufactures and markets a variety of implantable devices including implantable cardioverter defibrillator icd systems and implantable cardiac resynchronization therapy defibrillators including the worlds first and only commercially available subcutaneous implantable cardioverter defibrillator the sicd system and pacemaker systems that monitor the heart and deliver electricity to treat cardiac abnormalities in addition in most geographies we monitor device performance remotely allowing for more frequent monitoring in order to guide treatment decisionsour worldwide net sales of crm products were 1850 billion for 2016 or approximately 22 percent of our consolidated net sales for the year our worldwide net sales of crm products increased 43 million or two percent in 2016 as compared to 2015 excluding the impact of changes in foreign currency exchange rates which had a 17 million negative impact on our crm net sales in 2016 as compared to 2015 net sales of these products increased 60 million or three percent this yearoveryear increase was primarily driven by strong global pacemaker growth including the us launch of the accolade family of magnetic resonance imaging mri safe pacemakers and the ingevity mri pacing lead in the us global growth from our quadripolar cardiac resynchronization therapy pacemakers crtp global sicd sales growth and benefits from our sales collaboration agreement with preventice solutions inc preventice in the us the fourth quarter of 2016 represented our second full quarter of us mri pacemaker commercialization the third quarter of commercialization for our acuity x4 quadripolar lv pacing lead in both the cardiac resynchronization therapy defibrillator crtd and crtp franchises and global commercialization of our emblem mri sicd system these combined launches more than offset lower volumes of replacement procedures for our defibrillators due to their extended longevity and pressure from competitor high voltage mri technologies primarily in the us on april 30 2015 we acquired a 27 percent ownership interest in preventice which includes 185 percent of preventices common stock preventice is a privatelyheld company headquartered in minneapolis mn and a leading developer of mobile health solutions and services in addition to the equity agreement we entered into a commercial agreement with preventice under which we became preventices exclusive worldwide sales and marketing representative in october 2016 we notified preventice of our intent to terminate the commercial agreement and will transition the sales force back to preventice in 2017 under the terms of the agreement 37the following are the components of our crm net sales  year endedin millions december 31 2016 december 31 2015defibrillator systems 1274 1313pacemaker systems 576 494crm products 1850 1807electrophysiologyour electrophysiology business develops lessinvasive medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart our leading products include the blazer line of ablation catheters designed to deliver enhanced performance and responsiveness and the rhythmia mapping system a nextgeneration catheterbased 3d cardiac mapping and navigation solution designed to help diagnose and treat a variety of arrhythmiasour worldwide net sales of electrophysiology products were 243 million for 2016 or approximately three percent of our consolidated net sales for the year our worldwide net sales of electrophysiology products increased 10 million or four percent in 2016 as compared to 2015 excluding the impact from changes in foreign currency exchange rates which had a 3 million negative impact on our electrophysiology net sales in 2016 as compared to 2015 net sales of these products increased 13 million or five percent this yearoveryear increase was primarily driven by increased sales of our rhythmia mapping system and related products in the first quarter of 2016 we initiated a full european launch of our blazer intellanav oi catheter which is used with our rhythmia mapping system and in july of 2016 we received fda approval for this same catheter in the second quarter of 2016 we received fda approval for intellanav xp and the intellanav mifi xp navigationenabled ablation catheters that are used with the rhythmia mapping system we also received fda approval for our blazer open irrigated system with atrial flutter indication and began full us commercialization in the second quarter of 2016 our global rollout of our rhythmia mapping system including early europe commercialization of our next generation rhythmia hdx system late in the fourth quarter along with continued global expansion of our new navigation enabled therapeutic catheter portfolio will continue as we expand our global rhythmia installed base medsurgendoscopyour endoscopy division develops and manufactures devices to treat a variety of medical conditions including diseases of the digestive and pulmonary systems our worldwide net sales of endoscopy products were 1440 billion for 2016 or approximately 17 percent of our consolidated net sales for the year our worldwide net sales of endoscopy products increased 134 million or 10 percent in 2016 as compared to 2015 excluding the impact from changes in foreign currency exchange rates which had a negative 9 million impact on our endoscopy net sales in 2016 as compared to 2015 net sales of these products increased 143 million or 10 percent this yearoveryear increase was primarily driven by growth across several of our key product franchises including our biliary device franchise with our spyglass ds direct visualization system and our axios stent and electrocauteryenhanced delivery system for endoscopic ultrasoundguided transmural drainage of pancreatic pseudocysts our metal stent franchise driven by our biliary wallflex product family and our hemostasis franchise featuring our resolution and resolution 360 clips this increase also includes revenue of approximately 10 million with no prior year period related net sales due to the endochoice acquisition in november 2016 as described belowon november 22 2016 we completed our acquisition of endochoice endochoice is an alpharetta georgia based company focused on the development and commercialization of infection control products pathology services and singleuse devices for specialists treating a wide range of gastrointestinal gi conditions we began the process of integrating endochoice into our endoscopy business in the fourth quarter of 2016 and expect to be substantially complete by the end of 2017 on november 1 2016 we acquired the lumenr tissue retractor system from lumenr llc lumenr a privately held newark california based company the lumenr tissue retractor system is currently in development for use during endoscopic resection of lesions in the colon esophagus or stomachon april 2 2015 we acquired xlumena inc xlumena a medical device company that developed minimally invasive devices for endoscopic ultrasound eus guided transluminal drainage of targeted areas within the gastrointestinal tract in 2016 we completed the integration of xlumena into our endoscopy business  38urology and pelvic healthour urology and pelvic health division develops and manufactures devices to treat various urological and pelvic conditions such as kidney stones benign prostatic hyperplasia bph erectile dysfunction male incontinence pelvic floor disorders abnormal uterine bleeding and uterine fibroids and polyps our worldwide net sales of urology and pelvic health products were 1005 billion for 2016 or approximately 12 percent of our consolidated net sales for the year our worldwide net sales of urology and pelvic health products increased 312 million or 45 percent in 2016 as compared to 2015 excluding the impact from changes in foreign currency exchange rates which had a negative 18 million impact on our urology and pelvic health net sales in 2016 as compared to 2015 net sales of these products increased 330 million or 45 percent this yearoveryear increase was primarily attributable to revenue of approximately 226 million with no prior year period related net sales due to the ams portfolio acquisition in august 2015 along with growth across all of our other global franchises including our pelvic floor franchise as a result of market share gains primarily driven by a competitor exiting the market during the first quarter of 2016on november 15 2016 we completed the acquisition of the gynecology and urology portfolio of distal access llc distal a salt lake city based company that designs minimally invasive medical devices the portfolio includes the resectr tissue resection device a singleuse solution designed to remove uterine polyps we began the process of integrating the resectr device into our urology and pelvic health business during the fourth quarter of 2016 and expect to be substantially complete by the end of 2017 on august 3 2015 we completed the acquisition of the american medical systems male urology portfolio ams portfolio acquisition which includes the mens health and prostate health businesses from endo international plc the ams male urology portfolio was integrated with our formerly named urology and womens health business and the joint businesses became urology and pelvic health the integration was substantially complete by the end of 2016neuromodulationour neuromodulation business offers the precision precision spectra precision montage and precision novi spinal cord stimulator scs systems used for the management of chronic pain and our vercise deep brain stimulation dbs system in various international regions such as europe latin america and asia pacific for the treatment of parkinsons disease tremor and intractable primary and secondary dystonia a neurological movement disorder characterized by involuntary muscle contractions our worldwide net sales of neuromodulation products were 556 million for the year ended december 31 2016 or approximately seven percent of our consolidated net sales for the year ended december 31 2016 our worldwide net sales of neuromodulation products increased 55 million or 11 percent in 2016 as compared to 2015 excluding the impact from changes in foreign currency exchange rates which had a negative 7 million impact on our neuromodulation net sales in 2016 as compared to 2015 net sales of these products increased 62 million or 12 percent the yearoveryear increase was primarily driven by share gains from our montage system continued adoption of the precision spectra scs system in the us and increased net sales in europe driven by our vercise dbs systems and nonrechargeable precision novi scs systemon july 27 2016 we acquired cosman medical inc cosman a privately held manufacturer of radiofrequency ablation systems expanding our neuromodulation portfolio and offering physicians treating patients with chronic pain a wider choice of nonopioid therapeutic options we are in the process of integrating cosman into our neuromodulation business and expect the integration to be substantially complete by the end of 2017 emerging marketsas part of our strategic imperatives to drive global expansion described in item 1 of this annual report we are seeking to grow net sales and market share by expanding our global presence including in emerging markets we define emerging markets as including 20 countries that we believe have strong growth potential based on their economic conditions healthcare sectors and our global capabilities we are seeking to expand our presence and strengthen relationships in order to grow net sales and market share within our emerging markets and we have increased our investment in infrastructure in these countries in order to maximize opportunities our emerging markets revenue grew nine percent as compared to the prior year and was approximately 10 percent of our consolidated net sales in 2016 excluding the impact from changes in foreign currency exchange rates which had a negative impact of 11 percent net sales in these markets grew 20 percent 39results of operationsnet saleswe manage our global businesses on a constant currency basis and we manage market risk from currency exchange rate changes at the corporate level management excludes the impact of changes in foreign currency exchange rates for purposes of reviewing revenue growth rates to facilitate an evaluation of current operating performance and comparison to past operating performance to calculate revenue growth rates that exclude the impact of changes in foreign currency exchange rates we convert current period and prior period net sales from local currency to us dollars using standard internal currency exchange rates held constant for each year the following table provides our net sales by global business and the relative change on an as reported and constant currency basis the constant currency growth rates in the tables below can be recalculated from our net sales presented in note o  segment reporting to our consolidated financial statements contained in item 8 of this annual report net sales that exclude the impact of changes in foreign currency exchange rates and net sales from divested businesses are not financial measures prepared in accordance with us gaap and should not be considered in isolation from or as a replacement for the most directly comparable gaap financial measure refer to additional information of this item 7 for a further discussion of managements use of this nongaap financial measure     2016 versus 2015 2015 versus 2014 year endeddecember 31 as reportedcurrencybasisconstantcurrencybasis as reportedcurrencybasisconstantcurrencybasisin millions201620152014            interventional cardiology228120332057 1213 17peripheral interventions1011904850 1212 6 13cardiovascular329229372907 1212 1 9          cardiac rhythm management185018071912 23 51electrophysiology243233227 45 2 9rhythm management209320402139 33 51          endoscopy144013061323 1010 16urology and pelvic health1005693535 4545 30 36neuromodulation556501472 1112 6 8medsurg300125002330 2020 7 13          subtotal core businesses838674777376 1212 1 8divested businesses4 nana nananet sales838674777380 1212 1 8refer to executive summary for further discussion of our net sales and a comparison of our 2016 and 2015 net salesin 2015 we generated net sales of 7477 billion as compared to 7380 billion in 2014 an increase of 97 million or one percent our net sales were unfavorably impacted by 505 million from foreign currency fluctuations in 2015 as compared to 2014 excluding the impact of foreign currency and sales from divested businesses our net sales increased 606 million or eight percent as compared to the prior year this increase was due primarily to constant currency increases in net sales from our urology and pelvic health business of 193 million primarily due to the ams portfolio acquisition from our interventional cardiology business of 150 million from our peripheral interventions business of 114 million and from our endoscopy business of 79 million  40gross profit our gross profit was 5962 billion in 2016 5304 billion in 2015 and 5170 billion in 2014 as a percentage of net sales our gross profit increased to 711 percent in 2016 as compared to 709 percent in 2015 and 701 percent in 2014 the following is a reconciliation of our gross profit margins and a description of the drivers of the change from period to period year endeddecember 31 20162015gross profit  prior year709 701 manufacturing cost reductions20 18 sales pricing and mix0106inventory stepup due to acquisition accounting0204net impact of foreign currency0905 all other including other inventory charges and other period expense0605gross profit  current year711 709 the primary factor contributing to the increase in our gross profit margin for 2016 as compared to 2015 was the positive impact of cost reductions as a result of our restructuring and other process improvement programs partially offsetting these factors was the net negative impact of foreign currency fluctuations and other inventory charges and period expenses the increase in our gross profit margin for 2015 as compared to 2014 primarily resulted from manufacturing cost reductions as a result of our restructuring and other process improvement programs partially offsetting these factors was the net negative impact of pricing declines related primarily to sales of our drugeluting stent and crm products in addition in connection with the accounting for the ams portfolio acquisition we adjusted acquired inventory from manufacturing cost to fair value the stepup in value is amortized through gross profit over an average estimated inventory turnover period we recorded increased cost of 22 million in 2016 and 36 million in 2015 associated with the stepup operating expensesthe following table provides a summary of certain of our operating expenses  year ended december 31  2016 2015 2014    of net   of net   of netin millions sales sales salesselling general and administrative expenses 3099370 2873384 2902393research and development expenses 920110 876117 817111royalty expense 7909 7009 11115selling general and administrative sgampa expensesin 2016 our sgampa expenses increased 226 million or eight percent as compared to 2015 and were 140 basis points lower as a percentage of net sales this decrease in sgampa as a percentage of sales was primarily driven by the benefit of our targeted initiatives focused on reducing sgampa as well as the reduction in expenses resulting from the suspension of the medical device excise tax which was substantially reinvested into our strategic growth initiatives the medical device excise tax was temporarily suspended in december 2015 through december 31 2017 in 2015 our sgampa expenses decreased 29 million or one percent as compared to 2014 and were 90 basis points lower as a percentage of net sales this decrease was driven by the impacts of our foreign currency fluctuations and declines in spending as a result of our restructuring and other cost reduction initiatives we recorded 78 million in 2015 and 72 million in 2014 related to the medical device excise tax 41research and development rampd expenseswe remain committed to advancing medical technologies and investing in meaningful research and development projects across our businesses in 2016 our rampd expenses increased 44 million or five percent as compared to 2015 and were 70 basis points lower as a percentage of net sales in 2015 our rampd expenses increased 59 million or seven percent as compared to 2014 and were 60 basis points higher as a percentage of net sales the yearoveryear increase in expenses was due primarily to investments across all of our businesses in order to maintain a healthy pipeline of new products that we believe will contribute to profitable sales growth and increased cost related to recent acquisitions and alliances partially offset by the favorable impact of foreign currency fluctuationsroyalty expensein 2016 our royalty expense increased 9 million or 13 percent as compared to 2015 and remained flat at approximately one percent of net sales for both periods the increase in royalty expense was primarily due to increases in net sales of our drugeluting coronary stent systems in 2016in 2015 our royalty expense decreased 41 million or 37 percent as compared to 2014 and was 60 basis points lower as a percentage of net sales the decrease relates primarily to the renegotiation of a royalty agreement in the second quarter of 2014 that resulted in a lower royalty rate structureamortization expenseour amortization expense was 545 million in 2016 as compared to 495 million in 2015 an increase of 50 million or 10 percent amortization expense was 495 million in 2015 as compared to 438 million in 2014 an increase of 57 million or 13 percent the increases in each period were primarily due to amortizable intangible assets acquired in the ams portfolio acquisition on august 3 2015amortization expense is excluded by management for purposes of evaluating operating performanceintangible asset impairment chargeswe have recorded intangible asset impairment charges including impairments of inprocess research and development of 11 million in 2016 19 million in 2015 and 195 million in 2014 see note d  goodwill and other intangible assets to our consolidated financial statements contained in item 8 of this annual report on form 10k for additional details related to our intangible asset impairment chargesrefer to critical accounting estimates for a discussion of key assumptions used in our goodwill and intangible asset impairment testing and future events that could have a negative impact on the recoverability of our goodwill and amortizable intangible assets intangible asset impairment charges are excluded by management for purposes of evaluating operating performance and assessing liquiditycontingent consideration expensewe recorded a net expense related to the change in fair value of our contingent consideration liabilities of 29 million in 2016 a net expense of 123 million in 2015 and a net benefit of 85 million in 2014 refer to note b  acquisitions and strategic investments to our consolidated financial statements contained in item 8 of this annual report for additional details related to our contingent consideration expenses contingent consideration expense is excluded by management for purposes of evaluating operating performancerestructuringrelated activities and chargeswe recorded restructuring charges pursuant to our restructuring plans of 28 million during 2016 26 million during 2015 and 69 million during 2014 in addition we recorded expenses within other lines of our accompanying consolidated statements of operations related to our restructuring initiatives of 50 million during 2016 57 million during 2015 and 48 million during 2014 restructuring and restructuringrelated costs are excluded by management for purposes of evaluating operating performancethe 2016 restructuring plan is expected to result in total pretax charges of approximately 175 million to 225 million and reduce gross annual expenses by approximately 115 million to 150 million by the end of 2020 as program benefits are realized the  422014 restructuring plan resulted in total pretax charges of 261 million and will reduce annual expenses by approximately 200 million we expect a substantial portion of the savings to be reinvested in strategic growth initiatives we made cash payments of 82 million in 2016 95 million in 2015 and 112 million in 2014 associated with our restructuring initiatives see note h  restructuringrelated activities to our consolidated financial statements included in item 8 of this annual report for additional details on our restructuring planslitigationrelated charges and creditswe recorded net litigationrelated charges in the amount of 804 million in 2016 1105 billion in 2015 and 1036 billion in 2014 the net charges recorded in 2016 include primarily amounts related to transvaginal surgical mesh product liability cases and claims the net charges recorded in 2015 include amounts primarily related to transvaginal surgical mesh product liability cases and claims and the charge related to the mirowski family venture llc mirowski lawsuit following a jury verdict that guidant corporation guidant breached their license agreement with mirowski the net charges recorded in 2014 include a 600 million charge related to the agreement between our subsidiary guidant and johnson amp johnson signed on february 13 2015 to settle the breach of merger agreement lawsuit brought by johnson amp johnson stemming from our acquisition of guidant in exchange we made aggregate payments totaling 600 million to johnson amp johnson during 2015 the 2014 net charges also include amounts related to transvaginal surgical mesh product liability cases and claims and certain other items litigation related charges and credits are excluded by management for purposes of evaluating operating performancewe continue to assess certain litigation and claims to determine the amounts if any that management believes will be paid as a result of such claims and litigation and therefore additional losses may be accrued and paid in the future which could materially adversely impact our operating results cash flows andor our ability to comply with our debt covenants refer to note k  commitments and contingencies to our consolidated financial statements contained in item 8 of this annual report for additional discussion of our material legal proceedingspension termination charges we recorded pension termination charges of 44 million during 2015 associated with the termination of the guidant retirement plan a frozen defined benefit plan we do not expect to incur any additional charges in the future related to the termination of the guidant retirement plan the pension termination charges are excluded by management for purposes of evaluating operating performancegain on divestiturein january 2011 we closed the sale of our neurovascular business to stryker corporation we recorded a pretax gain of 12 million during 2014 associated with the transaction these divestiturerelated gains are excluded by management for purposes of evaluating operating performance interest expenseour interest expense was 233 million in 2016 with an average borrowing rate of 40 percent as compared to 284 million in 2015 with an average borrowing rate of 52 percent interest expense in 2015 included a pretax charge of approximately 45 million associated with debt extinguishment charges representing premiums accelerated amortization of debt issuance costs and investor discount costs net of interest rate hedge gains related to the early extinguishment of 1000 billion of debt during the second quarter of 2015 our interest expense was 284 million in 2015 with an average borrowing rate of 52 percent as compared to 216 million in 2014 with an average borrowing rates of 48 percent the increase was primarily due to the pretax charge of approximately 45 million associated with debt extinguishment charges along with incremental debt to finance the ams portfolio acquisition offset by savings from refinancing our senior notesdebt extinguishment charges are excluded by management for purposes of evaluating operating performance refer to liquidity and capital resources note e  fair value measurements and note f  borrowings and credit arrangements to our consolidated financial statements contained in item 8 of this annual report for information regarding our debt obligations 43other netour other net reflected expense of 37 million in 2016 expense of 39 million in 2015 and income of 8 million in 2014 the following are the components of other net  year ended december 31in millions 201620152014interest income 555foreign currency losses 132118net gains losses on investments 21927other expense net 8146  37398during 2016 we recognized net losses of 21 million due to equity method adjustments on investments and investment impairments which were partially offset by a gain on our neovasc investment during 2015 we recognized net losses of 9 million due to equity method adjustments on investments and investment impairments during 2014 we recognized gains of 19 million associated with the acquisition of iogyn inc related to previously held investments and other net gains related to our investment portfolio of 8 million the acquisitionrelated gains from previously held investments are excluded by management for purposes of evaluating operating performance refer to note b  acquisitions and strategic investments to our consolidated financial statements contained in item 8 of this annual report for information regarding our strategic investmentstax ratethe following table provides a summary of our reported tax rate  year endeddecember 31  201620152014reported tax rate 959632 767 impact of certain receiptscharges 1083 535645  124 97 122 these receiptscharges are taxed at different rates than our effective tax ratethe change in our reported tax rate for 2016 as compared to 2015 and 2014 relates primarily to the impact of certain receipts and charges that are taxed at different rates than our effective tax rate including intangible asset impairment charges acquisitionrelated net charges contingent consideration litigationrelated net charges restructuringrelated net charges pension termination charges and debt extinguishment charges as well as the impact of certain discrete tax itemsin 2016 these receipts and charges included intangible asset impairment charges acquisitionrelated net charges litigationrelated net charges and restructuringrelated net charges our reported tax rate for 2016 was also affected by discrete items primarily related to the resolution of various uncertain tax positions through settlement or expiration of statute offset by a charge related to changes in state apportionmentin 2015 these receipts and charges included intangible asset impairment charges acquisitionrelated net charges litigationrelated net charges restructuringrelated net charges pension termination charges and debt extinguishment charges our reported tax rate for 2015 was also affected by discrete items primarily related to benefits due to settlement of various uncertain tax positions and reinstatement of certain tax legislation that has been retroactively appliedin 2014 these receipts and charges included intangible asset impairment charges acquisition and divestiturerelated net charges litigationrelated net charges and restructuringrelated net charges our reported tax rate for 2014 was also affected by discrete tax items primarily related to resolution of various uncertain tax positions resulting from the expiration of the statute of limitations for assessing tax in certain jurisdictions and benefit due to change in uncertain tax positions due to a favorable court ruling offset by a charge due to translation gain on previously taxed incomewe are contesting in us tax court significant proposed adjustments from the internal revenue service irs related to its audit of our transfer pricing methodologies for the 2001 through 2007 tax years the irs also proposed similar transfer pricing adjustments for the 2008 through 2010 tax years we disagree with the transfer pricing methodologies being applied by the irs  44and we were scheduled to go to trial in the us tax court in late july 2016 on july 19 2016 we entered a stipulation of settled issues with the irs intended to resolve all of the aforementioned transfer pricing issues as well as issues related to our transaction with abbott for the 2001 through 2007 tax years the stipulation of settled issues is contingent upon the irs office of appeals irs appeals applying the same basis of settlement to all transfer pricing issues for the companys 2008 2009 and 2010 tax years and if applicable review by the united states congress joint committee on taxation in october 2016 we reached an agreement in principle with irs appeals as to the resolution of the transfer pricing issues in 2008 2009 and 2010 tax years subject to additional calculations of tax as well as documentation to memorialize our agreement in the event that the conditions in the stipulation of settled items are satisfied we expect to make net tax payments of approximately 275 million plus interest through the date of payment if finalized payments related to the resolution are expected in the next nine to 18 months we believe that our income tax reserves associated with these matters are adequate as of december 31 2016 and we do not expect to recognize any additional charges related to resolution of this controversy however the final resolution of these issues is contingent and if the stipulation of settled issues is not finalized it could have a material impact on our financial condition results of operations or cash flowssee note j  income taxes to our consolidated financial statements included in item 8 of this annual report for additional details on our tax rate and our tax litigationliquidity and capital resourcesbased on our current business plan we believe our existing balance of cash and cash equivalents future cash generated from operations and access to capital markets and credit facilities will be sufficient to fund our operations invest in our infrastructure pay our legalrelated liabilities pay taxes due fund possible mergers andor acquisitions and service and repay our existing debt please refer to our contractual obligations and commitments table for additional details on our future payment obligations and commitmentsas of december 31 2016 we had 196 million of cash and cash equivalents on hand comprised of 42 million invested in money market and government funds and 154 million in shortterm time deposits and interest bearing and noninterest bearing bank accounts we invest excess cash on hand in shortterm financial instruments that earn market interest rates while mitigating principal risk through instrument and counterparty diversification as well as what we believe to be prudent instrument selection we limit our direct exposure to securities in any one industry or issuer we also have full access to our 2000 billion revolving credit facility and 240 million of available borrowings under our credit and security facility secured by our us trade receivables as of december 31 2016 both described belowthe following provides a summary and description of our net cash inflows outflows for the years ended december 31 2016 2015 and 2014  year ended december 31in millions 201620152014cash provided by operating activities 9726001269cash used for investing activities 8872186745cash provided by used for financing activities 2061322150operating activitiesduring 2016 cash provided by operating activities was 972 million as compared to 600 million in 2015 an increase of 372 million or 62 percent this increase was primarily driven by the increase in net income for 2016 compared to 2015 partially offset by approximately 100 million increase in litigationrelated payments during 2016 we made litigationrelated payments primarily associated with the transvaginal surgical mesh product liability cases and to mirowskirefer to note k  commitments and contingencies for additional information on litigationrelated mattersduring 2015 we generated 600 million of cash from operating activities as compared to 1269 billion in 2014 a decrease of 669 million or 53 percent this decrease was primarily due to the 600 million of payments to johnson amp johnson 45investing activitiesduring 2016 cash used for investing activities was 887 million our investing activities primarily included 408 million of payments net of cash acquired for acquisitions including cosman endochoice lumenr distal and neovasc along with 376 million in purchases of property plant and equipment and 132 million of payments related to strategic investments partially offset by proceeds from the sale of one of two buildings located in quincy massachusetts for 29 million we intend to invest approximately 300 million in purchases of property plant and equipment during 2017during 2015 cash used for investing activities was 2186 billion our investing activities included 1734 billion of payments net of cash acquired for acquisitions including the ams portfolio acquisition celonova and xlumena along with 266 million of payments related to strategic investments including equity investments in preventice inc and frankenman medical equipment company cash used for investing activities also included purchases of property plant and equipment of 247 million during 2014 cash used for investing activities was 745 million our investing activities included 486 million of payments net of cash acquired for acquisitions including iogyn and the interventional division of bayer ag along with purchases of property plant and equipment of 259 million financing activitiesour cash flows from financing activities reflect issuances and repayments of debt payments of acquisitionrelated contingent consideration and cash used to new share settle and stock issuances related to our equity incentive programs as discussed in note l  stockholders equity to our consolidated financial statements included in item 8 of this annual report additionally our financing activities included 65 million of contingent payments in 2016 156 million of payments in 2015 and 34 million of payments in 2014 associated with our previous acquisitionsour liquidity plans are subject to a number of risks and uncertainties including those described in item 1a risk factors of this annual report some of which are outside our control macroeconomic conditions adverse litigation outcomes and other risk and uncertainties could limit our ability to successfully execute our business plans and adversely affect our liquidity plans debtwe had total debt of 5484 billion as of december 31 2016 and 5677 billion as of december 31 2015 which consisted of the followingrevolving credit facilityin april 2015 we entered into a new 2000 billion revolving credit facility the 2015 facility with a global syndicate of commercial banks and terminated our previous 2000 billion revolving credit facility the 2015 facility matures in april 2020 there were no amounts borrowed under our current or prior revolving credit facility as of december 31 2016 or december 31 2015 term loansas of december 31 2016 we had an aggregate 750 million outstanding under our unsecured term loan facilities and 1000 billion outstanding under these facilities as of december 31 2015 these facilities include an unsecured term loan facility entered into in august 2013 2013 term loan which had 150 million outstanding as of december 31 2016 and 250 million outstanding as of december 31 2015 along with an unsecured term loan credit facility entered into in april 2015 2015 term loan which had 600 million outstanding as of december 31 2016 and 750 million outstanding as of december 31 2015our revolving credit facility and our term loan facilities require that we maintain certain financial covenants as outlined in note f  borrowings and credit arrangements to our consolidated financial statements contained in item 8 of this annual report as of and through december 31 2016 we were in compliance with the required covenants any inability to maintain compliance with these covenants could require us to seek to renegotiate the terms of our credit facility or seek waivers from compliance with these covenants both of which could result in additional borrowing costs further there can be no assurance that our lenders would agree to such new terms or grant such waivers senior noteswe had senior notes outstanding of 4650 billion as of december 31 2016 and as of december 31 2015 our senior notes were issued in public offerings are redeemable prior to maturity and are not subject to any sinking fund requirements our senior notes are unsecured unsubordinated obligations and rank on parity with each other these notes are effectively junior to borrowings under our credit and security facility to the extent if borrowed by our subsidiaries and to liabilities of our subsidiaries  46on january 12 2017 we used our existing credit facilities to repay the 250 million plus interest of our senior notes due in january 2017the debt maturity schedule for the significant components of our debt obligations as of december 31 2016 is as follows    in millions2017 2018 2019 2020 2021 thereafter totalsenior notes250 600  1450  2350 4650term loans 225 150 375   750 250 825 150 1825  2350 5400notethe table above does not include unamortized discounts associated with our senior notes or amounts related to interest rate contracts used to hedge the fair value of certain of our senior notes or debt issuance costsother arrangementswe maintained a 300 million credit and security facility secured by our us trade receivables maturing on june 9 2017 we had borrowings of 60 million outstanding under this facility as of december 31 2016 and no borrowings outstanding as of december 31 2015 on february 7 2017 we amended the terms of this credit and security facility including increasing the facility size to 400 million this amendment retained a similar maximum leverage ratio requirement and extended the facility maturity to february 2019we also have accounts receivable factoring programs in certain european countries that we account for as sales under financial accounting standards board fasb accounting standards codification asc topic 860 transfers and servicing these agreements provide for the sale of accounts receivable to third parties without recourse of up to approximately 391 million as of december 31 2016 we derecognized 152 million of receivables as of december 31 2016 at an average interest rate of 18 percent and 151 million as of december 31 2015 at an average interest rate of 24 percent in addition we have uncommitted credit facilities with a commercial japanese bank that provide for borrowings promissory notes discounting and receivables factoring of up to 21000 billion japanese yen approximately 180 million as of december 31 2016 we derecognized 149 million of notes receivable as of december 31 2016 at an average interest rate of 16 percent and 132 million of notes receivable as of december 31 2015 at an average interest rate of 16 percent derecognized accounts and notes are excluded from trade accounts receivable net in the accompanying audited consolidated balance sheetswe had outstanding letters of credit of 44 million as of december 31 2016 and as of december 31 2015 as of december 31 2016 and 2015 none of the beneficiaries had drawn upon the letters of credit or guarantees we believe we will generate sufficient cash from operations to fund these arrangements and intend to fund these arrangements without drawing on the letters of creditfor additional details related to our debt including our revolving credit facility term loans senior notes and other arrangements see note f  borrowings and credit arrangements to our consolidated financial statements included in item 8 of this annual reportequityduring 2016 we received 111 million in proceeds from stock issuances related to our stock option and employee stock purchase plans as compared to 114 million in 2015 and 60 million 2014 proceeds from the exercise of employee stock options and employee stock purchases vary from period to period based upon among other factors fluctuations in the trading price of our common stock and in the exercise and stock purchase patterns of employeeswe repurchased 10 million shares for 125 million during 2014 no share repurchases were made in 2016 or 2015 as of december 31 2016 we had remaining approximately 535 million authorized under our 2013 share repurchase program there were approximately 248 million shares in treasury as of december 31 2016 and december 31 2015stockbased compensation expense related to our stock ownership plans was 116 million in 2016 107 million in 2015 and 103 million in 2014 stockbased compensation expense varies from period to period based upon among other factors the timing number and fair value of awards granted during the period forfeiture levels related to unvested awards and employee contributions to our employee stock purchase plan 47contractual obligations and commitmentsthe following table provides a summary of certain information concerning our obligations and commitments to make future payments and is based on conditions in existence as of december 31 2016    in millions 2017 2018 2019 2020 2021 thereafter totallongterm debt obligations 250 825 150 1825  2350 5400interest payments 1 224 216 194 151 111 899 1795lease obligations 1 66 60 42 34 25 64 291purchase obligations 1 321 52 39 19 12 15 458minimum royalty obligations 1 1 2 1 2 1 1 8legal reserves 1062      1062unrecognized tax benefits 2 577      577  2501 1155 426 2031 149 3329 95911in accordance with us gaap these obligations relate to expenses associated with future periods and are not reflected in our consolidated balance sheets2includes accrued interest and penalties and other related itemsthe amounts in the table above with respect to lease obligations represent amounts pursuant to contractual arrangements for the lease of property plant and equipment used in the normal course of business purchase obligations relate primarily to noncancellable inventory commitments and capital expenditures entered in the normal course of business royalty obligations reported above represent minimum contractual obligations under our current royalty agreements the table above does not include 584 million of unrecognized tax benefits and 197 million of accrued interest and penalties and other related items because the timing of their future cash settlement is uncertain refer to note j  income taxes to our consolidated financial statements included in item 8 of this annual report for more information on these unrecognized tax benefits in addition the table above does not reflect our accrual for legal matters that are probable and estimable of 961 million due to the timing of payment being uncertain refer to note k  commitments and contingencies to our consolidated financial statements included in item 8 of this annual report for more information on our legal accrualwith certain of our acquisitions we acquired inprocess research and development projects that require future funding to complete the projects the primary basis for determining the technological feasibility or completion of these projects is obtaining regulatory approval to market the underlying products in an applicable geographic region we estimate that the total remaining cost to complete the inprocess research and development projects we acquired is between 25 million and 50 million net cash inflows from the projects currently in development are expected to commence in 2017 through 2030 following the respective launches of these technologies in the us europe and japan certain of our acquisitions also involve the potential payment of contingent consideration the table above does not reflect any such obligations as the timing and amounts are uncertain see note b  acquisitions and strategic investments to our consolidated financial statements included in item 8 of this annual report for the estimated maximum potential amount of future contingent consideration we could be required to pay associated with prior acquisitions and the fair value of our contingent consideration liabilities as of december 31 2016legal mattersfor a discussion of our material legal proceedings see note k  commitments and contingencies to our consolidated financial statements included in item 8 of this annual reportcritical accounting policies and estimatesour financial results are affected by the selection and application of accounting policies and methods we have adopted accounting policies to prepare our consolidated financial statements in conformity with us gaap to prepare our consolidated financial statements in accordance with us gaap management makes estimates and assumptions that may affect the reported amounts of our assets and liabilities the disclosure of contingent liabilities as of the date of our financial statements and the reported amounts of our revenues and expenses during the reporting period our actual results may differ from these estimates we consider estimates to be critical if i we are required to make assumptions about material matters that are uncertain at the time of estimation or if ii materially different estimates could have been made or it is reasonably likely that the accounting estimate will change from period to period the following are areas considered to be critical and require managements  48judgment revenue recognition bad debt reserves inventory provisions valuation of contingent consideration liabilities and intangible assets goodwill valuation legal and product liability accruals and income taxessee note a  significant accounting policies to our consolidated financial statements included in item 8 of this annual report for additional information related to our accounting policies and our consideration of these critical accounting areas in addition see note b  acquisitions and strategic investments and note d  goodwill and other intangible assets for further discussion on the valuation of goodwill and intangible assets and contingent consideration note j  income taxes for further discussion on income tax related matters and note k  commitments and contingencies for further discussion on legal and product liability mattersrevenue recognitionwe generally allow our customers to return defective damaged and in certain cases expired products for credit we base our estimate for sales returns upon historical trends and record these amounts as a reduction of revenue when we sell the initial product in addition we may allow customers to return previously purchased products for nextgeneration product offerings for these transactions we defer recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount to be returned when the nextgeneration products are shipped to the customer uncertain timing of nextgeneration product approvals variability in product launch strategies product recalls and variation in product utilization all affect our estimates related to sales returns and could cause actual returns to differ from these estimatesmany of our crm product offerings combine the sale of a device with our latitude patient management system which represents a future service obligation for revenue arrangements with multiple deliverables where the sale of a device is combined with a future service obligation we defer revenue on the undelivered element and recognize this revenue over the related service period generally we do not have vendor specific objective evidence of selling price available related to our future service obligations therefore we determine our estimates of selling price using third party evidence when available otherwise we use our best estimate of selling price we allocate arrangement consideration using the relative selling price method the use of alternative estimates of fair value could result in a different amount of revenue deferralinventory provisionswe base our provisions for excess expired and obsolete inventory primarily on our estimates of forecasted net sales a significant change in the timing or level of demand for our products as compared to forecasted amounts may result in recording additional provisions for excess expired and obsolete inventory in the future further the industry in which we participate is characterized by rapid product development and frequent new product introductions uncertain timing of nextgeneration product approvals variability in product launch strategies product recalls and variation in product utilization all affect our estimates related to excess expired and obsolete inventoryvaluation of intangible assets and contingent consideration liabilitieswe base the fair value of identifiable intangible assets acquired in a business combination including inprocess research and development on detailed valuations that use information and assumptions provided by management which consider managements best estimates of inputs and assumptions that a market participant would use further for those arrangements that involve potential future contingent consideration we record on the date of acquisition a liability equal to the fair value of the estimated additional consideration we may be obligated to make in the future we remeasure this liability each reporting period and record changes in the fair value through a separate line item within our consolidated statements of operations increases or decreases in the fair value of the contingent consideration liability can result from changes in discount periods and rates as well as changes in the timing and amount of revenue estimates or in the timing or likelihood of achieving regulatory revenue or commercializationbased milestones the use of alternative valuation assumptions including estimated revenue projections growth rates cash flows and discount rates and alternative estimated useful life assumptions or probabilities surrounding the achievement of clinical regulatory or revenuebased milestones could result in different purchase price allocations amortization expense and contingent consideration expense in current and future periodswe review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life if an impairment indicator exists we test the intangible asset for recoverability if the carrying value of the intangible asset is not recoverable we will write the carrying value down to fair value in the period identified we calculate fair value of our intangible assets as the present value of estimated future cash flows we expect to generate from the asset using a riskadjusted discount rate the use of alternative assumptions including estimated cash flows discount rates and alternative estimated remaining useful lives could result in different calculations of impairment in addition we test our indefinitelived intangible assets at least annually for impairment and reassess their classification as indefinitelived assets or more frequently if change in circumstance or indicators exist we  49assess qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not that our indefinitelived intangible assets are impaired if we conclude that it is more likely than not that the asset is impaired we then determine the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying value in accordance with fasb asc topic 350 intangibles  goodwill and other topic 350 if the carrying value exceeds the fair value of the indefinitelived intangible asset we write the carrying value down to the fair valuegoodwill valuationwe allocate any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination to goodwill we test our goodwill balances during the second quarter of each year for impairment or more frequently if indicators are present or changes in circumstances suggest that impairment may exist we assess goodwill for impairment at the reporting unit level which is defined as an operating segment or one level below an operating segment referred to as a component in 2016 we identified six operating segments including interventional cardiology peripheral interventions rhythm management endoscopy urology and pelvic health and neuromodulation for purposes of identifying our reporting units we then assessed whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component we identified rhythm management as having two components cardiac rhythm management and electrophysiology for our 2016 2015 and 2014 annual impairment assessment we identified seven reporting units which align to our seven core businesses interventional cardiology peripheral interventions cardiac rhythm management electrophysiology endoscopy urology and pelvic health and neuromodulation for our 2016 annual impairment assessment we aggregated the cardiac rhythm management and electrophysiology reporting units components of the rhythm management operating segment based on the criteria prescribed in fasb asc topic 350 these reporting units were aggregated due to a reorganization that commenced in 2015 that resulted in integrated leadership shared resources and consolidation of certain sites in 2016in performing the goodwill impairment assessment we utilize both the optional qualitative assessment and the twostep approach prescribed under fasb asc topic 350 beginning in 2016 the qualitative assessment was used for testing certain reporting units where fair value has historically exceeded carrying value by greater than 100 all other reporting units were tested using the twostep approach described below the qualitative assessment requires an evaluation of whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount based on an assessment of relevant events including macroeconomic factors industry and market conditions cost factors overall financial performance and other entityspecific factors after assessing the totality of events if it is determined that it is not more likely than not that the fair value of the reporting unit is less than its carrying value the first and second steps of the goodwill impairment test are unnecessary if it is determined that impairment is more likely than not then we perform the first step of the twostep impairment test in 2016 for all reporting units tested using the optional qualitative assessment we concluded that it was not necessary to perform the first step of the twostep goodwill impairment test the first step requires a comparison of the carrying value of the reporting units to the fair value of these units for our 2016 2015 and 2014 annual impairment assessment for those reporting units for which a quantitative test was performed we used only the income approach specifically the discounted cash flow dcf method to derive the fair value of each of our reporting units in preparing our goodwill impairment assessments this approach calculates fair value by estimating the aftertax cash flows attributable to a reporting unit and then discounting these aftertax cash flows to a present value using a riskadjusted discount rate we selected this method as being the most meaningful in preparing our goodwill assessments because we believe the income approach most appropriately measures our income producing assets we have considered using the market approach and cost approach but concluded they are not appropriate in valuing our reporting units given the lack of relevant market comparisons available for application of the market approach and the inability to replicate the value of the specific technologybased assets within our reporting units for application of the cost approach therefore we believe that the income approach represents the most appropriate valuation technique for which sufficient data are available to determine the fair value of our reporting unitsin applying the income approach to our accounting for goodwill we make assumptions about the amount and timing of future expected cash flows terminal value growth rates and appropriate discount rates the amount and timing of future cash flows within our dcf analysis is based on our most recent operational budgets long range strategic plans and other estimates the terminal value growth rate is used to calculate the value of cash flows beyond the last projected period in our dcf analysis and reflects our best estimates for stable perpetual growth of our reporting units we use estimates of marketparticipant riskadjusted weightedaverage cost of capital wacc as a basis for determining the discount rates to apply to our reporting units future expected cash flowsif the carrying value of a reporting unit exceeds its fair value we then perform the second step of the goodwill impairment test to measure the amount of impairment loss if any if the carrying value of a reporting unit is zero or negative we evaluate whether  50it is more likely than not that a goodwill impairment exists if we determine adverse qualitative factors exist that would indicate it is more likely than not an impairment exists we then perform the second step of the goodwill test the second step of the goodwill impairment test compares the estimated fair value of a reporting units goodwill to its carrying valuealthough we use consistent methodologies in developing the assumptions and estimates underlying the fair value calculations used in our impairment tests these estimates are uncertain by nature and can vary from actual results the use of alternative valuation assumptions including estimated revenue projections growth rates cash flows and discount rates could result in different fair value estimatesin the second quarter of 2016 we performed our annual goodwill impairment test for all of our reporting units and concluded the fair value of each reporting unit exceeded its carrying value because our global electrophysiology reporting unit was identified as being at higher risk of potential goodwill impairment during our 2015 annual test it was tested for impairment on a standalone basis in the second quarter of 2016 immediately prior to aggregating it with our global cardiac rhythm management reporting unit the fair value of the standalone global electrophysiology reporting unit exceeded the carrying value by approximately 36 percent in comparison the global electrophysiology reporting unit had excess fair value of approximately 28 percent as of our 2015 annual test as of the date of our 2016 annual goodwill impairment test the aggregated global electrophysiology and cardiac rhythm management operating segment rhythm management had excess fair value over carrying value of approximately 70 percent and held 292 million of allocated goodwill as such it was not deemed at higher risk of future impairment changes in our reporting units or in the structure of our business as a result of future reorganizations acquisitions or divestitures of assets or businesses could result in future impairments of goodwill within our reporting unitsrefer to note d  goodwill and other intangible assets to our consolidated financial statements contained in item 7 of this annual report on form 10k for additional details related to our annual goodwill impairment testslegal and product liability accrualsin the normal course of business we are involved in various legal and regulatory proceedings including intellectual property breach of contract securities litigation and product liability suits in some cases the claimants seek damages as well as other relief which if granted could require significant expenditures or impact our ability to sell our products we accrue anticipated costs of settlement damages losses for product liability claims and under certain conditions costs of defense based on historical experience or to the extent specific losses are probable and estimable otherwise we expense these costs as incurred if the estimate of a probable loss is a range and no amount within the range is more likely we accrue the minimum amount of the range litigation and product liability matters are inherently uncertain and the outcomes of individual matters are difficult to predict and quantify as such significant judgment is required in determining our legal and product liability accruals our estimates related to our legal and product liability accruals may change as additional information becomes available to us including information related to the nature or existence of claims against us trial court or appellate proceedings and mediation arbitration or settlement proceedingsincome taxeswe provide for potential amounts due in various tax jurisdictions in the ordinary course of conducting business in multiple countries and tax jurisdictions there are many transactions and calculations where the ultimate tax outcome is uncertain therefore judgment is required based on individual facts circumstances and information available in determining whether or not based on technical merits the position will be sustained upon examination in our opinion we have made adequate provisions for income taxes in determining our worldwide income tax position for all years subject to audit new accounting pronouncementssee note q  new accounting pronouncements to our consolidated financial statements included in item 8 of this annual report for additional information on standards implemented since december 31 2015 and standards to be implementedadditional informationuse of nongaap financial measures by boston scientificto supplement our consolidated financial statements presented on a gaap basis we disclose certain nongaap financial measures including adjusted net income and adjusted net income per share that exclude certain amounts and adjusted net sales that exclude the impact of sales from divested businesses andor changes in foreign currency exchange rates these nongaap financial measures are not in accordance with generally accepted accounting principles in the united states 51the gaap financial measure most directly comparable to adjusted net income is gaap net income loss and the gaap financial measure most directly comparable to adjusted net income per share is gaap net income loss per share to calculate adjusted net sales that exclude sales from divested businesses andor changes in foreign currency exchange rates we convert actual net sales from local currency to us dollars using constant foreign currency exchange rates in the current and prior period andor eliminate the net sales from businesses that were divested during the period the gaap financial measure most directly comparable to constant currency growth rate andor growth rates excluding sales from divested business is growth rate percentages using net sales on a gaap basis reconciliations of each of these nongaap financial measures to the corresponding gaap financial measure are included in the relevant sections of this annual reportmanagement uses these supplemental nongaap financial measures to evaluate performance period over period to analyze the underlying trends in our business to assess our performance relative to our competitors and to establish operational goals and forecasts that are used in allocating resources in addition management uses these nongaap financial measures to further its understanding of the performance of our operating segments the adjustments excluded from our nongaap financial measures are consistent with those excluded from our operating segments measures of net sales and profit or loss these adjustments are excluded from the segment measures that are reported to our chief operating decision maker that are used to make operating decisions and assess performancewe believe that presenting adjusted net income adjusted net income per share and adjusted net sales that exclude certain amounts such as sales from divested businesses andor the impact of changes in foreign currency exchange rates in addition to the corresponding gaap financial measures provides investors greater transparency to the information used by management for its operational decisionmaking and allows investors to see our results through the eyes of management we further believe that providing this information assists our investors in understanding our operating performance and the methodology used by management to evaluate and measure such performancethe following is an explanation of each of the adjustments that management excluded as part of these nongaap financial measures as well as reasons for excluding each of these individual itemsadjusted net income and adjusted net income per shareintangible asset impairment charges  this amount represents writedowns of certain intangible asset balances during 2016 2015 and 2014we review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment and test our indefinitelived intangible assets at least annually for impairment if we determine the carrying value of the amortizable intangible asset is not recoverable or we conclude that it is more likely than not that the indefinitelive asset is impaired we will write the carrying value down to fair value in the period identified we exclude the impact of impairment charges from managements assessment of operating performance and from our operating segments measures of profit and loss used for making operating decisions and assessing performance accordingly management has excluded intangible asset impairment charges for purposes of calculating these nongaap financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performance acquisition and divestiture related net charges credits  these adjustments may consist of a contingent consideration fair value adjustments b gains on previously held investments c purchased andor funded inprocess research and development expenses incurred outside of a business combination d due diligence other fees inventory stepup amortization and integration and exit costs and e separation costs and gains primarily associated with the sale of our neurovascular business in january 2011 the contingent consideration adjustments represent accounting adjustments to state contingent consideration liabilities at their estimated fair value these adjustments can be highly variable depending on the assessed likelihood and amount of future contingent consideration payments due diligence other fees inventory stepup amortization and integration and exit costs include legal tax severance and other expenses associated with prior and potential future acquisitions and divestitures that can be highly variable and not representative of ongoing operations separation costs and gains on the sale of a business unit primarily represent those associated with the neurovascular divestiture and are not representative of ongoing operations accordingly management excluded these amounts for purposes of calculating these nongaap financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performance restructuring and restructuringrelated net charges credits  these adjustments represent severance and other direct costs associated with our restructuring plans these restructuring plans each consist of distinct initiatives that are fundamentally different from our ongoing core cost reduction initiatives in terms of among other things the frequency with which each action is performed and the required planning resourcing cost and timing examples of such initiatives include the movement of business activities facility consolidations and closures and the transfer of product lines  52between manufacturing facilities which due to the highly regulated nature of our industry requires a significant investment in time and cost to create duplicate manufacturing lines run product validations and seek regulatory approvals restructuring initiatives generally take approximately two years to complete and have a distinct project timeline that begins subsequent to approval by our board of directors in contrast to our ongoing cost reduction initiatives restructuring initiatives typically result in duplicative cost and exit costs over this period of time are onetime shut downs or transfers and are not considered part of our core ongoing operations because these restructuring plans are incremental to the core activities that arise in the ordinary course of our business management excluded these costs for purposes of calculating these nongaap financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performance litigationrelated net charges credits  these adjustments include certain significant product liability and other litigationrelated charges and credits we record these charges and credits which we consider to be unusual or infrequent and significant within the litigationrelated charges line in our consolidated statement of operations all other legal and product liability charges credits and costs are recorded within selling general and administrative expenses these amounts are excluded by management in assessing our operating performance as well as from our operating segments measures of profit and loss used for making operating decisions and assessing performance accordingly management excluded these amounts for purposes of calculating these nongaap financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performance debt extinguishment charges  this item represents premiums accelerated amortization of debt issuance costs and investor discount costs net of interest rate hedge gains related to the early extinguishment of 10 billion of senior notes during the second quarter of 2015 these adjustments are not expected to recur and do not reflect expected ongoing operating results accordingly management excluded these amounts for purposes of calculating these nongaap financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performance pension termination charges  this item represents charges associated with the termination of the guidant retirement plan a frozen defined benefit plan these charges are not expected to recur after 2015 and do not reflect expected ongoing operating results accordingly management has excluded these amounts for purposes of calculating these nongaap financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performance amortization expense  we record intangible assets at historical cost and amortize them over their estimated useful lives amortization expense is excluded from managements assessment of operating performance and is also excluded from our operating segments measures of profit and loss used for making operating decisions and assessing performance accordingly management has excluded amortization expense for purposes of calculating these nongaap financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performance discrete tax items  these items represent adjustments of certain tax positions which were initially established in prior periods in conjunction with the purchase accounting for an acquisition or as a result of intangible asset impairment charges acquisition divestiture restructuring or litigationrelated charges or credits these adjustments do not reflect expected ongoing operating results accordingly management excluded these amounts for purposes of calculating these nongaap financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performance adjusted net sales excluding the impact of sales from divested businesses andor changes in foreign currency exchange ratessales from divested businesses are primarily associated with the neurovascular divestiture and are not representative of ongoing operations the impact of changes in foreign currency exchange rates is highly variable and difficult to predict accordingly management excludes the impact of sales from divested businesses andor changes in foreign currency exchange rates for purposes of reviewing adjusted net sales to facilitate an evaluation of our current operating performance and a comparison to our past operating performance adjusted net income adjusted net income per share and adjusted net sales that exclude certain amounts such as the sales from divested businesses andor the impact of changes in foreign currency exchange rates are not in accordance with us gaap and should not be considered in isolation from or as a replacement for the most directly comparable gaap financial measures further other companies may calculate these nongaap financial measures differently than we do which may limit the usefulness of those measures for comparative purposes 53rule 10b51 trading plans by executive officersperiodically certain of our executive officers adopt written stock trading plans in accordance with rule 10b51 under the exchange act and our own stock trading policy a rule 10b51 trading plan is a written document that preestablishes the amount prices and dates or formulas for determining the amounts prices and dates of future purchases or sales of our stock including shares issued upon exercise of stock options or vesting of deferred stock units these plans are entered into at a time when the person is not in possession of material nonpublic information about our company we disclose details regarding individual rule 10b51 trading plans on the investor relations section of our website 54managements annual report on internal control over financial reportingas the management of boston scientific corporation we are responsible for establishing and maintaining adequate internal control over financial reporting we designed our internal control process to provide reasonable assurance to management and the board of directors regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principleswe assessed the effectiveness of our internal control over financial reporting as of december 31 2016 in making this assessment we used the criteria set forth by the committee of sponsoring organizations of the treadway commission in internal controlintegrated framework 2013 framework based on our assessment we believe that as of december 31 2016 our internal control over financial reporting is effective at a reasonable assurance level based on these criteriaernst amp young llp an independent registered public accounting firm has issued an audit report on the effectiveness of our internal control over financial reporting this report in which they expressed an unqualified opinion is included below        s michael f mahoney s daniel j brennan        michael f mahoney  daniel j brennan   president and chief executive officer  executive vice president and chieffinancial officer  55report of independent registered public accounting firmthe board of directors and shareholders of boston scientific corporationwe have audited boston scientific corporations internal control over financial reporting as of december 31 2016 based on criteria established in internal controlintegrated framework issued by the committee of sponsoring organizations of the treadway commission 2013 framework the coso criteria boston scientific corporations management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying managements annual report on internal control over financial reporting our responsibility is to express an opinion on the companys internal control over financial reporting based on our auditwe conducted our audit in accordance with the standards of the public company accounting oversight board united states those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects our audit included obtaining an understanding of internal control over financial reporting assessing the risk that a material weakness exists testing and evaluating the design and operating effectiveness of internal control based on the assessed risk and performing such other procedures as we considered necessary in the circumstances we believe that our audit provides a reasonable basis for our opinion a companys internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles a companys internal control over financial reporting includes those policies and procedures that 1 pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the company 2 provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company and 3 provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition use or disposition of the companys assets that could have a material effect on the financial statements because of its inherent limitations internal control over financial reporting may not prevent or detect misstatements also projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deterioratein our opinion boston scientific corporation maintained in all material respects effective internal control over financial reporting as of december 31 2016 based on the coso criteria we also have audited in accordance with the standards of the public company accounting oversight board united states the consolidated balance sheets of boston scientific corporation as of december 31 2016 and 2015 and the related consolidated statements of operations comprehensive income loss stockholders equity and cash flows for each of the three years in the period ended december 31 2016 of boston scientific corporation and our report dated february 23 2017 expressed an unqualified opinion thereon s ernst amp young llpboston massachusettsfebruary 23 2017  56item 7a quantitative and qualitative disclosures about market riskwe develop manufacture and sell medical devices globally and our earnings and cash flows are exposed to market risk from changes in currency exchange rates and interest rates we address these risks through a risk management program that includes the use of derivative financial instruments we operate the program pursuant to documented corporate risk management policies we do not enter derivative transactions for speculative purposes gains and losses on derivative financial instruments substantially offset losses and gains on underlying hedged exposures furthermore we manage our exposure to counterparty risk on derivative instruments by entering into contracts with a diversified group of major financial institutions and by actively monitoring outstanding positionsour currency risk consists primarily of foreign currency denominated firm commitments forecasted foreign currency denominated intercompany and thirdparty transactions and net investments in certain subsidiaries we use both nonderivative primarily european manufacturing operations and derivative instruments to manage our earnings and cash flow exposure to changes in currency exchange rates we had currency derivative instruments outstanding in the contract amount of 4100 billion as of december 31 2016 and 3547 billion as of december 31 2015 we recorded 199 million of other assets and 26 million of other liabilities to recognize the fair value of these derivative instruments as of december 31 2016 as compared to 237 million of other assets and 23 million of other liabilities as of december 31 2015 a ten percent appreciation in the us dollars value relative to the hedged currencies would increase the derivative instruments fair value by 257 million as of december 31 2016 and 155 million as of december 31 2015 a ten percent depreciation in the us dollars value relative to the hedged currencies would decrease the derivative instruments fair value by 223 million as of december 31 2016 and by 189 million as of december 31 2015 any increase or decrease in the fair value of our currency exchange rate sensitive derivative instruments would be substantially offset by a corresponding decrease or increase in the fair value of the hedged underlying asset liability or forecasted transaction resulting in minimal impact on our consolidated statements of operationsour interest rate risk relates primarily to us dollar borrowings partially offset by us dollar cash investments we have historically used interest rate derivative instruments to manage our earnings and cash flow exposure to changes in interest rates we have no interest rate derivative instruments outstanding as of december 31 2016 as of december 31 2016 4670 billion of our outstanding debt obligations was at fixed interest rates representing approximately 85 percent of our total debtsee note e  fair value measurements to our 2016 consolidated financial statements contained in item 8 of this annual report for further information regarding our derivative financial instruments 57report of independent registered public accounting firmthe board of directors and shareholders of boston scientific corporationwe have audited the accompanying consolidated balance sheets of boston scientific corporation as of december 31 2016 and 2015 and the related consolidated statements of operations comprehensive income loss stockholders equity and cash flows for each of the three years in the period ended december 31 2016 our audits also included the financial statement schedule listed in the index at item 15a2 these financial statements and schedule are the responsibility of the companys management our responsibility is to express an opinion on these financial statements and schedule based on our auditswe conducted our audits in accordance with the standards of the public company accounting oversight board united states those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement an audit includes examining on a test basis evidence supporting the amounts and disclosures in the financial statements an audit also includes assessing the accounting principles used and significant estimates made by management as well as evaluating the overall financial statement presentation we believe that our audits provide a reasonable basis for our opinionin our opinion the financial statements referred to above present fairly in all material respects the consolidated financial position of boston scientific corporation at december 31 2016 and 2015 and the consolidated results of its operations and its cash flows for each of the three years in the period ended december 31 2016 in conformity with us generally accepted accounting principles also in our opinion the related financial statement schedule when considered in relation to the basic financial statements taken as a whole presents fairly in all material respects the information set forth thereinwe also have audited in accordance with the standards of the public company accounting oversight board united states boston scientific corporations internal control over financial reporting as of december 31 2016 based on criteria established in internal controlintegrated framework issued by the committee of sponsoring organizations of the treadway commission 2013 framework and our report dated february 23 2017 expressed an unqualified opinion thereons ernst amp young llpboston massachusettsfebruary 23 2017  58item 8 financial statements and supplementary databoston scientific corporation and subsidiariesconsolidated statements of operations year ended december 31in millions except per share data201620152014    net sales838674777380cost of products sold242421732210gross profit596253045170    operating expenses   selling general and administrative expenses309928732902research and development expenses920876817royalty expense7970111amortization expense545495438intangible asset impairment charges1119195contingent consideration expense benefit2912385restructuring charges282669litigationrelated charges80411051036pension termination charges44gain on divestiture12 551556315471operating income loss 447327301    other income expense   interest expense233284216other net37398 income loss before income taxes177650509income tax benefit expense170411390net income loss347239119    net income loss per common share  basic026018009net income loss per common share  assuming dilution025018009    weightedaverage shares outstanding   basic135761341213243assuming dilution137721341213243see notes to the consolidated financial statements 59boston scientific corporation and subsidiariesconsolidated statements of comprehensive income loss   year ended december 31in millions 2016 2015 2014net income loss 347 239 119other comprehensive income loss net of tax      foreign currency translation adjustment 25 16 22net change in unrealized gains and losses on derivative financial instruments net of tax 45 67 78net change in availableforsale securities 6  net change in unrealized costs associated with certain retirement plans 11 27 18total other comprehensive income loss 87 56 38total comprehensive income loss 260 295 81see notes to the consolidated financial statements 60boston scientific corporation and subsidiariesconsolidated balance sheets as of december 31in millions except share and per share data2016 2015    assets   current assets   cash and cash equivalents196 319trade accounts receivable net1472 1275inventories955 1016deferred and prepaid income taxes75 496other current assets541 365total current assets3239 3471property plant and equipment net1630 1490goodwill6678 6473other intangible assets net5883 6194other longterm assets666 505total assets18096 18133    liabilities and stockholders equity   current liabilities   current debt obligations64 3accounts payable447 209accrued expenses2312 1970other current liabilities764 248total current liabilities3587 2430longterm debt5420 5674deferred income taxes18 735other longterm liabilities2338 2974    commitments and contingencies     stockholders equity   preferred stock 001 par value  authorized 50000000 shares none issued and outstanding common stock 001 par value  authorized 2000000000 shares issued 1609670817 shares as of december 31 2016 and 1594213786 shares as of december 31 201516 16treasury stock at cost  247566270 shares as of december 31 2016 and december 31 20151717 1717additional paidin capital17014 16860accumulated deficit8581 8927accumulated other comprehensive income loss net of tax   foreign currency translation adjustment79 54unrealized gain on derivative financial instruments107 152unrealized loss on availableforsale securities6 unrealized costs associated with certain retirement plans21 10total stockholders equity6733 6320total liabilities and stockholders equity18096 18133see notes to the consolidated financial statements 61boston scientific corporation and subsidiariesconsolidated statements of stockholders equity            accumulated        additional   other  common stock treasury paidin accumulated comprehensivein millions except share data shares issued par value stock capital deficit income lossbalance as of december 31 2013 1560302634 16 1592 16579 8570 106net loss         119  changes in other comprehensive income loss net of tax            foreign currency translation adjustment           22net change in derivative financial instruments           78net change in certain retirement plans           18impact of stockbased compensation plans net of tax 14715602    124    acquisition of treasury stock     125      balance as of december 31 2014 1575018236 16 1717 16703 8689 144net loss         239  changes in other comprehensive income loss net of tax            foreign currency translation adjustment           16net change in derivative financial instruments           67net change in certain retirement plans           27impact of stockbased compensation plans net of tax 19195550   157    rounding         1  balance as of december 31 2015 1594213786 16 1717 16860 8927 88             net income         347  changes in other comprehensive income loss net of tax            foreign currency translation adjustment           25net change in derivative financial instruments           45net change in availableforsale securities           6net change in certain retirement plans           11impact of stockbased compensation plans net of tax 15457031    153    rounding      1 1 balance as of december 31 2016 1609670817 16 1717 17014 8581 1see notes to the consolidated financial statements 62boston scientific corporation and subsidiariesconsolidated statements of cash flows  year ended december 31in millions201620152014operating activities   net income loss 347239119adjustments to reconcile net income loss to cash provided by operating activities   gain on sale of businesses12gain on sale of property plant and equipment11depreciation and amortization815769725deferred and prepaid income taxes305532397stockbased compensation expense116107103intangible asset impairment charges1119195net losses gains on investments and notes receivable21927contingent consideration expense benefit2912385payment of contingent consideration in excess of amounts established in purchase accounting5757103pension termination charges44inventory stepup amortization22369other net124118increase decrease in operating assets and liabilities net of acquisitions   trade accounts receivable2161753inventories40381other assets2532333accounts payable and accrued expenses55320620other liabilities128337403cash provided by operating activities9726001269    investing activities   purchases of property plant and equipment376247259proceeds on disposals of property plant and equipment29payments for acquisitions of businesses net of cash acquired4081734486proceeds from business divestitures net of costs12payments for investments and acquisitions of certain technologies13226626proceeds from investments and collections of notes receivable6114cash used for investing activities8872186745    financing activities   payments of contingent consideration amounts previously established in purchase accounting6515634proceeds from longterm borrowings net of debt issuance costs2580payments on longterm borrowings2501150proceeds from borrowings on credit facilities630565810payments on borrowings from credit facilities570565810payments for acquisitions of treasury stock125cash used to net share settle employee equity awards626651proceeds from issuances of shares of common stock11111460cash provided by used for financing activities2061322150    effect of foreign exchange rates on cash244    net increase decrease in cash and cash equivalents123268370cash and cash equivalents at beginning of period319587217cash and cash equivalents at end of period196319587    supplemental information   cash paid for income taxes net948074cash paid for interest233283221fair value of contingent consideration recorded in purchase accounting50633 see notes to the consolidated financial statements 63notes to the consolidated financial statementsnote a  significant accounting policies principles of consolidationour consolidated financial statements include the accounts of boston scientific corporation and our whollyowned subsidiaries after the elimination of intercompany transactions we assess the terms of our investment interests to determine if any of our investees meet the definition of a variable interest entity vie for any vies we perform an analysis to determine whether our variable interests give us a controlling financial interest in a vie the analysis identifies the primary beneficiary of a vie as the enterprise that has both 1 the power to direct activities of a vie that most significantly impact the entitys economic performance and 2 the obligation to absorb losses of the entity or the right to receive benefits from the entity based on our assessments under the applicable guidance we did not have controlling financial or operating interests in any vies and therefore did not consolidate any vies for 2016 2015 and 2014on january 3 2011 we closed the sale of our neurovascular business to stryker corporation stryker due to our continuing involvement in the operations of the neurovascular business following the divestiture the divestiture did not meet the criteria for presentation as a discontinued operation and therefore the results of the neurovascular business were included in our results of operations for 2014 refer to note c  divestitures for a description of this business divestiturebasis of presentationthe accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the united states us gaap and with the instructions to form 10k and regulation sxadditionally certain prior year balances related to debt issuance costs have been restated to reflect our adoption of accounting standards codification update no 201503 interestimputation of interest subtopic 83530 simplifying the presentation of debt issuance costs amounts reclassified from other longterm assets to longterm debt were not material refer to note q  new accounting pronouncements for additional information on our adoption of the accounting pronouncement subsequent eventswe evaluate events occurring after the date of our accompanying consolidated balance sheets for potential recognition or disclosure in our financial statements we did not identify any material subsequent events requiring adjustment to our accompanying consolidated financial statements recognized subsequent events those items requiring disclosure unrecognized subsequent events in the financial statements have been disclosed accordingly refer to note f  borrowings and credit arrangements and note k  commitments and contingencies for further details in addition in february 2017 we initiated a voluntary removal of all lotus valve devices including lotus with depth guard from global commercial and clinical sites due to reports of premature release of a pin connecting the lotus valve to the delivery system accounting estimatesto prepare our consolidated financial statements in accordance with us gaap management makes estimates and assumptions that may affect the reported amounts of our assets and liabilities the disclosure of contingent liabilities as of the date of our financial statements and the reported amounts of our revenues and expenses during the reporting period our actual results may differ from these estimates refer to critical accounting estimates included in item 7 of this annual report for further discussioncash and cash equivalentswe record cash and cash equivalents in our consolidated balance sheets at cost which approximates fair value our policy is to invest excess cash in shortterm marketable securities earning a market rate of interest without assuming undue risk to principal and we limit our direct exposure to securities in any one industry or issuer we consider all highly liquid investments purchased with a remaining maturity of three months or less at the time of acquisition to be cash equivalentswe record availableforsale investments at fair value and exclude unrealized gains and temporary losses on availableforsale securities from earnings reporting such gains and losses net of tax as a separate component of stockholders equity until realized we compute realized gains and losses on sales of availableforsale securities based on the average cost method adjusted for any otherthantemporary declines in fair value refer to investments in publicly traded and privately held entities below for additional details  64concentrations of credit riskfinancial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents derivative financial instrument contracts and accounts and notes receivable our investment policy limits exposure to concentrations of credit risk and changes in market conditions counterparties to financial instruments expose us to creditrelated losses in the event of nonperformance we transact our financial instruments with a diversified group of major financial institutions with investment grade credit ratings and actively monitor their credit ratings and our outstanding positions to limit our credit exposure we provide credit in the normal course of business to hospitals healthcare agencies clinics doctors offices and other private and governmental institutions and generally do not require collateral we record our accounts receivable in our consolidated balance sheets at net realizable value we perform ongoing credit evaluations of our customers and maintain allowances for potential credit losses based on historical information and managements best estimates amounts determined to be uncollectible are written off against this reserve we recorded writeoffs of uncollectible accounts receivable of 11 million in 2016 16 million in 2015 and 15 million in 2014 we are not dependent on any single institution and no single customer accounted for more than ten percent of our net sales in 2016 2015 and 2014 or accounts receivable at december 31 2016 or 2015 however large group purchasing organizations hospital networks and other buying groups have become increasingly important to our business and represent a substantial portion of our us net saleswe closely monitor outstanding receivables for potential collection risks including those that may arise from economic conditions in both the us and international economies our european sales to governmentowned or supported customers in southern europe specifically greece italy spain and portugal are subject to an increased number of days outstanding relative to other countries prior to payment historically receivable balances with certain publiclyowned hospitals in these countries accumulate over a period of time and are then subsequently settled as large lump sum payments while we believe our allowance for doubtful accounts in these countries is adequate as of december 31 2016 if significant changes were to occur in the payment practices of these european governments or if government funding becomes unavailable we may not be able to collect on receivables due to us from these customers and our writeoffs of uncollectible amounts may increase  revenue recognitionwe generate revenue primarily from the sale of singleuse medical devices and present revenue net of sales taxes in our consolidated statements of operations we sell our products primarily through a direct sales force in certain international markets we sell our products through independent distributors we consider revenue to be realized or realizable and earned when all of the following criteria are met persuasive evidence of a sales arrangement exists delivery has occurred or services have been rendered the price is fixed or determinable and collectability is reasonably assured revenue is recognized upon passage of title and risk of loss to customers unless we are required to provide additional services and provided we can form an estimate for sales returns we recognize revenue from consignment arrangements based on product usage or implant which indicates that the sale is complete for revenue arrangements with multiple deliverables where the sale of a device is combined with a future service obligation we defer revenue on the undelivered element and recognize this revenue over the related service period many of our cardiac rhythm management crm product offerings combine the sale of a device with our latitude patient management system which represents a future service obligation generally we do not have vendor specific objective evidence of selling price available related to our future service obligations therefore we determine our estimates of selling price using third party evidence when available otherwise we use our best estimate of selling price we allocate arrangement consideration using the relative selling price method we generally allow our customers to return defective damaged and in certain cases expired products for credit we base our estimate for sales returns upon historical trends and record the amount as a reduction to revenue when we sell the initial product in addition we may allow customers to return previously purchased products for nextgeneration product offerings for these transactions we defer recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the nextgeneration products are shipped to the customerwe also offer sales rebates and discounts to certain customers we treat sales rebates and discounts as a reduction of revenue and classify the corresponding liability as current we estimate rebates for products where there is sufficient historical information available to predict the volume of expected future rebates if we are unable to estimate the expected rebates reasonably we record a liability for the maximum rebate percentage offered we have entered certain agreements with group purchasing organizations to sell our products to participating hospitals at negotiated prices we recognize revenue from these agreements following the same revenue recognition criteria discussed above 65warranty obligationswe offer warranties on certain of our product offerings the majority of our warranty liability relates to implantable devices offered by our crm business which include defibrillator and pacemaker systems our crm products come with a standard limited warranty covering the replacement of these devices we offer a full warranty for a portion of the period postimplant and a partial warranty for a period of time thereafter we estimate the costs that we may incur under our warranty programs based on the number of units sold historical and anticipated rates of warranty claims and cost per claim and record a liability equal to these estimated costs as cost of products sold at the time the product sale occurs we assess the adequacy of our recorded warranty liabilities on a quarterly basis and adjust these amounts as necessarychanges in our product warranty accrual during 2016 2015 and 2014 consisted of the following in millions   year ended december 31  2016 2015 2014beginning balance 23 25 28provision 25 15 9settlements reversals 26 17 12ending balance 22 23 25inventorieswe state inventories at the lower of firstin firstout cost or market we base our provisions for excess expired and obsolete inventory primarily on our estimates of forecasted net sales a significant change in the timing or level of demand for our products as compared to forecasted amounts may result in recording additional provisions for excess expired and obsolete inventory in the future further the industry in which we participate is characterized by rapid product development and frequent new product introductions uncertain timing of nextgeneration product approvals variability in product launch strategies product recalls and variation in product utilization all affect our estimates related to excess expired and obsolete inventory approximately 40 percent of our finished goods inventory as of december 31 2016 and december 31 2015 was at customer locations pursuant to consignment arrangements or held by sales representativesproperty plant and equipmentwe state property plant equipment and leasehold improvements at historical cost we charge expenditures for maintenance and repairs to expense and capitalize additions and improvements that extend the life of the underlying asset we provide for depreciation using the straightline method at rates that approximate the estimated useful lives of the assets we depreciate buildings over a 20 to 40 year life building improvements over the remaining useful life of the building structure equipment furniture and fixtures over a three to ten year life and leasehold improvements over the shorter of the useful life of the improvement or the term of the related lease depreciation expense was 270 million in 2016 274 million in 2015 and 287 million in 2014valuation of business combinationswe allocate the amounts we pay for each acquisition to the assets we acquire and liabilities we assume based on their fair values at the dates of acquisition including identifiable intangible assets and inprocess research and development which either arise from a contractual or legal right or are separable from goodwill we base the fair value of identifiable intangible assets acquired in a business combination including inprocess research and development on detailed valuations that use information and assumptions provided by management which consider managements best estimates of inputs and assumptions that a market participant would use we allocate any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired to goodwill transaction costs associated with these acquisitions are expensed as incurred through selling general and administrative costsin those circumstances where an acquisition involves a contingent consideration arrangement we recognize a liability equal to the fair value of the contingent payments we expect to make as of the acquisition date we remeasure this liability each reporting period and record changes in the fair value through a separate line item within our consolidated statements of operations increases or decreases in the fair value of the contingent consideration liability can result from changes in discount periods and rates as well as changes in the timing and amount of revenue estimates or in the timing or likelihood of achieving regulatory revenue or commercializationbased milestones  66indefinitelived intangibles including inprocess research and development our indefinitelived intangible assets that are not subject to amortization include acquired balloon and other technology which is foundational to our continuing operations within the cardiovascular market and other markets within interventional medicine and inprocess research and development intangible assets acquired in a business combination our inprocess research and development represents intangible assets acquired in a business combination that are used in research and development activities but have not yet reached technological feasibility regardless of whether they have alternative future use the primary basis for determining the technological feasibility or completion of these projects is obtaining regulatory approval to market the underlying products in an applicable geographic region we classify inprocess research and development acquired in a business combination as an indefinitelived intangible asset until the completion or abandonment of the associated research and development efforts upon completion of the associated research and development efforts we will determine the useful life of the technology and begin amortizing the assets to reflect their use over their remaining lives upon permanent abandonment we would writeoff the remaining carrying amount of the associated inprocess research and development intangible asset we test our indefinitelived intangible assets at least annually during the third quarter for impairment and reassess their classification as indefinitelived assets in addition we review our indefinitelived assets for classification and impairment more frequently if changes in circumstances or indicators exist we assess qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not that our indefinitelived intangible assets are impaired if we conclude that it is more likely than not that the asset is impaired we then determine the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying value in accordance with financial accounting standards board fasb accounting standards codification asc topic 350 intangibles  goodwill and other topic 350 if the carrying value exceeds the fair value of the indefinitelived intangible asset we write the carrying value down to the fair valuewe use the income approach to determine the fair values of our inprocess research and development this approach calculates fair value by estimating the aftertax cash flows attributable to an inprocess project over its useful life and then discounting these aftertax cash flows back to a present value we base our revenue assumptions on estimates of relevant market sizes expected market growth rates expected trends in technology and expected levels of market share in arriving at the value of the inprocess projects we consider among other factors the inprocess projects stage of completion the complexity of the work completed as of the acquisition date the costs already incurred the projected costs to complete the contribution of other acquired assets the expected regulatory path and introduction dates by region and the estimated useful life of the technology we apply a marketparticipant riskadjusted discount rate to arrive at a present value as of the date of acquisition see note d  goodwill and other intangible assets for more information related to indefinitelived intangibles including inprocess research and development during 2016 2015 and 2014for asset purchases outside of business combinations we expense any purchased research and development assets as of the acquisition date amortization and impairment of intangible assets we record intangible assets at historical cost and amortize them over their estimated useful lives we use a straightline method of amortization unless a method that better reflects the pattern in which the economic benefits of the intangible asset are consumed or otherwise used up can be reliably determined the approximate useful lives for amortization of our intangible assets are as follows patents and licenses two to 20 years definitelived technologyrelated five to 25 years customer relationships five to 25 years other intangible assets variouswe review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life conditions that may indicate impairment include but are not limited to a significant adverse change in legal factors or business climate that could affect the value of an asset a product recall or an adverse action or assessment by a regulator if an impairment indicator exists we test the intangible asset for recoverability for purposes of the recoverability test we group our amortizable intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities if the carrying value of the intangible asset asset group exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset asset group we will write the carrying value down to the fair value in the period identified we calculate fair value of our intangible assets as the present value of estimated future cash flows we expect to generate from the asset using a riskadjusted discount rate in determining our estimated future cash flows associated with our intangible assets we use estimates and assumptions about future revenue contributions cost structures and remaining useful lives of the asset asset  67group see note d  goodwill and other intangible assets for more information related to impairments of intangible assets during 2016 2015 and 2014for patents developed internally we capitalize costs incurred to obtain patents including attorney fees registration fees consulting fees and other expenditures directly related to securing the patent goodwill valuationbased on information regularly reviewed by our chief operating decision maker we have three global reportable segments comprised of cardiovascular rhythm management and medsurg we determined our global reporting units by identifying our operating segments and assessing whether any components of these segments constituted a business for which discrete financial information is available and whether segment management regularly reviews the operating results of any components through this process we identified the following global reporting units interventional cardiology peripheral interventions cardiac rhythm management electrophysiology endoscopy urology and pelvic health and neuromodulation we allocate any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination to goodwill we test our goodwill balances during the second quarter of each year for impairment or more frequently if indicators are present or changes in circumstances suggest that impairment may exist we assess goodwill for impairment at the reporting unit level which is defined as an operating segment or one level below an operating segment referred to as a component in 2016 we identified six operating segments including interventional cardiology peripheral interventions rhythm management endoscopy urology and pelvic health and neuromodulation for purposes of identifying our reporting units we then assessed whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component we identified rhythm management as having two components cardiac rhythm management and electrophysiology for our 2016 2015 and 2014 annual impairment assessment we identified seven reporting units which align to our seven core businesses interventional cardiology peripheral interventions cardiac rhythm management electrophysiology endoscopy urology and pelvic health and neuromodulation as noted above for our 2016 annual impairment assessment we aggregated the cardiac rhythm management and electrophysiology reporting units components of the rhythm management operating segment based on the criteria prescribed in fasb asc topic 350 these reporting units were aggregated due to a reorganization that commenced in 2015 that resulted in integrated leadership shared resources and consolidation of certain sites in 2016 in performing the goodwill impairment assessment for 2016 we utilized both the optional qualitative assessment and the twostep approach prescribed under fasb asc topic 350 beginning in 2016 the qualitative assessment was used for testing certain reporting units where fair value has historically exceeded carrying value by greater than 100 all other reporting units were tested using the twostep approach the qualitative assessment requires an evaluation of whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount based on an assessment of relevant events including macroeconomic factors industry and market conditions cost factors overall financial performance and other entityspecific factors after assessing the totality of events if it is determined that it is not more likely than not that the fair value of the reporting unit is less than its carrying value the first and second steps of the goodwill impairment test are unnecessary if it is determined that impairment is more likely than not then we perform the first step of the twostep impairment test in 2016 for all reporting units tested using the optional qualitative assessment we concluded that it was not necessary to perform the first step of the twostep goodwill impairment test the first step requires a comparison of the carrying value of the reporting units to the fair value of these unitswhen allocating goodwill from business combinations to our reporting units we assign goodwill to the reporting units that we expect to benefit from the respective business combination at the time of acquisition in addition for purposes of performing our goodwill impairment tests assets and liabilities including corporate assets which relate to a reporting units operations and would be considered in determining its fair value are allocated to the individual reporting units we allocate assets and liabilities not directly related to a specific reporting unit but from which the reporting unit benefits based primarily on the respective revenue contribution of each reporting unitfor our 2016 2015 and 2014 annual impairment assessments for those reporting units for which a quantitative test was performedwe used only the income approach specifically the discounted cash flow dcf method to derive the fair value of each of our reporting units this approach calculates fair value by estimating the aftertax cash flows attributable to a reporting unit and then discounting these aftertax cash flows to a present value using a riskadjusted discount rate we selected this method as being the most meaningful in preparing our goodwill assessments because we believe the income approach most appropriately measures our income producing assets we have considered using the market approach and cost approach but concluded they are not appropriate in valuing our reporting units given the lack of relevant market comparisons available for application of the market approach and the inability to replicate the value of the specific technologybased assets within our reporting units for application  68of the cost approach therefore we believe that the income approach represents the most appropriate valuation technique for which sufficient data are available to determine the fair value of our reporting unitsin applying the income approach to our accounting for goodwill we make assumptions about the amount and timing of future expected cash flows terminal value growth rates and appropriate discount rates the amount and timing of future cash flows within our dcf analysis is based on our most recent operational budgets long range strategic plans and other estimates the terminal value growth rate is used to calculate the value of cash flows beyond the last projected period in our dcf analysis and reflects our best estimates for stable perpetual growth of our reporting units we use estimates of marketparticipant riskadjusted weighted average cost of capital wacc as a basis for determining the discount rates to apply to our reporting units future expected cash flowsif the carrying value of a reporting unit exceeds its fair value we then perform the second step of the goodwill impairment test to measure the amount of impairment loss if any if the carrying value of a reporting unit is zero or negative we evaluate whether it is more likely than not that a goodwill impairment exists if we determine adverse qualitative factors exist that would indicate it is more likely than not an impairment exists we then perform the second step of the goodwill test the second step of the goodwill impairment test compares the estimated fair value of a reporting units goodwill to its carrying value if we were unable to complete the second step of the test prior to the issuance of our financial statements and an impairment loss was probable and could be reasonably estimated we would recognize our best estimate of the loss in our current period financial statements and disclose that the amount is an estimate we would then recognize any adjustment to that estimate in subsequent reporting periods once we have finalized the second step of the impairment test refer to note d  goodwill and other intangible assets to our consolidated financial statements for additional details related to our annual goodwill impairment testinvestments in publicly traded and privately held entities we account for our publicly traded investments as availableforsale securities based on the quoted market price at the end of the reporting period unrealized holding gains or losses during the period net of tax are recorded to accumulated other comprehensive incomeloss we compute realized gains and losses on sales of availableforsale securities at fair value based on the average cost method adjusted for any otherthantemporary declines in fair value as of december 31 2016 we held 20 million of availableforsale securities we held no availableforsale securities during 2015 and 2014 we account for investments in entities over which we have the ability to exercise significant influence under the equity method if we hold 50 percent or less of the voting stock and the entity is not a vie in which we are the primary beneficiary in accordance with fasb asc topic 323 investments  equity method and joint ventures topic 323 we record these investments initially at cost and adjust the carrying amount to reflect our share of the earnings or losses of the investee including all adjustments similar to those made in preparing consolidated financial statements we account for investments in entities in which we have less than a 20 percent ownership interest under the cost method of accounting if we do not have the ability to exercise significant influence over the investee in accordance with fasb asc topic 325 investments  other in addition we have notes receivable from certain companies that we account for in accordance with fasb asc topic 320 investments  debt and equity securities topic 320 refer to note b  acquisitions and strategic investments for additional details on the balances of our equity and cost method investmentseach reporting period we evaluate our investments to determine if there are any events or circumstances that are likely to have a significant adverse effect on the fair value of the investment examples of such impairment indicators include but are not limited to a significant deterioration in earnings performance recent financing rounds at reduced valuations a significant adverse change in the regulatory economic or technological environment of an investee or a significant doubt about an investees ability to continue as a going concern if we identify an impairment indicator we will estimate the fair value of the investment and compare it to its carrying value our estimation of fair value considers all available financial information related to the investee including valuations based on recent thirdparty equity investments in the investee if the fair value of the investment is less than its carrying value the investment is impaired and we make a determination as to whether the impairment is otherthantemporary we deem an impairment to be otherthantemporary unless we have the ability and intent to hold an investment for a period sufficient for a market recovery up to the carrying value of the investment further evidence must indicate that the carrying value of the investment is recoverable within a reasonable period for otherthantemporary impairments we recognize an impairment loss equal to the difference between an investments carrying value and its fair value impairment losses on our investments are included in other net in our consolidated statements of operations 69income taxeswe utilize the asset and liability method of accounting for income taxes under this method we determine deferred tax assets and liabilities based on differences between the financial reporting and tax bases of our assets and liabilities we measure deferred tax assets and liabilities using the enacted tax rates and laws that will be in effect when we expect the differences to reverse we reduce our deferred tax assets by a valuation allowance if based upon the weight of available evidence it is more likely than not that we will not realize some portion or all of the deferred tax assets we consider relevant evidence both positive and negative to determine the need for a valuation allowance information evaluated includes our financial position and results of operations for the current and preceding years the availability of deferred tax liabilities and tax carrybacks as well as estimates of the impact of future taxable income and available prudent and feasible taxplanning strategieswe have not provided us income taxes and foreign withholding taxes on the undistributed earnings of foreign subsidiaries as of december 31 2016 because we intend to permanently reinvest such earnings outside the us as of december 31 2016 the cumulative amount of excess financial reporting basis over the tax basis of investments in foreign subsidiaries that is indefinitely reinvested is approximately 98 billion generally such amounts become subject to us taxation upon the remittance of dividends and under certain other circumstances it is not practicable to estimate the amount of deferred tax liability related to investments in these foreign subsidiarieswe provide for potential amounts due in various tax jurisdictions in the ordinary course of conducting business in multiple countries and tax jurisdictions there are many transactions and calculations where the ultimate tax outcome is uncertain therefore judgment is required based on individual facts circumstances and information available in determining whether or not based on technical merits the position will be sustained upon examination in our opinion we have made adequate provisions for income taxes in determining our worldwide income tax position for all years subject to audit although we believe our estimates are reasonable the final outcome of open tax matters may be different from that which we have reflected in our historical income tax provisions and accruals such differences could have a material impact on our income tax provision and operating results see note j  income taxes for further information and discussion of our income tax provision and balanceslegal and product liability costsin the normal course of business we are involved in various legal and regulatory proceedings including intellectual property breach of contract securities litigation and product liability suits in some cases the claimants seek damages as well as other relief which if granted could require significant expenditures or impact our ability to sell our products we are also the subject of certain governmental investigations which could result in substantial fines penalties and administrative remedies we maintain an insurance policy providing limited coverage against securities claims and we are substantially selfinsured with respect to product liability claims and fully selfinsured with respect to intellectual property infringement claims we accrue anticipated costs of settlement damages losses for product liability claims and under certain conditions costs of defense based on historical experience or to the extent specific losses are probable and estimable otherwise we expense these costs as incurred if the estimate of a probable loss is a range and no amount within the range is more likely we accrue the minimum amount of the range we analyze litigation settlements to identify each element of the arrangement we allocate arrangement consideration to patent licenses received based on estimates of fair value and capitalize these amounts as assets if the license will provide an ongoing future benefit we record certain legal and product liability charges credits and costs of defense which we consider to be unusual or infrequent and significant as litigationrelated charges within our consolidated statements of operations all other legal and product liability charges credits and costs are recorded within selling general and administrative expenses see note k  commitments and contingencies for discussion of our individual material legal proceedingscosts associated with exit activities we record employee termination costs in accordance with fasb asc topic 712 compensation  nonretirement and postemployment benefits topic 712 if we pay the benefits as part of an ongoing benefit arrangement which includes benefits provided as part of our established severance policies or that we provide in accordance with international statutory requirements we accrue employee termination costs associated with an ongoing benefit arrangement if the obligation is attributable to prior services rendered the rights to the benefits have vested the payment is probable and we can reasonably estimate the liability we account for employee termination benefits that represent a onetime benefit in accordance with fasb asc topic 420 exit or disposal cost obligations topic 420 we record such costs into expense over the employees future service period if any other costs associated with exit activities may include contract termination costs including costs related to leased facilities to be abandoned or subleased consultant fees and impairments of longlived assets the costs are expensed in accordance with fasb asc topic 420 and fasb asc topic 360 property plant and equipment and are included in restructuring charges in our consolidated statement of operations additionally costs directly related to our active restructuring initiatives including program  70management costs accelerated depreciation and costs to transfer product lines among facilities are included within costs of products sold and selling general and administrative expenses in our consolidated statement of operations see note h  restructuringrelated activities for further information and discussion of our restructuring planstranslation of foreign currencywe translate all assets and liabilities of foreign subsidiaries from local currency into us dollars using the yearend exchange rate and translate revenues and expenses at the average exchange rates in effect during the year we show the net effect of these translation adjustments in our consolidated financial statements as a component of accumulated other comprehensive income for any significant foreign subsidiaries located in highly inflationary economies we would remeasure their financial statements as if the functional currency were the us dollar we did not record any highly inflationary economy translation adjustments in 2016 2015 or 2014foreign currency transaction gains and losses are included in other net in our consolidated statements of operations net of losses and gains from any related derivative financial instruments we recognized net foreign currency transaction losses of 13 million in 2016 21 million in 2015 and 18 million in 2014financial instrumentswe recognize all derivative financial instruments in our consolidated financial statements at fair value in accordance with fasb asc topic 815 derivatives and hedging topic 815 and we present assets and liabilities associated with our derivative financial instruments on a gross basis in our financial statements in accordance with fasb asc topic 815 for those derivative instruments that are designated and qualify as hedging instruments the hedging instrument must be designated based upon the exposure being hedged as a fair value hedge cash flow hedge or a hedge of a net investment in a foreign operation the accounting for changes in the fair value ie gains or losses of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and further on the type of hedging relationship our derivative instruments do not subject our earnings or cash flows to material risk as gains and losses on these derivatives generally offset losses and gains on the item being hedged we do not enter into derivative transactions for speculative purposes and we do not have any nonderivative instruments that are designated as hedging instruments pursuant to fasb asc topic 815 refer to note e  fair value measurements for more information on our derivative instrumentsshipping and handling costswe generally do not bill customers for shipping and handling of our products shipping and handling costs of 101 million in 2016 93 million in 2015 and 100 million in 2014 are included in selling general and administrative expensesresearch and developmentwe expense research and development costs including new product development programs regulatory compliance and clinical research as incurred refer to indefinitelived intangibles including inprocess research and development for our policy regarding inprocess research and development acquired in connection with our business combinations and asset purchasesemployee retirement plans following our 2006 acquisition of guidant corporation we sponsored the guidant supplemental retirement plan a frozen nonqualified defined benefit plan for certain former officers and employees of guidant the plan was partially frozen as of september 25 1995 and completely frozen as of may 31 2007 and was terminated effective december 1 2014 during 2015 we finalized the termination process and settled the plans obligations as a result we recorded pension termination charges of 44 million for the year ended december 31 2015 the guidant supplemental retirement plan was partially funded through a rabbi trust that contains segregated company assets used to pay the benefit obligations related to the plan we also maintain an executive retirement plan a defined benefit plan covering executive officers and division presidents and certain persons that may have served in these roles participants may retire with unreduced benefits once retirement conditions have been satisfied in addition we maintain retirement plans covering certain international employees 71we use a december 31 measurement date for these plans and record the underfunded portion as a liability recognizing changes in the funded status through other comprehensive income oci the outstanding obligation as of december 31 2016 and 2015 is as follows  as of december 31 2016in millions accumulated benefit obligation abo projectedbenefitobligation pbo fair value of plan assets underfundedpbo recognizedexecutive retirement plan 15 17  17guidant supplemental retirement plan frozen 32 32  32international retirement plans 93 103 54 49  140 152 54 98  as of december 31 2015in millions accumulated benefit obligation abo projectedbenefitobligation pbo fair value of plan assets underfundedpbo recognizedexecutive retirement plan 12 14  14guidant supplemental retirement plan frozen 33 33  33international retirement plans 76 84 52 32  121 131 52 79the value of the rabbi trust assets used to pay the guidant supplemental retirement plan benefits included in our accompanying consolidated financial statements was approximately 8 million as of december 31 2016 and 11 million as of december 31 2015a rollforward of the changes in the pension benefit obligation for our funded retirement plans during 2016 and 2015 is as follows  year ended december 31in millions 2016 2015beginning obligations 131 138service and interest costs 10 9actuarial gain loss 10 5plan amendments 7 benefits paid 5 5foreign currency exchange 1 6ending obligation 152 131the critical assumptions associated with our employee retirement plans as of december 31 2016 are as follows   expected returnon plan assets rate of discountrate  compensationincreaseexecutive retirement plan350   300guidant supplemental retirement plan frozen400    international retirement plans050  213 300  410 250  678we base our discount rate on the rates of return available on highquality bonds with maturities approximating the expected period over which benefits will be paid the rate of compensation increase is based on historical and expected rate increases we base our rate of expected return on plan assets on historical experience our investment guidelines and expectations for longterm rates of return our international pension plan assets are invested in a variety of securities primarily equity securities and government bonds these securities are considered level 1 fair value investments and are valued at quoted market prices 72a rollforward of the changes in the fair value of plan assets for our funded retirement plans during 2016 and 2015 is as follows  year ended december 31in millions 2016 2015beginning fair value 52 191actual return on plan assets 1 1employer contributions 7 6benefits paid 5 145foreign currency exchange 1 1ending fair value 54 52we also sponsor a voluntary 401k retirement savings plan for eligible employees we match 200 percent of employee elective deferrals for the first two percent of employee eligible compensation and 50 percent of employee elective deferrals greater than two percent but not exceeding six percent of employee eligible compensation total expense for our matching contributions to the plan was 72 million in 2016 69 million in 2015 and 63 million in 2014net income loss per common sharewe base net income loss per common share upon the weightedaverage number of common shares and common stock equivalents outstanding during each year potential common stock equivalents are determined using the treasury stock method we exclude stock options whose effect would be antidilutive from the calculationnote b  acquisitions and strategic investmentsour consolidated financial statements include the operating results for each acquired entity from its respective date of acquisition we do not present pro forma financial information for these acquisitions given their results are not material to our consolidated financial statements transaction costs associated with these acquisitions were expensed as incurred and are not material for the years ended december 31 2016 2015 and 20142016 acquisitionsneovasc incs advanced biological tissue businesson december 12 2016 we completed the acquisition of certain manufacturing assets and capabilities of the neovasc inc neovasc advanced biological tissue business for a total upfront cash payment of 68 million with this acquisition we will integrate certain manufacturing assets and biologic tissue capabilities into our structural heart business for use in the manufacturing of the lotus valve system and future heart valve technologies within our interventional cardiology business we began the process of integrating neovasc into our interventional cardiology business in the fourth quarter of 2016 and expect to be substantially complete by the end of 2018 endochoice holdings incon november 22 2016 we completed our acquisition of endochoice holdings inc endochoice for 800 per share or approximately 214 million in addition total consideration for the acquisition also included repayment of endochoices existing senior term loan facility totaling 43 million and related acquisition fees and expenses endochoice is an alpharetta georgia based company focused on the development and commercialization of infection control products pathology services and singleuse devices for specialists treating a wide range of gastrointestinal gi conditions we began the process of integrating endochoice into our endoscopy business in the fourth quarter of 2016 and expect to be substantially complete by the end of 2017distal access llcs gynecology and urology portfolioon november 15 2016 we completed the acquisition of the gynecology and urology portfolio of distal access llc distal a salt lake city based company that designs minimally invasive medical devices for an upfront cash payment of 20 million plus a potential 35 million in future consideration based on future sales through 2020 in addition to regulatory and product launch milestones the portfolio includes the resectr tissue resection device a singleuse solution designed to remove uterine polyps we began the process of integrating the resectr device into our urology and pelvic health business during the fourth quarter of 2016 and expect to be substantially complete by the end of 2017  73lumenr tissue retractor systemon november 1 2016 we acquired the lumenr tissue retractor system from lumenr llc lumenr a privately held newark california based company for an upfront cash payment of 30 million plus a potential 70 million in future consideration based on future sales through the third quarter of 2026 in addition to development and technology transfer milestones the lumenr tissue retractor system is currently in development for use during endoscopic resection of lesions in the colon esophagus or stomachcosman medical incon july 27 2016 we acquired cosman medical inc cosman a privately held manufacturer of radiofrequency ablation systems expanding our neuromodulation portfolio and offering physicians treating patients with chronic pain a wider choice of nonopioid therapeutic options total consideration was comprised of 71 million in upfront cash plus related fees and expenses and a potential additional 20 million in consideration based on future sales through june 30 2019 we are in the process of integrating cosman into our neuromodulation business and expect the integration to be substantially complete by the end of 2017 purchase price allocationwe accounted for these acquisitions as a business combination and in accordance with fasb asc topic 805 business combinations topic 850 we recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date the components of the aggregate preliminary purchase price are as follows in millionscash net of cash acquired366fair value of contingent consideration50fair value of debt repaid43 459the following summarizes the preliminary purchase price allocation for our 2016 acquisitions as of december 31 2016 in millionsgoodwill208amortizable intangible assets228inventory11property plant and equipment6other net liabilities2deferred income taxes8 459we allocated a portion of the preliminary purchase price to specific intangible asset categories as follows amountassignedin millions weightedaverageamortizationperiodin years range of riskadjusted discountrates used inpurchase priceallocationamortizable intangible assets     technologyrelated176 913 11  20customer relationships51 913 11  12other intangible assets1 4 11 228     742015 acquisitionsinterventional radiology business of celonova bioscienceson december 31 2015 we completed the acquisition of the interventional radiology business of celonova biosciences celonova for an upfront payment of 70 million and additional payments contingent on regulatory and sales milestones the acquisition includes drugeluting microspheres designed to be loaded with chemotherapy drugs for delivery to cancerous tumors and spherical embolic products used to treat uterine fibroids and other conditions we are in the process of integrating celonova into our peripheral interventions business and expect to be substantially complete by the second half of 2017 ams portfolio acquisitionon august 3 2015 we completed the acquisition of the american medical systems male urology portfolio ams portfolio acquisition which includes the mens health and prostate health businesses from endo international plc total consideration was comprised of 1616 billion in upfront cash plus related fees and expenses and a potential additional 50 million in consideration based on 2016 sales the ams male urology portfolio was integrated with our formerly named urology and womens health business and the joint businesses became urology and pelvic health the integration was substantially complete by the end of 2016 in addition as part of the acquisition agreement we made a 60 million series b nonvoting preferred stock investment in the womens health business of endo health solutions a wholly owned subsidiary of endo international plc representing the remaining womens health business of the american medical systems portfolio this investment was subsequently repaid in the fourth quarter of 2015xlumena incon april 2 2015 we acquired xlumena inc xlumena a medical device company that developed minimally invasive devices for endoscopic ultrasound eus guided transluminal drainage of targeted areas within the gastrointestinal tract the purchase agreement called for an upfront payment of 63 million an additional payment of 13 million upon fda clearance of the hot axios product and further salesbased milestones based on sales achieved through 2018 in 2016 we completed the integration of xlumena into our endoscopy business in addition we completed other acquisitions during 2015 for total consideration of 6 million in cash at closing plus contingent consideration of up to 1 million purchase price allocationwe accounted for these acquisitions as business combinations and in accordance with fasb asc topic 850 we have recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition dates the components of the aggregate purchase prices are as follows in millionscash net of cash acquired1735fair value of contingent consideration63 1798the following summarizes the aggregate purchase price allocation for the 2015 acquisitions as of december 31 2015 in millionsgoodwill573amortizable intangible assets1074indefinitelived intangible assets6inventory103property plant and equipment43other net assets42deferred income taxes43 1798 75we allocated a portion of the purchase price to specific intangible asset categories as follows amountassignedin millions weightedaverageamortizationperiodin years range of riskadjusted discountrates used inpurchase priceallocationamortizable intangible assets     technologyrelated431 1113 14  23customer relationships625 1213 14  15other intangible assets18 13 14indefinitelived intangible assets     inprocess research amp development6 na 17 1080    2014 acquisitionsinterventional business of bayer agon august 29 2014 we completed the acquisition of the interventional division of bayer ag bayer for a total cash consideration of 414 million we believe that this acquisition enhances our ability to offer physicians and healthcare systems a more complete portfolio of solutions to treat challenging vascular conditions the transaction includes the angiojet thrombectomy system and the fetch 2 aspiration catheter which are used in endovascular procedures to remove blood clots from blocked arteries and veins and the jetstream atherectomy system used to remove plaque and thrombi from diseased arteries in 2016 we completed the integration of bayer into our peripheral interventions and interventional cardiology businesses iogyn incon may 7 2014 we completed the acquisition of the remaining fully diluted equity of iogyn inc iogyn prior to the acquisition we held a 28 percent minority interest in iogyn in addition to notes receivable of approximately 8 million total consideration was comprised of a net cash payment of 65 million at closing to acquire the remaining 72 percent of iogyn equity and repay outstanding debt iogyn has developed the symphion system a next generation system for hysteroscopic intrauterine tissue removal including fibroids myomas and polyps in march 2014 iogyn received us food amp drug administration fda approval for the system and in october 2014 we began a limited market release of the system in the united states we integrated the operations of the iogyn business into our urology and pelvic health business in addition we completed other acquisitions during 2014 for total consideration of 7 million cash at closing plus contingent consideration of up to 4 millionpurchase price allocationwe accounted for these acquisitions as business combinations and in accordance with fasb asc topic 850 we have recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date the components of the aggregate purchase price for our 2014 acquisitions are as follows in millionscash net of cash acquired479fair value of prior interests31 510in addition prior to the acquisition of iogyn we had an equity interest in iogyn and held 8 million of notes receivables we remeasured our previouslyheld investments to their estimated acquisitiondate fair value of 31 million and recorded a gain of 19 million in other net in the accompanying consolidated statements of operations during the second quarter of 2014 we measured the fair values of the previouslyheld investments based on the liquidation preferences and priority of the equity interest and debt including accrued interest 76the following summarizes the aggregate purchase price allocation for our 2014 acquisitions as of december 31 2014goodwill210amortizable intangible assets263inventory23property plant and equipment17prepaid transaction service agreement5other net assets1deferred income taxes7 510we allocated a portion of the purchase price to specific intangible asset categories as follows amountassignedin millions weightedaverageamortizationperiodin years range of riskadjusted discountrates used inpurchase priceallocationamortizable intangible assets     technologyrelated233 10  14 14  18 customer relationships29 10 18other intangible assets1 2 14 263    for our 2016 2015 and 2014 acquisitions our technologyrelated intangible assets consist of technical processes intellectual property and institutional understanding with respect to products and processes that we will leverage in future products or processes and will carry forward from one product generation to the next we used the income approach and relief from royalty approach to derive the fair value of the technologyrelated intangible assets and are amortizing them on a straightline basis over their assigned estimated useful livesinprocess research and development represents the estimated fair value of acquired inprocess research and development projects that have not yet reached technological feasibility these indefinitelived intangible assets are tested for impairment on an annual basis or more frequently if impairment indicators are present in accordance with us gaap and our accounting policies upon completion of the associated research and development efforts we will determine the useful life of the technology and begin amortizing the assets to reflect their use over their remaining lives the primary basis for determining the technological feasibility or completion of these projects is obtaining regulatory approval to market the underlying productscustomer relationships represent the estimated fair value of noncontractual customer payor and distributor relationships customer relationships are direct relationships with physicians and hospitals performing procedures with the acquired products payor relationships are contracts and relationships with healthcare payors relating to reimbursement of services and distributor relationships are relationships with third parties used to sell the acquired products all as of the acquisition date these relationships were valued separately from goodwill because there is a history and pattern of conducting business with customers and distributors we used the income approach or the replacement cost and lost profits methodology to derive the fair value of the customer relationships the customer relationships intangible assets are amortized on a straightline basis over their assigned estimated useful livesother intangible assets primarily include acquired tradenames these tradenames include brand names that we expect to continue using in our product portfolio and related marketing materials the tradenames are valued using a relief from royalty methodology and are amortized on a straightline basis over their assigned estimated useful liveswe believe that the estimated intangible asset values represent the fair value at the date of acquisition and do not exceed the amount a third party would pay for the assets these fair value measurements are based on significant unobservable inputs including management estimates and assumptions and accordingly are classified as level 3 within the fair value hierarchy prescribed by fasb asc topic 820 fair value measurements and disclosures 77we recorded the excess of the aggregate purchase price over the estimated fair values of the identifiable assets acquired as goodwill goodwill was established due primarily to synergies expected to be gained from leveraging our existing operations as well as revenue and cash flow projections associated with future technologies and has been allocated to our reportable segments based on the relative expected benefit of the goodwill recorded approximately 116 million based on preliminary estimates related to our 2016 acquisitions is deductible for tax purposes of the goodwill recorded related to our 2015 acquisitions 449 million is deductible for tax purposes and 160 million of the recorded goodwill related to our 2014 acquisitions is deductible for tax purposes refer to note d  goodwill and other intangible assets for more information related to goodwill allocated to our reportable segmentscontingent considerationcertain of our acquisitions involve contingent consideration arrangements payment of additional consideration is generally contingent on the acquired company reaching certain performance milestones including attaining specified revenue levels achieving product development targets andor obtaining regulatory approvals in accordance with us gaap we recognize a liability equal to the fair value of the contingent payments we expect to make as of the acquisition date we remeasure this liability each reporting period and record changes in the fair value through a separate line item within our consolidated statements of operations we recorded a net expense related to the changes in fair value of our contingent consideration liabilities of 29 million during 2016 net expense related to the changes in fair value of our contingent consideration liabilities of 123 million during 2015 and a net benefit related to the change in fair value of our contingent consideration liabilities of 85 million during 2014 we made contingent consideration payments of 122 million in 2016 213 million in 2015 and 137 million in 2014changes in the fair value of our contingent consideration liabilities were as follows in millionsbalance as of december 31 2014274amounts recorded related to new acquisitions63other amounts recorded related to prior acquisitions1fair value adjustment123contingent payments related to prior period acquisition213balance as of december 31 2015246amounts recorded related to new acquisitions50other amounts recorded related to prior acquisitions1fair value adjustment29contingent payments related to prior period acquisition122balance as of december 31 2016204as of december 31 2016 the maximum amount of future contingent consideration undiscounted that we could be required to pay was approximately 1308 billion contingent consideration liabilities are remeasured to fair value each reporting period using projected revenues discount rates probabilities of payment and projected payment dates the recurring level 3 fair value measurements of our contingent consideration liabilities include the following significant unobservable inputscontingent consideration liabilityfair value as of december 31 2016valuation techniqueunobservable inputrangerampd and commercializationbased milestone46 milliondiscounted cash flowdiscount rate2  3projected year of payment2017  2021revenuebased payments60 milliondiscounted cash flowdiscount rate11  15projected year of payment2017  202698 millionmonte carlorevenue volatility25risk free ratelibor term and cost of debt structureprojected year of payment2017  2022 78increases or decreases in the fair value of our contingent consideration can result from changes in discount periods and rates as well as changes in the timing and amount of revenue estimates or in the timing or likelihood of achieving rampd regulatory and commercializationbased and revenuebased milestones projected contingent payment amounts related to some of our rampd regulatory and commercializationbased and revenuebased milestones are discounted back to the current period using a discounted cash flow dcf model other revenuebased payments are valued using a monte carlo valuation model which simulates future revenues during the earn outperiod using managements best estimates projected revenues are based on our most recent internal operational budgets and longrange strategic plans increases in projected revenues and probabilities of payment may result in higher fair value measurements increases in discount rates and the time to payment may result in lower fair value measurements increases or decreases in any of those inputs together or in isolation may result in a significantly lower or higher fair value measurement strategic investmentson april 30 2015 we acquired a 27 percent ownership interest in preventice solutions inc preventice which includes 185 percent of preventices common stock preventice is a privatelyheld company headquartered in minneapolis mn and a leading developer of mobile health solutions and services in addition to the equity agreement we entered into a commercial agreement with preventice under which we have become preventices exclusive worldwide sales and marketing representative in october 2016 we notified preventice of our intent to terminate the commercial agreement and will transition the sales force back to preventice in 2017 under the terms of the agreement on april 13 2015 we acquired 25 percent of the common stock of frankenman medical equipment company frankenman frankenman is a privatelyheld company headquartered in suzhou china and is a local market leader in surgical staplers additionally we entered into copromotional and coselling agreements with frankenman to commercialize selected products jointly in china we believe this alliance will enable us to reach more clinicians and treat more patients in china by providing access to training on less invasive endoscopic technologies with clinical and economic benefitswe are accounting for our investments in preventice and frankenman as well as certain of our other strategic investments as equity method investments in accordance with fasb asc topic 323 the aggregate carrying amount of our strategic investments as of december 31 2016 and december 31 2015 were comprised of the following categories  as of  december 31 2016december 31 2015equity method investments 265173cost method investments 2045availableforsale securities 20notes receivable 4230  347248as of december 31 2016 the book value of our equity method investments exceeded our share of the book value of the investees underlying net assets by approximately 200 million which represents amortizable intangible assets and inprocess research and development corresponding deferred tax liabilities and goodwill the net losses from our equity method adjustments presented within the other net caption of our consolidated statement of operations were 17 million in 2016 and were immaterial in 2015 and 2014 note c  divestituresin january 2011 we closed the sale of our neurovascular business to stryker corporation for a purchase price of 1500 billion in cash at the time of divestiture due to our continuing involvement in the operations of the neurovascular business following the transaction the divestiture did not meet the criteria for presentation as a discontinued operation our sales related to our divested neurovascular business have declined as the various transition services and supply agreements have terminatedwe recorded a gain of 12 million during 2014 associated with the transaction and we recorded revenue related to the neurovascular business following its divestiture of 4 million in 2014  79note d  goodwill and other intangible assetsthe gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated writeoffs of goodwill as of december 31 2016 and 2015 are as follows   as of december 31 2016 as of december 31 2015  gross carrying accumulatedamortization gross carrying accumulatedamortizationin millions amount writeoffs amount writeoffsamortizable intangible assets        technologyrelated 9123 4468 8948 4054patents 529 374 520 358other intangible assets 1583 722 1529 610  11235 5564 10997 5022unamortizable intangible assets        goodwill 16578 9900 16373 9900inprocess research and development iprampd 92  99 technologyrelated 120  120   16790 9900 16592 9900our technologyrelated intangible assets that are not subject to amortization represent technical processes intellectual property andor institutional understanding acquired through business combinations that are fundamental to the ongoing operations of our business and have no limit to their useful life our technologyrelated intangible assets that are not subject to amortization are comprised primarily of certain acquired balloon and other technology which is foundational to our continuing operations within the cardiovascular market and other markets within interventional medicine we assess our indefinitelived intangible assets at least annually for impairment and reassess their classification as indefinitelived assets we assess qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not that our indefinitelived intangible assets are impaired if we conclude that it is more likely than not that the asset is impaired we then determine the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying value in accordance with fasb asc topic 350the following represents our goodwill balance by global reportable segmentin millions cardiovascular rhythm management medsurg totalbalance as of december 31 2014 3426 290 2182 5898purchase price adjustments 2 2 2 2goodwill acquired 23  550 573balance as of december 31 2015 3451 292 2730 6473purchase price adjustments  2 1 3goodwill acquired 62  146 208balance as of december 31 2016 3513 290 2875 6678the 2016 and 2015 purchase price adjustments relate primarily to adjustments in taxes payable and deferred income taxes including changes in the liability for unrecognized tax benefitsgoodwill impairment testingwe test our goodwill balances during the second quarter of each year for impairment or more frequently if indicators are present or changes in circumstances suggest that impairment may existin performing the goodwill impairment assessment we utilize both the optional qualitative assessment and the twostep approach prescribed under fasb asc topic 350 beginning in 2016 the qualitative assessment was used for testing certain reporting units where fair value has historically exceeded the carrying value by greater than 100 all other reporting units were tested using the twostep approach in 2016 for all reporting units tested using the optional qualitative assessment we concluded that it was not necessary to perform the first step of the twostep goodwill test for all reporting units tested under the two step approach we concluded that the fair value of each reporting unit exceeded its carrying value because our global electrophysiology reporting  80unit was identified as being at higher risk of potential goodwill impairment during our 2015 annual test it was tested for impairment on a standalone basis in the second quarter of 2016 immediately prior to aggregating it with our global cardiac rhythm management reporting unit the fair value of the standalone global electrophysiology reporting unit exceeded the carrying value by approximately 36 percent in comparison the global electrophysiology reporting unit had excess fair value of approximately 28 percent as of our 2015 annual test as of the date of our 2016 annual goodwill impairment test the aggregated global electrophysiology and cardiac rhythm management operating segment rhythm management had excess fair value over carrying value of approximately 70 percent and held 292 million of allocated goodwill as such it was not deemed at higher risk of future impairment changes in our reporting units or in the structure of our business as a result of future reorganizations acquisitions or divestitures of assets or businesses could result in future impairments of goodwill within our reporting units refer to note a  significant accounting policies and critical accounting policies and estimates within managements discussion and analysis of financial condition and results of operations contained in item 7 of this annual report on form 10k for a discussion of key assumptions used in our testingon a quarterly basis we monitor the key drivers of fair value to detect events or other changes that would warrant an interim impairment test of our goodwill the key variables that drive the cash flows of our reporting units and amortizable intangibles are estimated revenue growth rates and levels of profitability terminal value growth rate assumptions as well as the weighted average cost of capital wacc rate applied are additional key variables for reporting unit cash flows these assumptions are subject to uncertainty including our ability to grow revenue and improve profitability levels relatively small declines in the future performance and cash flows of a reporting unit or asset group or small changes in other key assumptions may result in the recognition of significant goodwill impairment charges for example as of the date of our annual goodwill impairment test keeping all other variables constant a combined increase of 50 basis points in the wacc along with a simultaneous decrease of 150 basis points in the long term growth rate applied would require that we perform the second step of the goodwill impairment test for our global electrophysiology reporting unit the estimates used for our future cash flows and discount rates represent managements best estimates which we believe to be reasonable but future declines in business performance may result in impairment of our goodwill future events or factors could have a negative impact on the levels of excess fair value over carrying value of our reporting units and negative changes in one or more of these events or factors could result in impairment chargesthe following is a rollforward of accumulated goodwill writeoffs by global reportable segmentin millions cardiovascular rhythm management medsurg totalaccumulated writeoffs as of december 31 2014 1479 6960 1461 9900goodwill written off    accumulated writeoffs as of december 31 2015 1479 6960 1461 9900goodwill written off    accumulated writeoffs as of december 31 2016 1479 6960 1461 9900intangible asset impairment chargesunamortizable intangible assets are tested for impairment on an annual basis during the third quarter of each year or more frequently if impairment indicators are present in accordance with us gaap and our accounting policies described in note a  significant accounting policies of this annual report on form 10k in addition on a quarterly basis we monitor all intangible assets for events or other potential indicators of impairment that would warrant an interim impairment test the intangible asset category and associated write downs recorded in 2016 2015 and 2014 were as follows  year ended december 31in millions 2016 2015 2014amortizable intangible assets 4 9 107inprocess research and development 7 10 88  11 19 195 812014 chargesduring the fourth quarter of 2014 as a result of revised estimates in conjunction with our annual operating plan we performed an interim impairment test of inprocess research and development projects associated with certain of our acquisitions based on our impairment assessment and lower expected future cash flows associated with our intangible assets we recorded an impairment charge of 18 million to writedown the balances of these inprocess projects to their fair value which was determined to be zeroduring the third quarter of 2014 we performed our annual impairment test of all inprocess research and development projects and our indefinite lived core technology assets based on the results of our annual test we recorded total impairment charges of 4 million to writedown the balances of certain inprocess projects to their fair value in addition as a result of revised estimates in conjunction with our annual operating plan we performed an interim impairment test of core technology associated with certain of our acquisitions and recorded an impairment charge of 8 million for a total of 12 million of impairment charges in the third quarter of 2014 during the second quarter of 2014 as a result of revised estimates developed in conjunction with our annual strategic planning process and annual goodwill impairment test we performed an interim impairment test of our inprocess research and development projects and core technology assets associated with certain of our acquisitions based on our impairment assessment and lower expected future cash flows associated with our intangible assets we recorded impairment charges of 110 million the impairment charges were due to changes in our clinical strategy and lower estimates of the european and global hypertension markets and the resulting amount of future revenue and cash flows associated with our hypertension technology as a result we recorded impairment charges of 67 million related to these technology intangible assets in addition in the second quarter of 2014 due to revised expectations and timing as a result of the announcement of a third fda circulatory system devices panel we recorded impairment charges of 35 million related to the inprocess research and development intangible assets acquired from atritech inc atritech we also recorded an 8 million intangible asset impairment charge associated with changes in the amount of the expected cash flows related to certain other acquired inprocess research and development projects during the first quarter of 2014 as a result of lower estimates of the resistant hypertension market following the announcement of data from a competitors clinical trial we performed an interim impairment test of our hypertensionrelated inprocess research and development projects and core technology assets the impairment assessments were based upon probabilityweighted cash flows of potential future scenarios based on our impairment assessment and lower expected future cash flows associated with our hypertensionrelated intangible assets we recorded impairment charges of 55 million in the first quarter of 2014 to writedown the balance of these intangible assets to their fair value 82the nonrecurring level 3 fair value measurements of our intangible asset impairment analysis included the following significant unobservable inputsintangible assetvaluation datefair valuevaluation techniqueunobservable inputratetechnologyrelated amortizableseptember 30 20158 millionincome approach excess earnings methoddiscount rate10inprocess rampdjune 30 20156 millionincome approach  excess earnings methoddiscount rate 165  20inprocess rampdseptember 30 201416 millionincome approach  excess earnings methoddiscount rate 165  20inprocess rampdjune 30 201483 millionincome approach  excess earnings methoddiscount rate 165  20technologyrelated amortizablejune 30 20148 millionincome approach  excess earnings methoddiscount rate15inprocess rampdmarch 31 20146 millionincome approach  excess earnings methoddiscount rate20technologyrelated amortizablemarch 31 201464 millionincome approach  excess earnings methoddiscount rate15estimated amortization expense for each of the five succeeding fiscal years based upon our intangible asset portfolio as of december 31 2016 is as follows     estimated amortization expensefiscal year in millions 2017 5352018 5252019 5232020 5192021 481note e  fair value measurementsderivative instruments and hedging activitieswe address market risk from changes in foreign currency exchange rates and interest rates through a risk management program that includes the use of derivative financial instruments and we operate the program pursuant to documented corporate risk management policies our derivative instruments do not subject our earnings or cash flows to material risk as gains and losses on these derivatives generally offset losses and gains on the item being hedged we do not enter into derivative transactions for speculative purposes and we do not have any nonderivative instruments that are designated as hedging instruments pursuant to fasb asc topic 815 83currency hedgingwe are exposed to currency risk consisting primarily of foreign currency denominated monetary assets and liabilities forecasted foreign currency denominated intercompany transactions and thirdparty transactions and net investments in certain subsidiaries we manage our exposure to changes in foreign currency exchange rates on a consolidated basis to take advantage of offsetting transactions we use derivative instruments and nonderivative transactions to reduce the risk that our earnings and cash flows associated with these foreign currency denominated balances and transactions will be adversely affected by foreign currency exchange rate changescurrently or previously designated foreign currency hedgesall of our designated currency hedge contracts outstanding as of december 31 2016 and december 31 2015 were cash flow hedges under topic 815 intended to protect the us dollar value of our forecasted foreign currency denominated transactions we record the effective portion of any change in the fair value of foreign currency cash flow hedges in other comprehensive income oci until the related thirdparty transaction occurs once the related thirdparty transaction occurs we reclassify the effective portion of any related gain or loss on the foreign currency cash flow hedge to earnings in the event the hedged forecasted transaction does not occur or it becomes no longer probable that it will occur we reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time we had currency derivative instruments designated as cash flow hedges outstanding in the contract amount of 2271 billion as of december 31 2016 and 1458 billion as of december 31 2015we recognized net gains of 133 million during 2016 on our cash flow hedges as compared to 213 million of net gains during 2015 and 105 million of net gains during 2014 all currency cash flow hedges outstanding as of december 31 2016 mature within 60 months as of december 31 2016 102 million of net gains net of tax were recorded in accumulated other comprehensive income aoci to recognize the effective portion of the fair value of any currency derivative instruments that are or previously were designated as foreign currency cash flow hedges as compared to net gains of 145 million as of december 31 2015 as of december 31 2016 63 million of net gains net of tax may be reclassified to earnings within the next twelve monthsthe success of our hedging program depends in part on forecasts of transaction activity in various currencies primarily british pound sterling euro and japanese yen we may experience unanticipated currency exchange gains or losses to the extent that there are differences between forecasted and actual activity during periods of currency volatility in addition changes in foreign currency exchange rates related to any unhedged transactions may impact our earnings and cash flowsnondesignated foreign currency contractswe use currency forward contracts as a part of our strategy to manage exposure related to foreign currency denominated monetary assets and liabilities these currency forward contracts are not designated as cash flow fair value or net investment hedges under fasb asc topic 815 are markedtomarket with changes in fair value recorded to earnings and are entered into for periods consistent with currency transaction exposures generally less than one year we had currency derivative instruments not designated as hedges under fasb asc topic 815 outstanding in the contract amount of 1830 billion as of december 31 2016 and 2090 billion as of december 31 2015interest rate hedgingour interest rate risk relates primarily to us dollar borrowings partially offset by us dollar cash investments we have historically used interest rate derivative instruments to manage our earnings and cash flow exposure to changes in interest rates by converting fixedrate debt into floatingrate debt or floatingrate debt into fixedrate debt we had no interest rate derivative instruments outstanding as of december 31 2016 and december 31 2015we designate these derivative instruments either as fair value or cash flow hedges under fasb asc topic 815 we record changes in the value of fair value hedges in interest expense which is generally offset by changes in the fair value of the hedged debt obligation interest payments made or received related to our interest rate derivative instruments are included in interest expense we record the effective portion of any change in the fair value of derivative instruments designated as cash flow hedges as unrealized gains or losses in oci net of tax until the hedged cash flow occurs at which point the effective portion of any gain or loss is reclassified to earnings we record the ineffective portion of our cash flow hedges in interest expense in the event the hedged cash flow does not occur or it becomes no longer probable that it will occur we reclassify the amount of any gain or loss on the related cash flow hedge to interest expense at that timeduring the first quarter of 2015 we terminated interest rate derivative contracts designated as fair value hedges having a notional amount of 450 million to convert fixedrate debt into floatingrate debt and received total proceeds of approximately 35 million which included approximately 7 million of net accrued interest receivable we assessed at inception and reassessed on an  84ongoing basis whether the interest rate derivative contracts were highly effective in offsetting changes in the fair value of the hedged fixed rate debt we had no fair value hedges outstanding during 2016 and recognized no gains or losses in interest expense during 2016 during 2015 we recognized in interest expense an 8 million loss on our hedged debt and an 8 million gain on the related interest rate derivatives contracts this resulted in immaterial net gains recorded in earning due to ineffectiveness in 2015during the second quarter of 2015 we entered into forward starting interest rate derivative contracts having a notional amount of 450 million to hedge interest rate risk associated with a planned issuance of fixedrate senior notes which we designated as cash flow hedges these hedges were terminated during the second quarter at the time we issued the fixedrate senior notes and we received total proceeds of approximately 11 million we had no amount outstanding under these hedges as of december 31 2016 and december 31 2015 we assessed at inception and reassessed on an ongoing basis whether the cash flow derivative contracts were highly effective in offsetting changes in interest rates the gain on this derivative contract was recorded within accumulated other comprehensive income and is being amortized into earnings as a reduction to interest expense over the life of the related senior noteswe are amortizing the gains and losses on previously terminated interest rate derivative instruments including fixedtofloating interest rate contracts designated as fair value hedges and forward starting interest rate derivative contracts and treasury locks designated as cash flow hedges into earnings as a component of interest expense over the remaining term of the hedged debt in accordance with topic 815 the carrying amount of certain of our senior notes included unamortized gains of 51 million as of december 31 2016 and 63 million as of december 31 2015 and immaterial unamortized losses as of december 31 2016 and december 31 2015 in addition we had pretax net gains within aoci related to terminated forward starting interest rate derivative contracts and treasury locks of 9 million as of december 31 2016 and 10 million as of december 31 2015 the net gains that we recognized in earnings related to previously terminated interest rate derivatives were 13 million in 2016 13 million in 2015 and 9 million in 2014 as of december 31 2016 13 million of net gains may be reclassified to earnings within the next twelve months from amortization of our previously terminated interest rate derivative contractscounterparty credit riskwe do not have significant concentrations of credit risk arising from our derivative financial instruments whether from an individual counterparty or a related group of counterparties we manage our concentration of counterparty credit risk on our derivative instruments by limiting acceptable counterparties to a diversified group of major financial institutions with investment grade credit ratings limiting the amount of credit exposure to each counterparty and by actively monitoring their credit ratings and outstanding fair values on an ongoing basis furthermore none of our derivative transactions are subject to collateral or other security arrangements and none contain provisions that are dependent on our credit ratings from any credit rating agencywe also employ master netting arrangements that reduce our counterparty payment settlement risk on any given maturity date to the net amount of any receipts or payments due between us and the counterparty financial institution thus the maximum loss due to counterparty credit risk is limited to the unrealized gains in such contracts net of any unrealized losses should any of these counterparties fail to perform as contracted although these protections do not eliminate concentrations of credit risk as a result of the above considerations we do not consider the risk of counterparty default to be significant 85fair value of derivative instrumentsthe following presents the effect of our derivative instruments designated as cash flow hedges under topic 815 on our accompanying consolidated statements of operations during 2016 2015 and 2014 in millions amount of pretaxgain lossrecognized in ocieffective portion amount of pretaxgain lossreclassified fromaoci into earningseffective portion location in statement ofoperationsyear ended december 31 2016     interest rate contracts 1 interest expensecurrency hedge contracts65 133 cost of products sold 65 134  year ended december 31 2015     interest rate contracts11 2 interest expensecurrency hedge contracts98 213 cost of products sold 109 215  year ended december 31 2014     interest rate contracts 1 interest expensecurrency hedge contracts227 105 cost of products sold 227 106  the amount of gain loss recognized in earnings related to the ineffective portion of hedging relationships was immaterial in all periods presentednet gains and losses on currency hedge contracts not designated as hedging instruments were offset by net losses and gains from foreign currency transaction exposures as shown in the following tablein millions   location in statement ofoperations year ended december 31   2016 2015 2014  gain loss on currency hedge contracts 20 48 52 other netgain loss on foreign currency transaction exposures 7 69 70 other netnet foreign currency gain loss 13 21 18  fasb asc topic 815 requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet we determine the fair value of our derivative instruments using the framework prescribed by fasb asc topic 820 by considering the estimated amount we would receive or pay to transfer these instruments at the reporting date and by taking into account current interest rates foreign currency exchange rates the creditworthiness of the counterparty for the assets and our creditworthiness for liabilities in certain instances we may utilize financial models to measure fair value in doing so we use inputs that include quoted prices for similar assets or liabilities in active markets quoted prices for identical or similar assets or liabilities in markets that are not active other observable inputs for the asset or liability and inputs derived principally from or corroborated by observable market data by correlation or other means as of december 31 2016 we have classified all of our derivative assets and liabilities within level 2 of the fair value hierarchy prescribed by topic 820 as discussed below because these observable inputs are available for substantially the full term of our derivative instruments 86the following are the balances of our derivative assets and liabilities as of december 31 2016 and december 31 2015  as of  december 31 december 31in millionslocation in balance sheet 12016 2015derivative assets    designated hedging instruments    currency hedge contractsother current assets98 138currency hedge contractsother longterm assets65 66  163 204nondesignated hedging instruments    currency hedge contractsother current assets36 33total derivative assets 199 237     derivative liabilities    designated hedging instruments    currency hedge contractsother current liabilities3 1currency hedge contractsother longterm liabilities4   7 1nondesignated hedging instruments    currency hedge contractsother current liabilities19 22total derivative liabilities 26 231we classify derivative assets and liabilities as current when the remaining term of the derivative contract is one year or lessother fair value measurementsrecurring fair value measurementson a recurring basis we measure certain financial assets and financial liabilities at fair value based upon quoted market prices where available where quoted market prices or other observable inputs are not available we apply valuation techniques to estimate fair value topic 820 establishes a threelevel valuation hierarchy for disclosure of fair value measurements the categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value the three levels of the hierarchy are defined as followslevel 1  inputs to the valuation methodology are quoted market prices for identical assets or liabilitieslevel 2  inputs to the valuation methodology are other observable inputs including quoted market prices for similar assets or liabilities and marketcorroborated inputslevel 3  inputs to the valuation methodology are unobservable inputs based on managements best estimate of inputs market participants would use in pricing the asset or liability at the measurement date including assumptions about risk 87assets and liabilities measured at fair value on a recurring basis consist of the following as of december 31 2016 and december 31 2015 as of december 31 2016 as of december 31 2015in millionslevel 1 level 2 level 3 total level 1 level 2 level 3 totalassets               money market and government funds42   42 118   118availableforsalesecurities20   20    currency hedge contracts 199  199  237  237 62 199  261 118 237  355liabilities               currency hedge contracts 26  26  23  23accrued contingent consideration  204 204   246 246  26 204 230  23 246 269our investments in money market and government funds are classified within level 1 of the fair value hierarchy because they are valued using quoted market prices these investments are classified as cash and cash equivalents within our accompanying consolidated balance sheets in accordance with us gaap and our accounting policies in addition to 42 million invested in money market and government funds as of december 31 2016 we had 19 million in shortterm time deposits and 135 million in interest bearing and noninterest bearing bank accounts in addition to 118 million invested in money market and government funds as of december 31 2015 we had 31 million in shortterm time deposits and 170 million in interest bearing and noninterest bearing bank accounts on december 1 2016 we signed a subscription agreement to acquire 11817000 shares of neovascs common stock for 060 per share or 7 million the subscription agreement was accounted for as a derivative forward contract in accordance with fasb asc topic 815 until the settlement date on december 12 2016 the contract was settled and we acquired the shares of neovascs common stock for 7 million the fair value of the shares purchased on the settlement date was 26 million therefore we recognized a gain of 12 million net of tax in earnings on the forward contract during 2016 subsequently we are accounting for the investment as an availableforsale security in accordance with fasb asc topic 320our recurring fair value measurements using significant unobservable inputs level 3 relate solely to our contingent consideration liability refer to note b  acquisitions and strategic investments for a discussion of the changes in the fair value of our contingent consideration liability and additional details on our neovasc strategic investmentnonrecurring fair value measurementswe hold certain assets and liabilities that are measured at fair value on a nonrecurring basis in periods subsequent to initial recognition the fair value of a cost method investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment refer to note b  acquisitions and strategic investments for a discussion of our strategic investmentsthe fair value of our outstanding debt obligations was 5739 billion as of december 31 2016 and 5887 billion as of december 31 2015 which was determined by using quoted market prices for our publiclyregistered senior notes classified as level 1 within the fair value hierarchy refer to note f  borrowings and credit arrangements for a discussion of our debt obligations 88note f  borrowings and credit arrangementswe had total debt of 5484 billion as of december 31 2016 and 5677 billion as of december 31 2015 the debt maturity schedule for the significant components of our debt obligations as of december 31 2016 is as followsin millions2017 2018 2019 2020 2021 thereafter totalsenior notes250 600  1450  2350 4650term loans 225 150 375   750 250 825 150 1825  2350 5400 note the table above does not include unamortized discounts associated with our senior notes or amounts related to interest rate contracts used to hedge the fair value of certain of our senior notes or debt issuance costsrevolving credit facilityon april 10 2015 we entered into a new 2000 billion revolving credit facility the 2015 facility with a global syndicate of commercial banks and terminated our previous 2000 billion revolving credit facility the 2015 facility matures on april 10 2020 eurodollar and multicurrency loans under the 2015 facility bear interest at libor plus an interest margin of between 0900 percent and 1500 percent based on our corporate credit ratings and consolidated leverage ratio 1300 percent as of december 31 2016 in addition we are required to pay a facility fee based on our credit ratings consolidated leverage ratio and the total amount of revolving credit commitments regardless of usage under the agreement 0200 percent as of december 31 2016 the 2015 facility contains covenants which among other things require that we maintain a minimum interest coverage ratio of 30 times consolidated ebitda and a maximum leverage ratio of 45 times consolidated ebitda for the first four fiscal quarterends following the closing of the ams portfolio acquisition on august 3 2015 and decreasing to 425 times 400 times and 375 times consolidated ebitda for the next three fiscal quarterends after such four fiscal quarterends respectively and then to 350 times for each fiscal quarterend thereafter there were no amounts borrowed under our current and prior revolving credit facilities as of december 31 2016 or december 31 2015 our revolving credit facility agreement in place as of december 31 2016 requires that we maintain certain financial covenants as follows covenantrequirement as of december 31 2016 actual as of december 31 2016maximum leverage ratio 140 times 24 timesminimum interest coverage ratio 230 times 98 times1ratio of total debt to consolidated ebitda as defined by the credit agreement for the preceding four consecutive fiscal quarters 2ratio of consolidated ebitda as defined by the credit agreement to interest expense for the preceding four consecutive fiscal quartersthe credit agreement for the 2015 facility provides for an exclusion from the calculation of consolidated ebitda as defined by the credit agreement through the credit agreement maturity of any noncash charges and up to 620 million in restructuring charges and restructuringrelated expenses related to our current or future restructuring plans as of december 31 2016 we had 485 million of the restructuring charge exclusion remaining in addition any cash litigation payments net of any cash litigation receipts as defined by the agreement are excluded from the calculation of consolidated ebitda and any new debt issued to fund any tax deficiency payments is excluded from consolidated total debt as defined in the agreement provided that the sum of any excluded net cash litigation payments and any new debt issued to fund any tax deficiency payments not exceed 2000 billion in the aggregate as of december 31 2016 we had approximately 885 million of the combined legal and debt exclusion remaining as of and through december 31 2016 we were in compliance with the required covenantsany inability to maintain compliance with these covenants could require us to seek to renegotiate the terms of our credit facility or seek waivers from compliance with these covenants both of which could result in additional borrowing costs further there can be no assurance that our lenders would agree to such new terms or grant such waivers 89term loansas of december 31 2016 we had an aggregate 750 million outstanding under our unsecured term loan facilities and 1000 billion outstanding under these facilities as of december 31 2015 these facilities include an unsecured term loan facility entered into in august 2013 2013 term loan which had 150 million outstanding as of december 31 2016 and 250 million outstanding as of december 31 2015 along with an unsecured term loan credit facility entered into in april 2015 2015 term loan which had 600 million outstanding as of december 31 2016 and 750 million outstanding as of december 31 2015borrowings under the 2013 term loan bear interest at libor plus an interest margin of between 10 percent and 175 percent currently 15 percent based on our corporate credit ratings and consolidated leverage ratio we repaid 150 million of our 2013 term loan facility in the fourth quarter of 2015 and repaid an additional 100 million during the second quarter of 2016 as a result and in accordance with the credit agreement the outstanding balance of 150 million is the remaining principal amount due at the final maturity date in august 2018the 2013 term loan borrowings are repayable at any time without premium or penalty our term loan facility requires that we comply with certain covenants including financial covenants with respect to maximum leverage and minimum interest coverage consistent with the 2015 term loan facility the maximum leverage ratio requirement is 40 times our actual leverage ratio as of december 31 2016 is 24 times and the minimum interest coverage ratio requirement is 30 times our actual interest coverage ratio as of december 31 2016 is 98 times on april 10 2015 we entered into a new 750 million unsecured term loan credit facility which matures on august 3 2020 the 2015 term loan was funded on august 3 2015 and was used to partially fund the ams portfolio acquisition including the payment of fees and expenses term loan borrowings under this facility bear interest at libor plus an interest margin of between 100 percent and 175 percent currently 150 percent based on our corporate credit ratings and consolidated leverage ratio we repaid 150 million of our 2015 term loan during the second quarter of 2016 the remaining 2015 term loan requires quarterly principal payments of 38 million commencing in the third quarter of 2018 and the remaining principal amount is due at the final maturity date of august 3 2020 the 2015 term loan agreement requires that we comply with certain covenants including financial covenants with respect to maximum leverage and minimum interest coverage consistent with our revolving credit facility the maximum leverage ratio requirement is 40 times our actual leverage ratio as of december 31 2016 is 24 times and the minimum interest coverage ratio requirement is 30 times our actual interest coverage ratio as of december 31 2016 is 98 times senior noteswe had senior notes outstanding of 4650 billion as of december 31 2016 and december 31 2015 in may 2015 we completed the offering of 1850 billion in aggregate principal amount of senior notes consisting of 600 million in aggregate principal amount of 2850 notes due 2020 500 million in aggregate principal amount of 3375 notes due 2022 and 750 million in aggregate principal amount of 3850 notes due 2025 the net proceeds from the offering of the notes after deducting underwriting discounts and estimated offering expenses were approximately 1830 billion we used a portion of the net proceeds from the senior notes offering to redeem 400 million aggregate principal amount of our 5500 notes due november 2015 and 600 million aggregate principal amount of our 6400 notes due june 2016 the remaining senior notes offering proceeds together with the 2015 term loan were used to fund the ams portfolio acquisition we recorded a charge of 45 million in interest expense during the second quarter of 2015 for premiums accelerated amortization of debt issuance costs and investor discount costs net of interest rate hedge gains related to the early debt extinguishment our senior notes were issued in public offerings are redeemable prior to maturity and are not subject to any sinking fund requirements our senior notes are unsecured unsubordinated obligations and rank on parity with each other these notes are effectively junior to borrowings under our credit and security facility to the extent if borrowed by our subsidiaries and to liabilities of our subsidiaries see other arrangements below on january 12 2017 we used our existing credit facilities to repay the 250 million plus interest of our senior notes due in january 2017 90our senior notes consist of the following as of december 31 2016 amountin millions issuancedate maturity date semiannualcoupon ratejanuary 2017 notes250 november 2004 january 2017 5125october 2018 notes600 august 2013 october 2018 2650january 2020 notes850 december 2009 january 2020 6000may 2020 notes600 may 2015 may 2020 2850may 2022 notes500 may 2015 may 2022 3375may 2025 notes750 may 2015 may 2025 3850october 2023 notes450 august 2013 october 2023 4125november 2035 notes350 november 2005 november 2035 6250january 2040 notes300 december 2009 january 2040 7375 4650      our 4050 billion of senior notes issued in 2009 2013 and 2015 contain a changeincontrol provision which provides that each holder of the senior notes may require us to repurchase all or a portion of the notes at a price equal to 101 percent of the aggregate repurchased principal plus accrued and unpaid interest if a rating event as defined in the indenture occurs as a result of a changeincontrol as defined in the indenture any other credit rating changes may impact our borrowing cost but do not require us to repay any borrowings the interest rate payable on our november 2035 notes is currently 700 percent corporate credit rating improvements may result in a decrease in the adjusted interest rate on our november 2035 notes to the extent that our lowest credit rating is above bbb or baa3 the interest rates on our november 2035 notes will be permanently reinstated to the issuance rate if the lowest credit ratings assigned to these senior notes is either a or a3 or higherother arrangementswe maintained a 300 million credit and security facility secured by our us trade receivables maturing on june 9 2017 the credit and security facility required that we maintain a maximum leverage covenant consistent with our revolving credit facility the maximum leverage ratio requirement was 40 times and our actual leverage ratio as of december 31 2016 was 24 times we had borrowings of 60 million outstanding under this facility as of december 31 2016 and no borrowings outstanding as of december 31 2015 on february 7 2017 we amended the terms of this credit and security facility including increasing the facility size to 400 million this amendment retained a similar maximum leverage ratio requirement and extended the facility maturity to february 2019we have accounts receivable factoring programs in certain european countries that we account for as sales under fasb asc topic 860 transfers and servicing these agreements provide for the sale of accounts receivable to third parties without recourse of up to approximately 391 million as of december 31 2016 we have no retained interests in the transferred receivables other than collection and administrative responsibilities and once sold the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy we derecognized 152 million of receivables as of december 31 2016 at an average interest rate of 18 percent and 151 million as of december 31 2015 at an average interest rate of 24 percentin addition we have uncommitted credit facilities with a commercial japanese bank that provide for borrowings promissory notes discounting and receivables factoring of up to 210 billion japanese yen approximately 180 million as of december 31 2016 we derecognized 149 million of notes receivable as of december 31 2016 at an average interest rate of 16 percent and 132 million of notes receivable as of december 31 2015 at an average interest rate of 16 percent derecognized accounts and notes receivable are excluded from trade accounts receivable net in the accompanying consolidated balance sheetsas of december 31 2016 and december 31 2015 we had outstanding letters of credit of 44 million which consisted primarily of bank guarantees and collateral for workers compensation insurance arrangements as of december 31 2016 and 2015 none of the beneficiaries had drawn upon the letters of credit or guarantees accordingly we have not recognized a related liability for our outstanding letters of credit in our consolidated balance sheets as of december 31 2016 or 2015note g  leases and other purchase obligationsrent expense amounted to 80 million in 2016 76 million in 2015 and 76 million in 2014 91future minimum rental commitments as of december 31 2016 under all noncancellable lease agreements including capital leases were as follows in millions201766201860201942202034202125thereafter64   291  future minimum purchase obligations as of december 31 2016 were as follows in millions2017321201852201939202019202112thereafter15   458  note h  restructuringrelated activitieswe monitor the dynamics of the economy the healthcare industry and the markets in which we compete and assess opportunities for improved operational effectiveness and efficiency and better alignment of expenses with revenues while preserving our ability to make the investments in research and development projects capital our people that we believe are essential to our longterm success as a result of these assessments we have undertaken various restructuring initiatives in order to enhance our growth potential and position us for longterm success these initiatives are described below2016 restructuring plan on june 6 2016 our board of directors approved and we committed to a restructuring initiative the 2016 restructuring plan the 2016 restructuring plan is intended to develop global commercialization technology and manufacturing capabilities in key growth markets build on our plant network optimization pno strategy which is intended to simplify our manufacturing plant structure by transferring certain production lines among facilities and expand operational efficiencies in support of our operating income margin goals key activities under the 2016 restructuring plan include strengthening global infrastructure through evolving global real estate and workplaces developing global commercial and technical competencies enhancing manufacturing and distribution expertise in certain regions and continuing implementation of our pno strategy these activities initiated in the second quarter of 2016 and are expected to be substantially completed by the end of 2018 the implementation of the 2016 restructuring plan is expected to result in total pretax charges of approximately 175 million to 225 million and approximately 160 million to 210 million of these charges are estimated to result in cash outlays of which we have made payments of 27 million in 2016 we have recorded related costs of 47 million in 2016 and recorded a portion of these expenses as restructuring charges and the remaining portion through other lines within our consolidated statements of operations 92the following table provides a summary of our estimates of costs associated with the 2016 restructuring plan through the end of 2018 by major type of costtype of costtotal estimated amount expected to be incurredrestructuring charges termination benefits65 million to 80 millionother 115 million to 25 millionrestructuringrelated expenses other 295 million to 120 million 175 million to 225 million1 consists primarily of consulting fees and costs associated with contract cancellations2 comprised of other costs directly related to the 2016 restructuring plan including program management accelerated depreciation and costs to transfer product lines among facilities2014 restructuring planon october 22 2013 our board of directors approved and we committed to a restructuring initiative the 2014 restructuring plan the 2014 restructuring plan built on the progress we made to address financial pressures in a changing global marketplace further strengthened our operational effectiveness and efficiency and supported new growth investments key activities under the plan included continued implementation of our pno strategy continued focus on driving operational effectiveness and efficiencies and business and commercial model changes the pno strategy simplified our manufacturing plant structure by transferring certain production lines among facilities other activities involved rationalizing organizational reporting structures to streamline various functions eliminate bureaucracy increase productivity and better align resources to business strategies and marketplace dynamics these activities were initiated in the fourth quarter of 2013 and were substantially completed by the end of 2015 except for certain actions associated with our pno strategy which were completed by the end of 2016the implementation of the 2014 restructuring plan resulted in total pretax charges of 261 million and 244 million of cash outlays we recorded a portion of these expenses as restructuring charges and the remaining portion through other lines within our consolidated statements of operationsthe following table provides a summary of our total costs associated with the 2014 restructuring plan through december 31 2016 by major type of costtype of costtotal amount incurredrestructuring charges termination benefits91 millionother 134 millionrestructuringrelated expenses other 2136 million 261 million1 consists primarily of consulting fees and costs associated with contractual cancellations2 comprised of other costs directly related to the 2014 restructuring plan including program management accelerated depreciation and costs to transfer product lines among facilitieswe recorded restructuring charges pursuant to our restructuring plans of 28 million during 2016 26 million during 2015 and 69 million during 2014 in addition we recorded expenses within other lines of our accompanying consolidated statements of operations related to our restructuring initiatives of 50 million during 2016 57 million during 2015 and 48 million during 2014 93the following presents these costs credits by major type and line item within our accompanying consolidated statements of operations as well as by programyear ended december 31 2016           in millionsterminationbenefits accelerateddepreciation transfercosts fixed asset writeoffs other totalrestructuring charges19   2 7 28restructuringrelated expenses           cost of products sold  34   34selling general and administrative expenses 5   11 16  5 34  11 50 19 5 34 2 18 78            in millionsterminationbenefits accelerateddepreciation transfercosts fixed asset writeoffs other total2016 restructuring plan24 1 15  7 472014 restructuring plan5 4 19 2 11 31 19 5 34 2 18 78            year ended december 31 2015         in millionsterminationbenefits accelerateddepreciation transfercosts other totalrestructuring charges23   3 26restructuringrelated expenses         cost of products sold  31  31selling general and administrative expenses 3  23 26  3 31 23 57 23 3 31 26 83          in millionsterminationbenefits accelerateddepreciation transfercosts other total2014 restructuring plan27 3 31 26 87substantially complete restructuring plan4    4 23 3 31 26 83           94year ended december 31 2014         in millionsterminationbenefits accelerateddepreciation transfer costs other totalrestructuring charges42   27 69restructuringrelated expenses         cost of products sold  24  24selling general and administrative expenses 5  19 24  5 24 19 48 42 5 24 46 117          in millionsterminationbenefits accelerateddepreciation transfer costs other total2014 restructuring plan41 5 24 43 113substantially complete restructuring plan1   3 4 42 5 24 46 117          termination benefits represent amounts incurred pursuant to our benefit arrangements and amounts for onetime involuntary termination benefits and have been recorded in accordance with fasb asc topic 712 and fasb asc topic 420 other restructuring costs which represent primarily consulting fees and costs related to contract cancellations are being recorded as incurred in accordance with fasb asc topic 420 accelerated depreciation is being recorded over the adjusted remaining useful life of the related assets and production line transfer costs are being recorded as incurredas of december 31 2016 we have incurred cumulative restructuring charges related to our 2016 restructuring plan and our 2014 restructuring plan of 153 million and restructuringrelated costs of 155 million since we committed to the plans the following presents these costs by major type and by planin millions2016 restructuring plan 2014 restructuring plan totaltermination benefits24 91 115fixed asset writeoffs 2 2other4 32 36total restructuring charges28 125 153accelerated depreciation1 12 13transfer costs15 75 90other3 49 52restructuringrelated expenses19 136 155 47 261 308 95we made cash payments of 82 million in 2016 associated with restructuring initiatives and as of december 31 2016 we had made total cash payments of 271 million related to our 2016 restructuring plan and 2014 restructuring plan since committing to the plans these payments were made using cash generated from operations and are comprised of the followingin millions2016 restructuring plan 2014 restructuring plan totalyear ended december 31 2016     termination benefits8 24 32transfer costs15 19 34other4 12 16 27 55 82      program to date     termination benefits8 93 101transfer costs15 74 89other4 77 81 27 244 271our restructuring liability is primarily comprised of accruals for termination benefits the following is a rollforward of the termination benefit liability associated with our 2016 restructuring plan our 2014 restructuring plan and our substantially complete restructuring plan which is reported as a component of accrued expenses included in our accompanying consolidated balance sheets restructuring plan termination benefitsin millions2016 restructuring plan 2014 restructuring plan substantially complete restructuring plan totalaccrued as of december 31 2014 39 4 43charges 27 4 23cash payments 37  37accrued as of december 31 2015 29  29charges24 5  19cash payments8 24  32accrued as of december 31 201616   16in addition to our accrual for termination benefits we had a 6 million liability as of december 31 2016 and a 3 million liability as of december 31 2015 for other restructuringrelated itemsnote i  supplemental balance sheet informationcomponents of selected captions in our accompanying consolidated balance sheets are as followstrade accounts receivable net  as ofin millions december 31 2016december 31 2015accounts receivable 15911394less allowance for doubtful accounts 7375less allowance for sales returns 4644  14721275 96the following is a rollforward of our allowance for doubtful accounts for 2016 2015 and 2014  year ended december 31in millions 201620152014beginning balance 757681net charges to expenses 91510utilization of allowances 111615ending balance 737576inventories  as ofin millions december 31 2016december 31 2015finished goods 625706workinprocess 94102raw materials 236208  9551016prepaids and other current assets  as ofin millions december 31 2016december 31 2015prepaid expenses 5857restricted cash 24354other 240254  541365property plant and equipment net  as ofin millions december 31 2016december 31 2015land 9186buildings and improvements 981981equipment furniture and fixtures 29552793capital in progress 338202  43654062less accumulated depreciation 27352572  16301490accrued expenses  as ofin millions december 31 2016december 31 2015legal reserves 1062773payroll and related liabilities 572504accrued contingent consideration 63119other 615574  23121970 97other longterm liabilities  as ofin millions december 31 2016december 31 2015accrued income taxes 7811253legal reserves 9611163accrued contingent consideration 141127other longterm liabilities 455431  23382974note j  income taxes our income loss before income taxes consisted of the following  year ended december 31in millions 201620152014domestic 101916231263foreign 1196973754  177650509the related benefit for income taxes consisted of the following  year ended december 31in millions 201620152014current     federal 31592 state 635 foreign 136132111  173194104     deferred     federal 337545458 state 144123 foreign 81913  343605494  170411390 98the reconciliation of income taxes at the federal statutory rate to the actual benefit for income taxes is as follows  year ended december 31  201620152014us federal statutory income tax rate 350 350350state income taxes net of federal benefit 174865effect of foreign taxes 991344291acquisitionrelated 94 60 75research credit 1504470valuation allowance 42223 40 compensationrelated 64 16 07 nondeductible expenses 93 24 19 uncertain domestic tax positions 55 27 20 other net 3504 02  959632767     we had net deferred tax assets of 62 million as of december 31 2016 and net deferred tax liabilities of 264 million as of december 31 2015 gross deferred tax liabilities of 1760 billion as of december 31 2016 and 1875 billion as of december 31 2015 relate primarily to goodwill and intangible assets acquired in connection with our prior acquisitions gross deferred tax assets of 1822 billion as of december 31 2016 and 1611 billion as of december 31 2015 relate primarily to the establishment of inventory and productrelated reserves litigation product liability and other reserves and accruals compensation related accruals net operating loss carryforwards and tax credit carryforwards and the federal benefit of uncertain tax positions 99significant components of our deferred tax assets and liabilities are as follows  as of december 31 in millions 2016 2015      deferred tax assets    inventory costs and related reserves 37 49tax benefit of net operating loss and credits 798 742reserves and accruals 228 232restructuringrelated charges 14 17litigation and product liability reserves 752 689investment writedown 17 7compensation related 142 138federal benefit of uncertain tax positions 238 197other 42 39  2268 2110less valuation allowance 446 499  1822 1611 deferred tax liabilities    property plant and equipment 42 44unrealized gains and losses on derivative financial instruments 67 82intangible assets 1651 1749  1760 1875      net deferred tax assets  liabilities 62 264     prepaid on intercompany profit 75 63 net deferred tax assets  liabilities and prepaid on intercompany profit 137 201our deferred tax assets deferred tax liabilities and prepaid on intercompany profit are included in the following locations within our accompanying consolidated balance sheets in millions location inas of december 31componentbalance sheet20162015current deferred tax asset and prepaid on intercompany profitdeferred income taxes75496noncurrent deferred tax assetother longterm assets8040deferred tax assets and prepaid on intercompany profit 155536    current deferred tax liabilityother current liabilities2noncurrent deferred tax liabilitydeferred income taxes18735deferred tax liabilities 18737    net deferred tax assets  liabilities and prepaid on intercompany profit 137201as of december 31 2016 we had us federal and state tax net operating loss carryforwards and tax credits the tax effect of which was 724 million as of december 31 2015 we had us federal and state tax net operating loss carryforwards and tax credits the tax effect of which was 500 million in addition we had foreign tax net operating loss carryforwards and tax credits the tax effect of which was 172 million as of december 31 2016 as compared to 273 million as of december 31 2015 these tax attributes will expire periodically beginning in 2017 the tax effect of both us federal and state tax net operating loss carryforwards and tax credits and foreign tax net operating loss carryforwards and tax credits as of december 31 2015 was  100previously disclosed in the amounts of 624 million and 288 million respectively we are updating these amounts to reflect unrecognized tax benefits that reduce the amountsthe current accounting standard for stockbased compensation prohibits the recognition of windfall tax benefits from stockbased compensation deducted for tax return purposes until realized through a reduction of income taxes payable we have 76 million and 32 million of us tax net operating loss and credits as of december 31 2016 and december 31 2015 respectively these amounts were not included in the gross deferred tax balances as of december 31 2016 and december 31 2015after consideration of all positive and negative evidence we believe that it is more likely than not that a portion of the deferred tax assets will not be realized as a result we established a valuation allowance of 446 million as of december 31 2016 and 499 million as of december 31 2015 representing a decrease of 53 million the decrease in the valuation allowance as of december 31 2016 as compared to december 31 2015 is primarily attributable to the release of valuation allowance related to certain foreign tax net operating losses which expired in 2016 the release was offset by an increase to the valuation allowance related to federal and state tax credits and state tax net operating loss carryforwards the income tax impact of the unrealized gain or loss component of other comprehensive income and stockholders equity was a charge of 9 million in 2016 a charge of 25 million in 2015 and a charge of 21 million in 2014 we have not provided us income taxes and foreign withholding taxes on the undistributed earnings of foreign subsidiaries as of december 31 2016 because we intend to permanently reinvest such earnings outside the us as of december 31 2016 the cumulative amount of excess financial reporting basis over the tax basis of investments in foreign subsidiaries that is indefinitely reinvested is approximately 98 billion generally such amounts become subject to us taxation upon the remittance of dividends and under certain other circumstances it is not practicable to estimate the amount of deferred tax liability related to investments in these foreign subsidiarieswe obtain tax incentives through free trade zone regime offered in costa rica which allows 100 exemption from income tax in the first eight years of operations and 50 exemption in the following four years this tax incentive resulted in income tax savings of 123 million for 2016 7 million for 2015 and 7 million for 2014 the tax incentive for 100 exemption from income tax is expected to expire in 2023 the impact of per share earnings is 009 for 2016 and immaterial for 2015 and 2014as of december 31 2016 we had 1095 billion of gross unrecognized tax benefits of which a net 1006 billion if recognized would affect our effective tax rate as of december 31 2015 we had 1056 billion of gross unrecognized tax benefits of which a net 900 million if recognized would affect our effective tax rate as of december 31 2014 we had 1047 billion of gross unrecognized tax benefits of which a net 903 million if recognized would affect our effective tax rate a reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows in millions  year ended december 31  2016 2015 2014       beginning balance 1056 1047 1102additions based on positions related to the current year 47 32 44additions based on positions related to prior years 14 38 3reductions for tax positions of prior years 17 36 87settlements with taxing authorities 3 18 5statute of limitation expirations 2 7 10ending balance 1095 1056 1047we are subject to us federal income tax as well as income tax of multiple state and foreign jurisdictions we have concluded all us federal income tax matters through 2000 all foreign income tax matters through 2002 and substantially all material state and local income tax matters through 2005we have received notices of deficiency from the internal revenue service irs reflecting proposed audit adjustments for guidant corporation for its 2001 through 2006 tax years and boston scientific corporation for its 2006 and 2007 tax years the total incremental tax liability asserted by the irs for the applicable periods is 1162 billion plus interest the primary issue in dispute for all years is the transfer pricing associated with the technology license agreements between domestic and foreign subsidiaries of guidant in addition the irs has proposed adjustments in connection with the financial terms of our transaction agreement with abbott laboratories pertaining to the sale of guidants vascular intervention business to abbott in april 2006 during 2014  101we received a revenue agent report from the irs reflecting significant proposed audit adjustments to our 2008 2009 and 2010 tax years based upon the same transfer pricing methodologies that the irs applied to our 2001 through 2007 tax yearswe do not agree with the transfer pricing methodologies applied by the irs or its resulting assessment we have filed petitions with the us tax court tax court contesting the notices of deficiency for the 2001 through 2007 tax years in challenge and submitted a letter to the irs office of appeals irs appeals protesting the revenue agent report for the 2008 through 2010 tax years and requesting an administrative appeal hearing the issues in dispute were scheduled to be heard in tax court in late july 2016 on july 19 2016 we entered into a stipulation of settled issues with the irs intended to resolve all of the aforementioned transfer pricing issues as well as the issues related to our transaction with abbott the stipulation of settled issues is contingent upon irs appeals applying the same basis of settlement to all transfer pricing issues for the companys 2008 2009 and 2010 tax years and if applicable review by the us congress joint committee on taxation in october 2016 we reached an agreement in principle with irs appeals as to the resolution of the transfer pricing issues in 2008 2009 and 2010 tax years subject to additional calculations of tax as well as documentation to memorialize our agreementin the event that the conditions in the stipulation of settled items are satisfied we expect to make net tax payments to the irs of approximately 275 million plus interest through the date of payment if finalized payments related to the resolution are expected in the next nine to 18 months we believe that our income tax reserves associated with these matters are adequate as of december 31 2016 and we do not expect to recognize any additional charges related to resolution of this controversy however the final resolution of these issues is contingent and if the stipulation of settled issues is not finalized it could have a material impact on our financial condition results of operations or cash flowswe recognize interest and penalties related to income taxes as a component of income tax expense we had 572 million accrued for gross interest and penalties as of december 31 2016 and 500 million as of december 31 2015 the increase in gross interest and penalties of 72 million was recognized in our consolidated statements of operations we recognized net tax expense related to interest and penalties of 46 million in 2016 37 million in 2015 and 26 million in 2014it is reasonably possible that within the next 12 months we will resolve multiple issues including transfer pricing and transactional related issues with foreign federal and state taxing authorities in which case we could record a reduction in our balance of unrecognized tax benefits of up to approximately 758 millionnote k  commitments and contingenciesthe medical device market in which we primarily participate is largely technology driven as a result intellectual property rights particularly patents and trade secrets play a significant role in product development and differentiation over the years there has been litigation initiated against us by others including our competitors claiming that our current or former product offerings infringe patents owned or licensed by them intellectual property litigation is inherently complex and unpredictable in addition competing parties frequently file multiple suits to leverage patent portfolios across product lines technologies and geographies and to balance risk and exposure between the parties in some cases several competitors are parties in the same proceeding or in a series of related proceedings or litigate multiple features of a single class of devices these forces frequently drive settlement not only for individual cases but also for a series of pending and potentially related and unrelated cases although monetary and injunctive relief is typically sought remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal accordingly the outcomes of individual cases are difficult to time predict or quantify and are often dependent upon the outcomes of other cases in other geographies during recent years we successfully negotiated closure of several longstanding legal matters and have received favorable rulings in several other matters however there continues to be outstanding intellectual property litigation adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins financial position results of operations andor liquidityin the normal course of business product liability securities and commercial claims are asserted against us similar claims may be asserted against us in the future related to events not known to management at the present time we maintain an insurance policy providing limited coverage against securities claims and we are substantially selfinsured with respect to product liability claims and fully selfinsured with respect to intellectual property infringement claims the absence of significant thirdparty insurance coverage increases our potential exposure to unanticipated claims or adverse decisions product liability claims securities and commercial litigation and other legal proceedings in the future regardless of their outcome could have a material adverse effect on our financial position results of operations andor liquidityin addition like other companies in the medical device industry we are subject to extensive regulation by national state and local government agencies in the united states and other countries in which we operate from time to time we are the subject of qui  102tam actions and governmental investigations often involving regulatory marketing and other business practices these qui tam actions and governmental investigations could result in the commencement of civil and criminal proceedings substantial fines penalties and administrative remedies and have a material adverse effect on our financial position results of operations andor liquidityin accordance with fasb asc topic 450 contingencies we accrue anticipated costs of settlement damages losses for product liability claims and under certain conditions costs of defense based on historical experience or to the extent specific losses are probable and estimable otherwise we expense these costs as incurred if the estimate of a probable loss is a range and no amount within the range is more likely we accrue the minimum amount of the rangeour accrual for legal matters that are probable and estimable was 2023 billion as of december 31 2016 and 1936 billion as of december 31 2015 and includes certain estimated costs of settlement damages and defense the increase in our legal accrual was primarily due to litigationrelated charges recorded during the year during 2016 2015 and 2014 we recorded litigationrelated net charges in the amount of 804 million 1105 billion and 1036 billion respectively we continue to assess certain litigation and claims to determine the amounts if any that management believes will be paid as a result of such claims and litigation and therefore additional losses may be accrued and paid in the future which could materially adversely impact our operating results cash flows andor our ability to comply with our debt covenantsin managements opinion we are not currently involved in any legal proceedings other than those specifically identified below which individually or in the aggregate could have a material adverse effect on our financial condition operations andor cash flows unless included in our legal accrual or otherwise indicated below a range of loss associated with any individual material legal proceeding cannot be estimated patent litigation on may 19 2005 g david jang md filed suit against us alleging breach of contract relating to certain patent rights covering stent technology the suit was filed in the us district court for the central district of california seeking monetary damages and rescission of contract after a markman ruling relating to the jang patent rights dr jang stipulated to the dismissal of certain claims alleged in the complaint with a right to appeal and the parties subsequently agreed to settle the other claims in may 2007 dr jang filed an appeal with respect to the remaining patent claims and in july 2008 the court of appeals vacated the district courts consent judgment and remanded the case back to the district court for further clarification in august 2011 the district court entered a stipulated judgment that we did not infringe the jang patent dr jang filed an appeal on september 21 2011 and on august 22 2012 the court of appeals vacated the district courts judgment and remanded the case to the district court for further proceedings on july 8 2015 a jury found that our express stent family did not literally infringe a jang patent but that the stents infringed under the doctrine of equivalents the court reserved judgment until the conclusion of further proceedings related to the doctrine of equivalents finding on september 29 2015 the court ruled that our express stent family did not infringe under the doctrine of equivalents and on october 30 2015 the court entered judgment in our favor on november 25 2015 dr jang filed a motion for judgment as a matter of law on literal infringement andor for a new trial on february 3 2016 the court denied dr jangs motion for a new trial and judgment as a matter of law dr jang filed a notice of appealon september 27 2010 boston scientific scimed inc boston scientific ltd endovascular technologies inc and we filed suit against taewoong medical co ltd standard scitech inc endochoice inc and sewoon medical co ltd for infringement of three patents on stents for use in the gi system the pulnev and hankh patents and against cook medical inc and related entities for infringement of the same three patents and an additional patent the thompson patent the suit was filed in the us district court for the district of massachusetts seeking monetary damages and injunctive relief in december 2010 we amended our complaint to add infringement of six additional pulnev patents in january 2011 the defendants filed a counterclaim of invalidity and unenforceability in september 2011 we amended the complaint to add chekmed systems dba gi supply as a defendant on december 22 2016 the following defendants were dismissed taewoong medical co ltd gi supply inc standard scitech inc endochoice inc and sewoon medical co trial against the remaining parties is scheduled to begin september 11 2017 on october 30 2015 a subsidiary of boston scientific filed suit against edwards lifesciences corporation and edwards lifesciences services gmbh in dsseldorf district court in germany for patent infringement we allege that edwards sapien 3 heart valve infringes our patent related to adaptive sealing technology on february 25 2016 we extended the action to allege infringement of a second patent related to adaptive sealing technology the trial began on february 7 2017 on november 9 2015 edwards lifesciences llc filed an invalidity claim against one of our subsidiaries sadra medical inc in the high court of justice chancery division patents court in the united kingdom alleging that a european patent owned by sadra relating to a repositionable heart valve is invalid on january 15 2016 we filed our defense and counterclaim for a declaration  103that our european patent is valid and infringed by edwards on february 25 2016 we amended our counterclaim to allege infringement of a second patent related to adaptive sealing technology a trial was held from january 18 to january 27 2017 on november 23 2015 edwards lifesciences pvt inc filed a patent infringement action against us and one of our subsidiaries boston scientific medizintechnik gmbh in the district court of dsseldorf germany alleging a european patent spenser owned by edwards is infringed by our lotus transcatheter heart valve system the trial began on february 7 2017 on november 23 2015 edwards lifesciences corporation filed a patent infringement action against us and boston scientific medizintechnik gmbh in the district court of dsseldorf germany alleging an european patent bourang owned by edwards is infringed by our lotus transcatheter heart valve system the trial began on february 7 2017on april 19 2016 a subsidiary of boston scientific filed suit against edwards lifesciences corporation in the united states district court for the district of delaware for patent infringement we allege that edwards sapien 3 valve infringes a patent related to adaptive sealing technology on june 9 2016 edwards filed a counterclaim alleging that our lotus transcatheter heart valve system infringes three patents owned by edwards on october 12 2016 edwards filed a petition for inter partes review of our patent with the us patent and trademark office patent trial and appeal board the trial has been set to begin on july 30 2018on april 19 2016 a subsidiary of boston scientific filed suit against edwards lifesciences corporation in the united states district court for the central district of california for patent infringement we allege that edwards aortic valve delivery systems infringe eight of our catheter related patents on october 13 2016 edwards filed a petition for inter partes review of one asserted patent with the us patent amp trademark office patent trial and appeal board the trial has been set to begin on may 29 2018 on april 26 2016 edwards lifesciences pvt inc filed a patent infringement action against us and one of our subsidiaries boston scientific medizintechnik gmbh in the district court of dsseldorf germany alleging a european patent spenser owned by edwards is infringed by our lotus transcatheter heart valve system the trial began on february 7 2017 on october 27 2016 edwards lifesciences pvt inc filed a patent infringement action against us and one of our subsidiaries boston scientific ltd in the federal court of canada alleging that three canadian patents spenser owned by edwards are infringed by our lotus transcatheter heart valve system on october 28 2016 the regents of the university of california filed a patent infringement action against us in the united states district court for the northern district of california alleging that two us patents lesh owned by the regents of the university of california are infringed by certain of our catheters and other devices used to treat atrial fibrillationon november 29 2016 nevro corp filed a patent infringement action against us and one of our subsidiaries boston scientific neuromodulation corporation in the united states district court for the northern district of california alleging that six us patents alataris owned by nevro corp are infringed by our spinal cord stimulation systemson december 9 2016 the company and boston scientific neuromodulation corporation filed a patent infringement action against nevro corp in united states district court for the district of delaware alleging that ten us patents owned by boston scientific neuromodulation corporation are infringed by nevros senza spinal cord stimulation systemon december 22 2016 edwards lifesciences pvt inc and edwards lifesciences sa ag filed a plenary summons against boston scientific limited and boston scientific group public company in the high court of ireland alleging that a european patent spenser owned by edwards is infringed by our lotus transcatheter heart valve systemproduct liability litigation no individual lawsuits remain pending in state court jurisdictions against guidant alleging personal injuries associated with defibrillators or pacemakers involved in certain 2005 and 2006 product communications further we are aware of approximately 8 guidant product liability lawsuits pending in international jurisdictions associated with defibrillators or pacemakers including devices involved in the 2005 and 2006 product communications four of these suits are pending in canada involving certain models of guidant pacemakers three of which are stayed pending the outcome of one lead class action on may 8 2009 the justice of ontario court certified a class of persons in whom pacemakers were implanted in canada and a class of family members with derivative claims in each case these matters generally seek monetary damages from us this class action has been inactive since 2011 on march 24 2014 the ontario superior court approved a 3 million settlement of a class action involving certain models of guidant defibrillators we believe guidant has satisfied its obligations pursuant to the settlement agreement  104as of february 21 2017 approximately 43000 product liability cases or claims related to transvaginal surgical mesh products designed to treat stress urinary incontinence and pelvic organ prolapse have been asserted against us the pending cases are in various federal and state courts in the united states and include eight putative class actions there were also fewer than 20 cases in canada inclusive of one certified and three putative class actions and fewer than 20 claims in the united kingdom generally the plaintiffs allege personal injury associated with use of our transvaginal surgical mesh products the plaintiffs assert design and manufacturing claims failure to warn breach of warranty fraud violations of state consumer protection laws and loss of consortium claims over 3100 of the cases have been specially assigned to one judge in state court in massachusetts on february 7 2012 the judicial panel on multidistrict litigation mdl established mdl2326 in the us district court for the southern district of west virginia and transferred the federal court transvaginal surgical mesh cases to mdl2326 for coordinated pretrial proceedings during the fourth quarter of 2013 we received written discovery requests from certain state attorneys general offices regarding our transvaginal surgical mesh products we have responded to those requests as of february 21 2017 we have entered into master settlement agreements in principle or are in the final stages of entering one with certain plaintiffs counsel to resolve an aggregate of approximately 31000 cases and claims the master settlement agreements provide that the settlement and distribution of settlement funds to participating claimants are conditional upon among other things achieving minimum required claimant participation thresholds of the approximately 31000 cases and claims approximately 12000 have met the conditions of the settlement and are final all settlement agreements were entered into solely by way of compromise and without any admission or concession by us of any liability or wrongdoingon or about january 12 2016 teresa l stevens filed a claim against us and three other defendants asserting for herself and on behalf of a putative class of similarlysituated women that she was harmed by a vaginal mesh implant that she alleges contained a counterfeit or adulterated resin product that we imported from china the complaint was filed in the united states district court for the southern district of west virginia before the same court that is hearing the mesh mdl the complaint which alleges racketeer influenced and corrupt organizations act rico violations fraud misrepresentation deceptive trade practices and unjust enrichment seeks both equitable relief and damages under state and federal law on january 26 2016 the court issued an order staying the case and directing the plaintiff to submit information to allow the fda to issue a determination with respect to her allegations in addition we are in contact with the us attorneys office for the southern district of west virginia and are responding voluntarily to their requests in connection with that offices review of the allegations concerning the use of mesh resin in the complaint we deny the plaintiffs allegations and intend to defend ourselves vigorouslywe have established a product liability accrual for known and estimated future cases and claims asserted against us as well as with respect to the actions that have resulted in verdicts against us and the costs of defense thereof associated with our transvaginal surgical mesh products while we believe that our accrual associated with this matter is adequate changes to this accrual may be required in the future as additional information becomes available while we continue to engage in discussions with plaintiffs counsel regarding potential resolution of pending cases and claims and intend to vigorously contest the cases and claims asserted against us that do not settle the final resolution of the cases and claims is uncertain and could have a material impact on our results of operations financial condition andor liquidity initial trials involving our transvaginal surgical mesh products have resulted in both favorable and unfavorable judgments for us we do not believe that the judgment in any one trial is representative of potential outcomes of all cases or claims related to our transvaginal surgical mesh productsgovernmental investigations and qui tam matterson august 3 2012 we were served with a qui tam complaint that had previously been filed under seal against boston scientific neuromodulation corp in the us district court for the district of new jersey on march 2 2011 on august 8 2012 we learned that the federal government had previously declined to intervene in this matter the relators complaint now unsealed alleges that boston scientific neuromodulation corp violated the federal and various states false claims acts through submission of fraudulent bills for implanted devices underreporting of certain adverse events and promotion of offlabel uses on september 10 2012 the relators filed an amended complaint revising and restating certain of the claims in the original complaint our motion to dismiss filed subsequently was denied on may 31 2013 and on june 28 2013 we answered the amended complaint and brought certain counterclaims arising from relators unauthorized removal of documents from the business during their employments which the relators moved to dismiss on july 22 2013 the court denied relators motion to dismiss the counterclaims on september 4 2014on may 5 2014 we were served with a subpoena from the us department of health and human services office of the inspector general the subpoena seeks information relating to the launch of the cognis and teligen line of devices in 2008 the performance of those devices from 2007 to 2009 and the operation of the physician guided learning program we are cooperating with this request on may 6 2016 a qui tam lawsuit in this matter was unsealed in the us district court for the district of minnesota at the same time we learned that the us government and the state of california had earlier declined to intervene in that lawsuit on april 15 2016 the complaint was served on us on july 21 2016 on october 7 2016 the plaintiffrelator served an amended complaint that dropped the allegations relating to the physician guided learning program  105on february 23 2015 a judge for the court of modena italy ordered a trial for boston scientific spa and three of its employees as well as numerous other defendants charged in criminal proceedings the charges arise from allegations that the defendants made improper donations to certain health care providers and other employees of the hospital of modena in order to induce them to conduct unauthorized clinical trials as well as related government fraud in relation to the financing of such clinical trials a trial began on february 24 2016 and is ongoing we deny these allegations and intend to defend ourselves vigorously on december 1 2015 the brazilian governmental entity known as cade the administrative council of economic defense served a search warrant on the offices of our brazilian subsidiary as well as on the brazilian offices of several other major medical device makers who do business in brazil in furtherance of an investigation into alleged anticompetitive activity with respect to certain tender offers for government contracts we are cooperating fully with cades inquiryon december 14 2016 we learned that the associacao brasileira de medicina de grupo dba abramge filed a complaint against the company arthrex and zimmer biomet holdings in the us district court for the district of delaware this complaint which abramge never served against the company alleges that the defendants or their agents paid kickbacks to health care providers in order to increase sales and prices and are liable under a variety of common law theories on february 6 2017 abramge filed and served an amended complaint on the company and the other defendants the amended complaint does not contain any material changes in the allegations against the company we deny these allegations and intend to defend ourselves vigorously if abramge serves the complaintother proceedings in june of 2016 guidant asserted three arbitrations claims which are pending related to three insurance policies for indemnity arising out of previously incurred and satisfied liabilities tied to allegedly defective cardiac rhythm management devices which guidant had manufactured guidant has claimed indemnities against such liabilities under insurance policies which it purchased for the 2004 policy year the three insurance policies were issued respectively by markel bermuda zurich now swiss re international se uk branch and swiss reon november 2 2015 acacia research corporation arc filed an arbitration demand with the american arbitration association alleging that the company breached an agreement relating to the sale of patents from the company to arc the hearing began on february 20 2017refer to note j  income taxes for information regarding our tax litigation matters concluded since december 31 2015on september 22 2014 the board of trustees for the university of alabama filed a complaint in the united states district court for the northern district of alabama alleging that the sale of our cardiac resynchronization therapy devices infringe a patent owned by the university of alabama on august 21 2015 the court ordered a stay pending our requests for inter partes review of all claims related to the patent before the patent trial and appeal board of the us patent and trademark office uspto our requests were rejected on september 24 2015 and october 19 2015 on march 7 2016 the uspto granted our reconsideration motion and initiated an inter partes review and on march 29 2016 the district court stayed the case pending a decision in the inter partes review on october 6 2016 the parties reached a settlement agreement on october 19 2016 the case was dismissed with prejudice on march 12 2010 we received a civil investigative demand cid from the civil division of the us department of justice doj requesting documents and information relating to reimbursement advice offered by us relating to certain crm devices on february 9 2016 the doj informed us that we are no longer required to retain documents and information relating to the cidon july 11 2014 we were served with a subpoena from the us attorney for the district of new jersey the subpoena seeks information relating to bridgepoint medical inc which we acquired in october 2012 including information relating to its sale of crossboss and stingray products educational and training activities that relate to those sales and our acquisition of bridgepoint medical on august 20 2015 the court unsealed a qui tam lawsuit brought by a former employee named robin levy against the company as well as a decision by the us attorney for new jersey declining to intervene in the lawsuit the lawsuit alleges that the company violated the federal and various state false claims acts through seeking to upcode chronic total occlusion cto procedures and requiring inpatient treatment and purchases of coronary stents in order for physicians to receive training on the cto procedure on january 26 2016 the court dismissed the qui tam lawsuiton march 18 2015 denise fretter and maria korsgaard claiming to represent a class of current and former female field sales employees at boston scientific neuromodulation corporation bsnc filed a lawsuit against bsnc in the us district court  106for the central district of california the plaintiffs allege gender discrimination in pay promotions and differential treatment against them and the putative class on february 6 2016 the parties entered into a confidential settlement agreement and the case has been dismissedon april 24 2014 dr qingsheng zhu and dr julio spinelli acting jointly on behalf of the stockholder representative committee of action medical inc action medical filed a lawsuit against us and our subsidiary cardiac pacemakers inc cpi in the us district court for the district of delaware the stockholder representatives alleged that we and cpi breached a contractual duty to pursue development and commercialization of certain patented heart pacing methods and devices and to return certain patents on march 15 2016 the court granted summary judgment in our favor as to all of plaintiffs claims for damages the parties subsequently reached a resolution on the remaining claim and counterclaim concerning specific performance and the case was dismissed on june 29 2016 on february 18 2014 atlas ip llc filed a complaint in the united states district court for the southern district of florida alleging that the sale of our latitude patient management system and implantable devices that communicate with the latitude device infringe a patent owned by atlas on july 9 2014 the district court granted our motion to transfer venue to the united states district court for the district of minnesota on january 12 2015 atlas dismissed its complaint on september 22 2015 atlas ip llc filed a complaint in federal court in ottawa ontario canada alleging that the sale of our latitude patient management system and implantable devices that communicate with the latitude device infringe certain claims of a canadian patent owned by atlas on october 25 2016 the claim against us in canada was dismissedon september 28 2011 we served a complaint against mirowski family ventures llc in the us district court for the southern district of indiana for a declaratory judgment that we have paid all royalties owed and did not breach any contractual or fiduciary obligations arising out of a license agreement mirowski answered and filed counterclaims requesting damages on may 13 2013 mirowski family ventures served us with a complaint alleging breach of contract in montgomery county circuit court maryland and they amended this complaint on august 1 2013 on july 29 2013 the indiana case was dismissed on september 10 2013 we removed the case to the united states district court for the district of maryland on june 5 2014 the district court granted mirowskis motion to remand the case to the montgomery county circuit court on september 24 2014 following a jury verdict against us the montgomery county circuit court entered a judgment that we breached our license agreement with mirowski and awarded damages of 308 million on october 28 2014 the montgomery county circuit court denied our posttrial motions seeking to overturn the judgment on november 19 2014 we filed an appeal with the maryland court of special appeals on january 29 2016 the maryland court of special appeals affirmed the decision of the montgomery county circuit court on february 2 2016 we filed a motion for reconsideration which was denied on july 12 2016 the maryland court of appeals denied our petition for certiorari on july 26 2016 we paid 366 million in satisfaction of the judgment and interest subject to a right of rescission should the judgment be reversed on october 7 2016 we filed a petition for writ of certiorari with the united states supreme court on february 21 2017 the court denied our petition note l  stockholders equitypreferred stockwe are authorized to issue 50 million shares of preferred stock in one or more series and to fix the powers designations preferences and relative participating option or other rights thereof including dividend rights conversion rights voting rights redemption terms liquidation preferences and the number of shares constituting any series without any further vote or action by our stockholders as of december 31 2016 and 2015 we had no shares of preferred stock issued or outstandingcommon stockwe are authorized to issue 20 billion shares of common stock 001 par value per share holders of common stock are entitled to one vote per share holders of common stock are entitled to receive dividends if and when declared by the board of directors and to share ratably in our assets legally available for distribution to our stockholders in the event of liquidation holders of common stock have no preemptive subscription redemption or conversion rights the holders of common stock do not have cumulative voting rights the holders of a majority of the shares of common stock can elect all of the directors and can control our management and affairson january 25 2013 our board of directors approved a stock repurchase program authorizing the repurchase of up to 10 billion of our common stock we did not repurchase any shares of our common stock during 2016 or 2015 during 2014 we repurchased approximately 10 million shares of our common stock for 125 million repurchased shares are available for reissuance under our equity incentive plans and for general corporate purposes including acquisitions as of december 31 2016 we had remaining 535 million authorized under our 2013 share repurchase program there were approximately 248 million shares in treasury as of december 31 2016 and december 31 2015 107note m  stock ownership plans employee and director stock incentive plansin march and may 2011 our board of directors and stockholders respectively approved our 2011 longterm incentive plan the 2011 ltip authorizing up to 146 million shares of our common stock the 2011 ltip covers officers directors employees and consultants and provides for the grant of restricted or unrestricted common stock deferred stock units dsu options to acquire our common stock stock appreciation rights performance awards marketbased and performancebased dsus and other stock and nonstock awards shares reserved under our current and former stock incentive plans totaled approximately 150 million as of december 31 2016 the executive compensation and human resources committee of the board of directors consisting of independent nonemployee directors may authorize the issuance of common stock and authorize cash awards under the 2011 ltip in recognition of the achievement of longterm performance objectives established by the committeenonqualified options issued to employees are generally granted with an exercise price equal to the market price of our stock on the grant date vest over a fouryear service period and have a tenyear contractual life in the case of qualified options if the recipient owns more than ten percent of the voting power of all classes of stock the option granted will be at an exercise price of 110 percent of the fair market value of our common stock on the date of grant and will expire over a period not to exceed five years nonvested stock awards including restricted stock awards and deferred stock units issued to employees are generally granted with an exercise price of zero and typically vest in five equal annual installments these awards represent our commitment to issue shares to recipients after the vesting period upon each vesting date such awards are no longer subject to risk of forfeiture and we issue shares of our common stock to the recipientthe following presents the impact of stockbased compensation on our consolidated statements of operations for the years ended december 31 2016 2015 and 2014  year ended december 31in millions except per share data 2016 2015 2014cost of products sold 6 7 6selling general and administrative expenses 90 81 79research and development expenses 20 19 18  116 107 103income tax benefit 29 28 28  87 79 75       net impact per common share  basic 006 006 006net impact per common share  assuming dilution 006 006 006stock optionswe use the blackscholes optionpricing model to calculate the grantdate fair value of stock options granted to employees under our stock incentive plans we calculated the fair value for options granted during 2016 2015 and 2014 using the following estimated weightedaverage assumptions  year ended december 31  2016 2015 2014options granted in thousands 4186 4441 4943weightedaverage exercise price 1746 1649 1302weightedaverage grantdate fair value 560 554 507blackscholes assumptions      expected volatility 30 31 37expected term in years weighted 60 60 60riskfree interest rate 114  208 149  192 169  209expected volatilitywe use our historical volatility and implied volatility as a basis to estimate expected volatility in our valuation of stock options 108expected termwe estimate the expected term of options using historical exercise and forfeiture data we believe that this historical data provides the best estimate of the expected term of new option grantsriskfree interest ratewe use yield rates on us treasury securities for a period approximating the expected term of the award to estimate the riskfree interest rate in our grantdate fair value assessmentexpected dividend yieldwe have not historically paid cash dividends to our stockholders and currently do not intend to pay cash dividends therefore we have assumed an expected dividend yield of zero in our grantdate fair value assessmentinformation related to stock options for 2016 2015 and 2014 under stock incentive plans is as follows  stock optionsin thousands weightedaverageexercise price weighted averageremainingcontractual life in years aggregateintrinsicvaluein millionsoutstanding as of december 31 2013 44892 12    granted 4943 13    exercised 4418 8    cancelledforfeited 5909 17    outstanding as of december 31 2014 39508 11    granted 4441 16    exercised 9040 9    cancelledforfeited 3820 25    outstanding as of december 31 2015 31089 11    granted 4186 17    exercised 6612 12    cancelledforfeited 2019 21    outstanding as of december 31 2016 26644 11 58 281exercisable as of december 31 2016 17293 9 44 226expected to vest as of december 31 2016 8664 16 83 51total vested and expected to vest as of december 31 2016 25957 11 57 277the total intrinsic value of stock options exercised was 64 million in 2016 69 million in 2015 and 24 million in 2014 109nonvested stockwe value restricted stock awards and dsus based on the closing trading value of our shares on the date of grant information related to nonvested stock awards during 2016 2015 and 2014 is as follows  nonvestedstock award unitsin thousands weighted averagegrant date fair valuebalance as of december 31 2013 37339 7granted 7072 13vested 1 11205 7forfeited 2671 8balance as of december 31 2014 30535 9granted 6606 16vested 1 11607 8forfeited 1770 10balance as of december 31 2015 23764 11granted 6132 17vested 1 10045 10forfeited 1054 13balance as of december 31 2016 18797 141the number of restricted stock units vested includes shares withheld on behalf of employees to satisfy statutory tax withholding requirementsthe total vesting date fair value of stock award units that vested was approximately 179 million in 2016 186 million in 2015 and 146 million in 2014marketbased dsu awardsduring 2016 2015 and 2014 we granted marketbased dsu awards to certain members of our senior management team the number of shares ultimately issued to the recipient is based on the total shareholder return tsr of our common stock as compared to the tsr of the common stock of the other companies in the sampp 500 health care index over a threeyear performance period in addition award recipients must remain employed by us throughout the threeyear performance period to attain the full amount of the marketbased dsus that satisfied the market performance criteriawe determined the fair value of the marketbased dsu awards to be approximately 6 million for 2016 7 million for 2015 and 6 million for 2014 we determined these fair values based on monte carlo simulations as of the date of grant utilizing the following assumptions  2016 2015 2014  awards awards awardsstock price on date of grant 1726 1631 1308measurement period in years 29 30 30riskfree rate 090 098 066we recognize the expense on these awards in our consolidated statements of operations on a straightline basis over the threeyear measurement periodfree cash flow performancebased dsu awardsduring 2016 2015 and 2014 we granted free cash flow performancebased dsu awards to certain members of our senior management team the attainment of these performancebased dsus is based on our adjusted free cash flow fcf measured against our internal annual financial plan performance for fcf fcf is measured over a oneyear performance period beginning january 1st of each year and ending december 31st the number of performancebased dsus as to which the performance criteria under this program shall be determined to have been satisfied will be in a range of 0 to 150 of the target number of performancebased dsus awarded to the participant in addition award recipients must remain employed by us throughout a threeyear service  110period inclusive of the oneyear performance period to attain the full amount of the performancebased dsus that satisfied the performance criteriawe determined the fair value of the 2016 fcf awards to be approximately 8 million based on the closing stock price at december 31 2016 and an achievement of approximately 114 of the target payout the per unit fair value is 2163 which is the closing stock price on december 31 2016 we determined the fair value of the 2015 fcf awards to be approximately 6 million and the per unit fair value was 1844 and we determined the fair value of the 2014 fcf awards to be approximately 5 million and the per unit fair value was 1325we recognize the expense on these awards in our consolidated statements of operations over the vesting period which is three years after the date of grantexpense attributionwe recognize compensation expense for our stock using a straightline method over the substantive vesting period most of our stock awards provide for immediate vesting upon death or disability of the participant in addition our stock grants to employees provide for accelerated vesting of our stockbased awards other than performancebased and marketbased awards upon retirement in accordance with the terms of our stock grants for employees who will become retirement eligible prior to the vest date we expense stockbased awards other than performancebased and marketbased awards over the greater of one year or the period between grant date and retirementeligibility the performancebased and marketbased awards discussed above do not contain provisions that would accelerate the full vesting of the awards upon retirementeligibilitywe recognize stockbased compensation expense for the value of the portion of awards that are ultimately expected to vest fasb asc topic 718 compensation  stock compensation requires forfeitures to be estimated at the time of grant and revised if necessary in subsequent periods if actual forfeitures differ from those estimates the term forfeitures is distinct from cancellations or expirations and represents only the unvested portion of the surrendered stockbased award we have applied based on an analysis of our historical forfeitures a weightedaverage annual forfeiture rate of approximately eight percent to all unvested stockbased awards as of december 31 2016 which represents the portion that we expect will be forfeited each year over the vesting period we reevaluate this analysis annually or more frequently if there are significant changes in circumstances and adjust the forfeiture rate as necessary ultimately we will only recognize expense for those shares that vestunrecognized compensation costwe expect to recognize the following future expense for awards outstanding as of december 31 2016   unrecognized compensation  costin millions1 weighted averageremaining vesting periodin yearsstock options 27  nonvested stock awards 136    163 131amounts presented represent compensation cost net of estimated forfeituresemployee stock purchase plansour global employee stock purchase plan provides for the granting of options to purchase up to 50 million shares of our common stock to all eligible employees under the global employee stock purchase plan we grant each eligible employee at the beginning of each sixmonth offering period an option to purchase shares of our common stock equal to not more than ten percent of the employees eligible compensation or the statutory limit under the us internal revenue code such options may be exercised only to the extent of accumulated payroll deductions at the end of the offering period at a purchase price equal to 85 percent of the fair market value of our common stock at the beginning or end of each offering period whichever is less as of december 31 2016 there were approximately 15 million shares available for future issuance under the employee stock purchase planinformation related to shares issued or to be issued in connection with the employee stock purchase plan based on employee contributions and the range of purchase prices is as follows shares in thousands 2016 2015 2014shares issued or to be issued 2337 2529 2618range of purchase prices 1529  1839 1124  1513 1012  1104 111we use the blackscholes optionpricing model to calculate the grantdate fair value of shares issued under the employee stock purchase plan we recognize expense related to shares purchased through the employee stock purchase plan ratably over the offering period we recognized 11 million in expense associated with our employee stock purchase plan in 2016 9 million in 2015 and 8 million in 2014note n  weighted average shares outstanding  year ended december 31in millions 2016 2015 2014weighted average shares outstanding  basic 13576 13412 13243net effect of common stock equivalents 196  weighted average shares outstanding  assuming dilution 13772 13412 13243our weightedaverage shares outstanding for earnings per share calculations excluded common stock equivalents of 22 million in 2015 and 24 million in 2014 due to our net loss positionsweightedaverage shares outstanding assuming dilution excludes the impact of less than 1 million stock options for 2016 2 million stock options for 2015 and 12 million stock options for 2014 due to the exercise prices of these stock options being greater than the average fair market value of our common stock during the year note o  segment reportingwe have three reportable segments comprised of cardiovascular rhythm management and medsurg which represent an aggregation of our operating segments each of our reportable segments generates revenues from the sale of medical devices we measure and evaluate our reportable segments based on segment net sales and operating income excluding the impact of changes in foreign currency and sales from divested businesses sales generated from reportable segments and divested businesses as well as operating results of reportable segments and corporate expenses are based on internallyderived standard currency exchange rates which may differ from year to year and do not include intersegment profits as needed we restate segment information for the prior period based on our internallyderived standard currency exchange rates used for the current period in order to remove the impact of foreign currency exchange fluctuation we exclude from segment operating income certain corporaterelated expenses and certain transactions or adjustments that our chief operating decision maker considers to be nonoperational such as amounts related to intangible asset impairment charges acquisition divestiture litigation restructuring and restructuringrelated net charges and credits pension termination charges and amortization expense although we exclude these amounts from segment operating income they are included in reported consolidated operating income loss and are included in the reconciliation below 112a reconciliation of the totals reported for the reportable segments to the applicable line items in our accompanying consolidated statements of operations is as follows  year ended december 31in millions 2016 2015 2014net sales      interventional cardiology 2524 2242 2092peripheral interventions 1093 975 861cardiovascular 3617 3217 2953       cardiac rhythm management 1994 1934 1922electrophysiology 261 248 228rhythm management 2255 2182 2150       endoscopy 1565 1422 1343urology and pelvic health 1065 735 542neuromodulation 574 512 474medsurg 3204 2669 2359net sales allocated to reportable segments 9076 8068 7462sales generated from business divestitures   4impact of foreign currency fluctuations 690 591 86  8386 7477 7380  year ended december 31in millions 2016 2015 2014depreciation expense      cardiovascular 122 116 120rhythm management 83 94 92medsurg 74 73 75depreciation expense allocated to reportable segments 279 283 287impact of foreign currency fluctuations 9 9   270 274 287  year ended december 31in millions 2016 2015 2014income loss before income taxes      cardiovascular 1137 972 767rhythm management 404 328 289medsurg 1045 856 746operating income allocated to reportable segments 2586 2156 1802corporate expenses and currency exchange 565 486 308intangible asset impairment charges pension termination charges and acquisition and divestiturerelated net charges litigationrelated net charges and restructuring and restructuringrelated net charges 1029 1502 1357amortization expense 545 495 438operating income loss 447 327 301other expense net 270 323 208  177 650 509 113  as of december 31in millions 2016 2015total assets    cardiovascular 1748 1583rhythm management 1250 1279medsurg 1499 1141total assets allocated to reportable segments 4497 4003goodwill 6678 6473other intangible assets net 5883 6194all other corporate assets 1038 1463  18096 18133enterprisewide information based on actual currency exchange rates  year ended december 31in millions 2016 2015 2014net sales      interventional cardiology 2281 2033 2057cardiac rhythm management 1850 1807 1912endoscopy 1440 1306 1323peripheral interventions 1011 904 850urology and pelvic health 1005 693 535neuromodulation 556 501 472electrophysiology 243 233 227  8386 7477 7376sales generated from divested businesses   4  8386 7477 7380       united states 4759 4229 3885japan 750 602 678other countries 2877 2646 2813  8386 7477 7376sales generated from divested businesses   4  8386 7477 7380  as of december 31in millions 2016 2015 2014longlived assets      united states 1082 1018 1002ireland 181 170 197other foreign countries 367 302 308property plant and equipment net 1630 1490 1507goodwill 6678 6473 5898other intangible assets net 5883 6194 5606  14191 14157 13011 114note p  changes in other comprehensive income the following table provides the reclassifications out of other comprehensive income for the years ended december 31 2016 and december 31 2015 amounts in the chart below are presented net of taxyear ended december 31 2016     in millionsforeign currency translation adjustmentsunrealized gainslosses on derivative financial instrumentsunrealized gainslosses on availableforsale securitiesdefined benefit pension items  othertotalbeginning balance541521088other comprehensive incomeloss before reclassifications25406178gainloss reclassified from accumulated other comprehensive income85679net currentperiod other comprehensive income254561187ending balance791076211      year ended december 31 2015    in millionsforeign currency translation adjustmentsunrealized gainslosses on derivative financial instrumentsdefined benefit pension items  othertotalbeginning balance3821937144other comprehensive incomeloss before reclassifications1670351gainloss reclassified from accumulated other comprehensive income13730107net currentperiod other comprehensive income16672756ending balance541521088the income tax impact of the amounts in other comprehensive income for unrealized gainslosses on derivative financial instruments before reclassifications was an expense of 23 million in 2016 and an expense of 39 million in 2015 the gains and losses on derivative financial instruments reclassified from accumulated other comprehensive income were reduced by income tax impacts of 48 million in 2016 and 78 million in 2015 refer to note e  fair value measurements for further detail on the reclassifications related to derivativesthe income tax impact of the amounts in other comprehensive income for defined benefit and pension items before reclassifications was a benefit of 9 million in 2016 and a benefit of 2 million in 2015 the gains and losses on defined benefit and pension items reclassified from accumulated other comprehensive income were reduced by income tax impacts of 2 million in 2016 and 17 million in 2015the gains and losses on availableforsale securities were reduced by immaterial income tax impacts in 2016 refer to note e  fair value measurements for further detail on the gains and losses on availableforsale securitiesnote q  new accounting pronouncements from time to time new accounting pronouncements are issued by the fasb or other standard setting bodies recently issued standards typically do not require adoption until a future effective date prior to their effective date we evaluate the pronouncements to determine the potential effects of adoption on our consolidated financial statements 115standards implemented since december 31 2015asc update no 201505in april 2015 the fasb issued asc update no 201505 intangibles  goodwill and other  internaluse software subtopic 35040 customers accounting for fees paid in a cloud computing arrangement update no 201505 provides accounting guidance on how customers should treat cloud computing arrangements if a cloud computing arrangement includes a software license then the customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses if a cloud computing arrangement does not include a software license the customer should account for the arrangement as a service contract update no 201505 is effective for annual reporting periods beginning after december 15 2015 and interim periods within those reporting periods we elected to adopt the amendments prospectively to all arrangements entered into or materially modified after the effective date the adoption of update no 201505 did not have a material impact on our financial position or results of operationsasc update no 201512in july 2015 the fasb issued asc update no 201512 plan accounting defined benefit pension plans topic 960 defined contribution pension plans topic 962 and health and welfare benefit plans topic 965 update no 201512 has three parts part i designates contract value as the only required measure for fully benefitresponsive investment contracts part ii simplifies the investment disclosure requirements under topics 820 960 962 and 965 for employee benefits plans and part iii provides an alternative measurement date for fiscal periods that do not coincide with a monthend date update no 201512 is effective for fiscal years beginning after december 15 2015 the adoption of update no 201512 did not have a material impact on our financial position or results of operations asc update no 201516in september 2015 the fasb issued asc update no 201516 business combinations topic 805 simplifying the accounting for measurement  period adjustments update no 201516 eliminates the requirement to restate prior period financial statements for measurement period adjustments following a business combination update no 201516 requires that the cumulative impact of a measurement period adjustment including the impact on prior periods be recognized in the reporting period in which the adjustment is identified the prior period impact of the adjustment should be either presented separately on the face of the income statement or disclosed in the notes update no 201516 is effective for fiscal years beginning after december 15 2015 the adoption of update no 201516 did not impact our financial position or results of operationsasc update no 201517in november 2015 the fasb issued asc update no 201517 income taxes topic 740 balance sheet classification of deferred taxes update no 201517 requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position it is effective for fiscal years beginning after december 15 2016 however earlier application is permitted we elected to early adopt update no 201517 on a prospective basis during the first quarter of 2016 as such prior periods were not retrospectively adjusted the adoption of update no 201517 did not have a material impact on our financial position or results of operations asc update no 201607in march 2016 the fasb issued asc update no 201607 investments  equity method and joint ventures topic 323 when a previously held investment qualifies for equity method accounting due to an increase in ownership interest or influence update no 201607 eliminates the requirement for investors to adjust results retroactively as if the equity method had been in effect during prior periods the investment was held instead it requires investors to adopt the equity method of accounting as of the date the investment becomes qualified for equity method accounting we elected to early adopt update no 201607 on a prospective basis the adoption of update no 201607 did not impact our financial position or results of operations 116standards to be implementedasc update no 201409in may 2014 the fasb issued asc update no 201409 revenue from contracts with customers topic 606 update no 201409 provides enhancements to the quality and consistency of how revenue is reported while also improving comparability in the financial statements of companies using international financial reporting standards and us gaap the core principle requires entities to recognize revenue in a manner that depicts the transfer of goods or services to customers in amounts that reflect the consideration an entity expects to be entitled to in exchange for those goods or services in july 2015 the fasb voted to approve a one year deferral making the standard effective for public entities for annual and interim periods beginning after december 15 2017 in march 2016 the fasb issued asc update no 201608 revenue from contracts with customers topic 606 principal versus agent considerations reporting revenue gross versus net the purpose of update no 201608 is to clarify the guidance on principal versus agent considerations it includes indicators that help to determine whether an entity controls the specified good or service before it is transferred to the customer and to assist in determining when the entity satisfied the performance obligation and as such whether to recognize a gross or a net amount of consideration in their consolidated statement of operationsin april 2016 the fasb issued asc update no 201610 revenue from contracts with customers topic 606 identifying performance obligations and licensing update no 201610 clarifies that entities are not required to assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract update no 201610 also addresses how to determine whether promised goods or services are separately identifiable and permits entities to make a policy election to treat shipping and handling costs as fulfillment activities in addition it clarifies key provisions in topic 606 related to licensingin may 2016 the fasb issued asc update no 201611 revenue recognition topic 605 and derivatives and hedging topic 815 update no 201611 rescinds previous sec comments that were codified in topic 605 topic 932 and topic 815 upon adoption of asc 606 certain sec comments including guidance on accounting for shipping and handling fees and costs and consideration given by a vendor to a customer should not be relied uponin may 2016 the fasb also issued asc update no 201612 revenue from contracts with customers topic 606 narrow scope improvements and practical expedients update no 201612 provides clarity around collectibility presentation of sales taxes noncash consideration contract modifications at transition and completed contracts at transition update no 201612 also includes a technical correction within asc 606 related to required disclosures if the guidance is applied retrospectively upon adoptionin december 2016 the fasb issued asc update no 201620 technical corrections and improvements to topic 606 revenue from contracts with customers update no 201620 allows entities not to make quantitative disclosures about remaining performance obligations in certain cases and requires entities that use any of the optional exemptions to expand their qualitative disclosures update no 201620 also clarifies other areas of the new revenue standard including disclosure requirements for prior period performance obligations impairment guidance for contract costs and the interaction of impairment guidance in asc 34040 with other guidance elsewhere in the codificationwe expect to adopt topic 606 and the aforementioned updates effective january 1 2018 we established a crossfunctional implementation team consisting of representatives from all of our business divisions and regions during 2016 we analyzed the impact of the standard on our contract portfolio by reviewing a representative sample of our contracts to identify potential differences that would result from applying the requirements of the new standard the implementation team has apprised both management and the audit committee of project status on a recurring basiswe have not finalized our assessment of the impact of topic 606 we continue to analyze performance obligations variable consideration and disclosures additionally we are monitoring updates issued by the fasb during the first half of 2017 we expect to substantially complete our impact assessment and initiate efforts to redesign impacted processes policies and controlsasc update no 201601in january 2016 the fasb issued asc update no 201601 financial instrumentsoverall subtopic 82510 recognition and measurement of financial assets and financial liabilities it is effective for fiscal years beginning after december 15 2017 including interim periods within those fiscal years early application of certain provisions is permitted update 201601 requires entities to measure equity investments that do not result in consolidation and are not accounted for under the equity method at fair  117value with changes recognized in net income however an entity may choose to measure equity investments that do not have readily determinable fair values at cost minus impairment if any plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer it also simplifies the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment to identify impairment update 201601 also requires separate presentation of financial assets and financial liabilities by measurement category and form of financial asset and liability the adoption of update no 201601 is not expected to have a material impact on our financial position or results of operationsasc update no 201602in february 2016 the fasb issued asc update no 201602 leases topic 842 it is effective for fiscal years beginning after december 15 2018 including interim periods within those fiscal years earlier application is permitted update no 201602 is intended to increase the transparency and comparability among organizations by recognizing lease asset and lease liabilities on the balance sheet including those previously classified as operating leases under current us gaap and disclosing key information about leasing arrangements we are in the process of determining the effect that the adoption of this standard will have on our financial position and results of operationsasc update no 201609in march 2016 the fasb issued asc update no 201609 compensation stock compensation topic 718 improvements to employee sharebased payment accounting this update is effective for annual reporting periods after december 15 2016 including interim periods within those fiscal periods early adoption is permitted the purpose of the update is to simplify several areas of the accounting for sharebased payment transactions including the income tax consequences classification of awards as either equity or liabilities and classification on the statement of cash flows upon adoption in 2017 a cumulative effect adjustment of an amount still being determined will be recorded to retained earnings for windfall tax benefits not previously recognized and all future windfall tax benefits will be recognized through income tax expense we estimate the benefit to income tax expense to be between 20 million and 30 million in 2017 with the majority of the benefit occurring during the first quarter of 2017 due to vesting of the companys annual grants beginning in the first quarter of 2017 we will disclose the actual effect that the adoption has on our financial position and results of operationsasc update no 201613in june 2016 the fasb issued asc update no 201613 financial instruments  credit losses topic 326 measurement of credit losses on financial instruments the update is effective for fiscal years beginning after december 15 2019 early adoption is permitted for fiscal years beginning after december 15 2018 the purpose of update no 201613 is to replace the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information including forecasted information to develop credit loss estimates we are in the process of determining the effect that the adoption will have on our financial position and results of operationsasc update no 201615in august 2016 the fasb issued asc update no 201615 statement of cash flows topic 230 classification of certain cash receipts and cash payments the update is effective for fiscal years beginning after december 15 2017 and interim periods within those fiscal years early adoption is permitted including adoption in an interim period the purpose of update no 201615 is to reduce the diversity in practice in presentation and classification of the following items within the statement of cash flows debt prepayments settlement of zero coupon debt instruments contingent consideration payments insurance proceeds securitization transactions and distributions from equity method investees the update also addresses classification of transactions that have characteristics of more than one class of cash flows we are in the process of determining the effect that the adoption will have on our financial position and results of operationsasc update no 201616in october 2016 the fasb issued asu update no 201616 income taxes topic 740 intraentity transfers of assets other than inventory the update is effective for fiscal years beginning after december 15 2017 including interim reporting periods within those fiscal years early adoption is permitted as of the beginning of an annual reporting period for which financial statements interim or annual have not been issued or made available for issuance the purpose of update no 201616 is to allow an entity to recognize the income tax consequences of an intraentity transfer of an asset other than inventory when the transfer occurs as  118opposed to waiting until the asset is sold to an outside party we are in the process of determining the effect that the adoption will have on our financial position and results of operationsasc update no 201617in october 2016 the fasb issued asu update no 201617 consolidation topic 810 interests held through related parties that are under common control the update is effective for fiscal years beginning after december 15 2016 including interim periods within those fiscal years the purpose of update no 201617 is to amend the consolidation guidance from asu update no 201502 on how a reporting entity that is the single decision maker of a variable interest entity vie should treat indirect interests in the entity held through related parties that are under common control with the reporting entity when determining whether it is the primary beneficiary of that vie the amendment requires that a single decision maker include those indirect interests held through related parties that are under common control with the single decision maker on a proportionate basis consistent with indirect interests held through other related parties update no 201617 is not expected to have a material impact on our financial position or results of operationsasc update no 201618 in november 2016 the fasb issued asc update no 201618 statement of cash flows topic 230 restricted cash the update is effective for fiscal years beginning after december 15 2017 including interim reporting periods within those fiscal years early adoption is permitted the purpose of update no 201618 is to clarify guidance and presentation related to restricted cash in the statement of cash flows the amendment requires beginningofperiod and endofperiod total amounts shown on the statement of cash flows to include cash and cash equivalents as well as restricted cash and restricted cash equivalents we are in the process of determining the effect that the adoption will have on our financial position and results of operationsasc update no 201619in december 2016 the fasb issued asc update no 201619 technical corrections and improvements the purpose of update no 201619 is primarily to clarify or correct unintended application of guidance that affects a wide variety of topics in the asc the update is effective immediately for most of the amendments six amendments in update no 201619 clarify guidance or correct references in the asc are effective for fiscal years beginning after december 15 2016 including interim reporting periods within those fiscal years early application is permitted we are in the process of determining the effect that the adoption will have on our financial position and results of operationsasc update no 201701in january 2017 the fasb issued asc update no 201701 business combinations topic 805 clarifying the definition of a business the update is effective for fiscal years beginning after december 15 2017 including interim periods within those periods early adoption is permitted including for interim or annual periods in which the financial statements have not been issued or made available for issuance the purpose of update no 201701 is to change the definition of a business to assist entities with evaluating when a set of transferred assets and activities is a business the adoption of update no 201701 is not expected to have a material impact on our financial position or results of operationsasc update no 201704in january 2017 the fasb issued asc update no 201704 intangibles  goodwill and other topics topic 350 simplifying the test for goodwill impairment the update is effective for fiscal years beginning after december 15 2019 including interim periods within those periods early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after january 1 2017 the purpose of update no 201704 is to reduce the cost and complexity of evaluating goodwill for impairment it eliminates the need for entities to calculate the impaired fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination under this amendment an entity will perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount an impairment charge is recognized for the amount by which the carrying value exceeds the reporting units fair value we anticipate early adopting update no 201704 in fiscal year 2017 on a prospective basisno other new accounting pronouncements issued or effective during the period had or is expected to have a material impact on our consolidated financial statements 119quarterly results of operationsin millions except per share dataunaudited  three months ended  mar 31 june 30 sept 30 dec 312016        net sales 1964 2126 2105 2191gross profit 1391 1487 1511 1572operating income loss 293 334 348 140net income loss 202 207 228 124net income loss per common share  basic 015 015 017 009net income loss per common share  assuming dilution 015 015 017 009         2015        net sales 1768 1843 1888 1978gross profit 1248 1303 1349 1405operating income loss 24 219 299 271net income loss 1 102 198 142net income loss per common share  basic 000 008 015 011net income loss per common share  assuming dilution 000 008 015 011our reported results for 2016 included intangible asset impairment charges acquisition litigation restructuring and restructuringrelated charges and amortization expense after tax of 176 million in the first quarter 580 million in the second quarter 140 million in the third quarter and 291 million in the fourth quarter these aftertax net charges consisted primarily of 512 million of litigationrelated net charges and 478 million of amortization expenseour reported results for 2015 included intangible asset impairment charges acquisition litigation restructuring and restructuringrelated charges pension termination charges debt extinguishment charges discrete tax items and amortization expense after tax of 287 million in the first quarter 192 million in the second quarter 524 million in the third quarter and 504 million in the fourth quarter these aftertax net charges consisted primarily of 705 million of litigationrelated net charges and 446 million of amortization expense 120item 9 changes in and disagreements with accountants on accounting and financial disclosurenone